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Abbreviations 
 
ACA antigen capture assay 
ADCC antibody dependent cellular cytotoxicity 
ASC antibody secreting cell 
BALF bronchioalveolar lavage fluid 
CD cluster of differentiation 
CMV cytomegalovirus 
Con A concanavalin A 
CPM counts per minute 
CT cell targeting 
CTL cytotoxic T lymphocyte 
ELISA enzyme-linked immunosorbent assay 
Fc fragment crystalizable 
HA haemagglutinin 
HBc hepatitis B core protein 
Het-I heterosubtypic immunity 
HI haemagglutination inhibition 
Hom-I homologous immunity 
HRPO horseradish peroxidase 
IDAS indirect double antibody sandwich 
Ig immunoglobulin 
M matrix 
M2e extracellular domain of M2 protein 
MAb monoclonal antibody 
MDA maternally derived antibodies 
MDCK Madin Darby canine kidney 
MHC major-histocompatibility-complex 
MLN mesenteric lymph nodes 
NA neuraminidase 
NI neuraminidase inhibition 
NK natural killer 
NLF nasal lavage fluid 
NP nucleoprotein 
NS non-structural or nasal swab 
P polymerase 
PBMC peripheral blood mononuclear cell 
PCD post-challenge day 
PID post-immunisation day 
PRV pseudorabies virus 
RNA ribonucleic acid 
SD standard deviation 
SPF specified pathogen-free 
SWC swine workshop cluster 
TCID50  median tissue culture infective dose 
TCR T-cell receptor 
Th helper T lymphocyte 
VN virus neutralisation 
WHO World Health Organisation
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Introduction
Introduction 
 
History and classification 
Influenza viruses are the cause of outbreaks of acute respiratory disease, known as 
influenza or flu, which has afflicted humans and animals since ancient times. They are 
classified as members of the family Orthomyxoviridae (from the Greek orthos, 
standard, correct and myxo, mucus), because of their ability to bind to mucus and to 
distinguish them from another family of enveloped negative-strand RNA viruses, the 
Paramyxoviridae (reviewed in [76]). The Orthomyxoviridae are divided into two genera: 
influenza A and B viruses, and influenza C virus. Influenza virus types A, B, and C can 
be distinguished on the basis of antigenic differences between their nucleoprotein (NP) 
and matrix (M) protein. Influenza B and C viruses are almost exclusively isolated from 
humans, although influenza C virus has also been isolated from pigs and influenza B 
virus recently from seals [53,69,103]. In contrast, influenza A viruses infect a wide range 
of avian species as well as mammalian species including humans, pigs, horses and 
aquatic mammals [38]. The influenza A viruses are further divided into subtypes based 
on the antigenic nature of their surface glycoproteins haemagglutinin (HA) and 
neuraminidase (NA). So far, 15 different HAs (H1 to 15) and 9 NAs (N1 to 9) have been 
identified among all influenza viruses. The name influenza has its origin in early 
fifteenth century Italy and was adopted in Europe to explain the sudden appearance of an 
epidemic disease thought to be under the influence of the stars [62].  
Despite the importance of influenza as a disease of humans, influenza virus was 
first isolated from poultry. A disease causing extremely high mortality in domestic fowl 
was first defined in 1878 and became known as fowl plague. As early as 1901 the 
causative agent was shown to be an ultra-filterable agent (i.e. virus), although not until 
1955 was the close relationship between this agent and mammalian influenza A viruses 
demonstrated [117]. Isolation of influenza virus from pigs also preceded the isolation of 
human influenza virus. It was the causative agent of a new disease of pigs termed 
swine influenza, with clinical signs similar to those in humans first described at the 
time of the 1918 human pandemic [34]. In 1930, Shope demonstrated the ability to 
transmit swine influenza between pigs using ultrafiltered material [126]. In 1933, a virus 
demonstrated to be related to the pig virus was eventually isolated from a human patient, 
by inoculating a filtrate of throat washings into the noses of ferrets [129]. It was later 
classified as influenza A virus, and was followed in 1940 and 1947 by influenza B and C 
viruses, respectively [46,84,136].  
The current system of nomenclature of influenza viruses, introduced in 1980, 
designates the type, host, place, strain number (if any), year of isolation, and antigenic 
subtype [147]. For example, a swine influenza virus isolated in Wisconsin in 1984 would 
be designated A/Swine/Wisconsin/1/84(H1N1). 
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The virus 
An enormous amount of information is available on antigenic, genetic, structural, and 
biological characteristics of influenza A viruses (for review, see [76,96]). Influenza A 
viruses have a spherical or filamentous morphology, and are medium-sized with a 
diameter of 80 to 120 nm (Fig. 1). The virus is enveloped, and the lipid membrane of the 
virion, is derived from the host cell in which the virus replicated. From the surface of the 
envelope the two transmembrane glycoproteins, HA and NA, commonly called spikes, 
extend (Fig. 2). The third transmembrane protein is the matrix protein M2, of which only 
20-60 molecules per virion are found. Underneath the envelope, the matrix protein M1 
forms a layer, which gives structure to the virus and encapsidates the ribonucleoprotein 
(RNP) complexes. These complexes consist of ribonucleic acid (RNA) associated with 
nucleoprotein (NP) and the polymerases PA, PB1, and PB2, responsible for RNA 
replication and transcription. Of the two nonstructural proteins, NS2 is found in the 
virion, while NS1 is only found in infected cells. The genome consists of eight unique 
segments of single-stranded RNA which are of negative polarity. 
Each RNA strand encodes only one protein, except for strands 7 and 8, which encode 
two proteins (Table 1). 
Figure 1. Electron micrographs of purified influenza virus virions and virions budding from the
surface of MDCK cells. Influenza virus negatively stained with HA (A) or M2 (B) (x 159,250), and
sections of influenza virus-infected MDCK cell with HA (C) or M2 (D), decorated with 10 nm gold
(x 40,600). Courtesy of George Leser, Northwestern University, Evanston, IL. 
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Figure 2. Schematic representation of influenza A virus.  
(Reproduced with permission from Fields Virology, third edition, 1996, Lippincott Williams and
Wilkins, Philadelphia). 
Table 1. Influenza A virus gene segments and encoded proteins (adapted from [76]) 
RNA segment Nucleotides Protein 
Amino 
acids 
Molecules 
per virion 
1 2341 polymerase PB2 759 30-60 
2 2341 polymerase PB1 757 30-60 
3 2233 polymerase PA 716 30-60 
4 1778 haemagglutinin HA 566 500 
5 1565 nucleoprotein NP 498 1000 
6 1413 neuraminidase NA 454 100 
7 1027 matrix protein M1 
matrix protein M2 
252 
  97 
3000 
20-60 
8 890 non structural protein NS1 
non structural protein NS2 
230 
121 
- 
130-200 
  
The replication cycle of influenza virus starts with the cleavage of the HA into HA1 and 
HA2 by enzymes present in the respiratory tract. These enzymes are produced by the 
host but also by bacteria, which can thus promote the influenza infection [132,133]. 
Virus grown in cells that lack a cleavage enzyme can be activated by treatment with 
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trypsin. After cleavage, the receptor-binding site of HA1 can attach to a terminal sialic 
acid residue of a cell surface receptor. Once attached to the host cell, the virus is 
endocytosed (receptor-mediated endocytosis) (Fig. 3). NA functions as a receptor-
destroying enzyme by cleavage of terminal sialic acid residues from the receptor. The 
NA thus releases progeny virions from the host cell in which they arose, and facilitates 
virus spread. The progeny virions can infect other cells or can be transmitted to another 
individual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of replication cycle of influenza viruses. (Reproduced with
permission from Fields Virology, third edition, 1996, Lippincott Williams and Wilkins,
Philadelphia). 
Host range and interspecies transmission 
Ducks and other waterfowl are the main natural hosts of influenza A viruses (Fig. 4). All 
15 HA and 9 NA subtypes exist among waterfowl. In these species, influenza viruses 
target the gastrointestinal tract rather than the respiratory tract, and the infections are 
almost without exception, completely subclinical, some ducks shedding virus for as long 
as 30 days. This, along with the migratory behaviour of waterfowl and the ability of 
influenza viruses to persist in cold lake water, contributes to the capacity of waterfowl to 
form an immense reservoir for influenza viruses in nature [99,144]. From this natural 
reservoir viruses are sometimes transmitted to other host species, less often are able to 
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continue spreading in the novel host, and sporadically cause high mortality. Examples of 
direct transmission to pigs, horses, mink, domestic poultry, and aquatic mammals 
causing infections of varying severity have been described [52,57,59,71,120,143,144]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4. The reservoir of influenza A viruses. The working hypothesis is that wild aquatic birds
are the primordial reservoir of all influenza A viruses. Transmission has been demonstrated from
pigs to humans, and vice versa, and from poultry to humans. There is extensive evidence for
transmission between other species. Adapted with permission from [96]. 
Occasionally, influenza A viruses of avian origin are directly transmitted to humans [72]. 
A recent example of direct transmission from birds to humans is the H5N1 virus that was 
isolated in 1997 from people in Hong Kong [19,28,131]. Eighteen people were shown to 
be infected of whom 6 died. The same virus had been shown to cause an outbreak in 
chicken farms with high mortality. Therefore, all poultry in Hong Kong, approximately 
1.5 million, were slaughtered. This mass slaughter may have prevented adaptation of the 
avian H5N1 virus to humans, which could have resulted in a human pandemic. Also, an 
H9N2 virus of avian origin was recently reported to have infected two children in Hong 
Kong [106] and five people in China. The greatest threat of these infections is probably 
the risk of a dual infection with a human virus, resulting in a reassortant virus with H5 or 
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H9 haemagglutinin, combined with all or some of the other genes from the human virus, 
thereby allowing transmission between humans (see below). 
It is still unclear which influenza virus proteins determine host range restriction 
and the available evidence indicates it is a polygenic trait. The receptor specificity of HA 
is considered one important determinant in host range restriction. Although influenza A 
viruses uniformly recognise cell surface oligosaccharides with a terminal sialic acid, 
their receptor-specificity varies. Most avian and equine viruses preferentially bind to the 
N-acetylneuraminic acid-α2,3-galactose (NeuAcα2,3Gal), linkage on sialyloligosaccha-
rides, while human and swine influenza viruses prefer the NeuAcα2,6Gal linkage 
[21,61,87,110,111]. Some amino acid substitutions in the HA responsible for this 
difference in receptor specificity were identified. Because for H1, the identified 
substitutions were also found in early H1N1 human and swine viruses, compared to 
avian viruses, it was suggested that they are important for the generation of H1 human 
pandemic strains [86]. The NP has been suggested to be another major determinant in 
host range restriction [47,121]. 
 
Reassortment, antigenic shift, antigenic drift, pandemics, and 
epidemics 
The two surface glycoproteins of the influenza virus, haemagglutinin (HA) and 
neuraminidase (NA), are the most important antigens for inducing protective immunity 
in the host and therefore show the greatest variation. Pandemics of influenza occur when 
a virus is introduced which is fully capable of replication and spread, and for which all 
or a large proportion of the population have had no immunological experience of at least 
the functionally important haemagglutinin.  
The sudden emergence of antigenically different strains in humans, termed 
antigenic shift (Fig. 5), is thought to have occurred through one of the following three 
mechanisms: 1) direct transfer of whole virus from another species. This probably 
happened in 1918, when the H1N1 Spanish flu virus entered the human population, 
resulting in the most devastating pandemic ever known. During the pandemic an 
estimated 20 to 40 million people died. 2) genetic reassortment of avian and human 
influenza A viruses infecting the same host. Because the genome of the virus is 
segmented, influenza virus gene segments can be exchanged in mixed infections with 
different strains of influenza viruses. When two viruses infect the same cell, progeny 
viruses may inherit sets of segments made up of combinations of segments of the parent 
viruses. By reassortment, the H2N2 Asian flu virus causing the pandemic of 1957 
acquired the HA, NA, and PB1 gene segment from an avian virus and kept the other five 
segments from the human H1N1 strain already circulating. The H3N2 Hong Kong flu 
virus of 1968, acquired the HA and PB1 of avian origin and six from the H2N2. 3) the 
re-emergence of a virus which may have caused an epidemic many years earlier. The 
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H1N1 Russian flu virus was a virus that circulated in humans prior to 1950, and re-
emerged in 1977, possibly following escape from a laboratory [144]. 
In 1957 and 1968, the introduction of a new influenza virus coincided with the 
disappearance of the earlier subtype, but this did not occur in 1977, and currently both 
H3N2 and H1N1 viruses are co-circulating. The reason for the sudden disappearance of 
the subtypes previously circulating is unknown but the earlier strain is possibly 
disadvantaged compared with the new strain because it has already elicited widespread 
immunity in the population. In addition, subtype cross-reactive (heterosubtypic) 
immunity may not allow the co-circulation of subtypes in a limited population.  
The emergence of new subtypes of influenza virus and the ensuing pandemics are 
unmistakable, but the epidemics occurring between the pandemics may nevertheless be 
severe. These are a result of the gradual change of the antigenicity of the circulating 
virus by point mutations in the HA, until the virus is sufficiently different from earlier 
strains so that a large proportion of the population is susceptible and cases reach 
epidemic levels. This accumulative variation is termed antigenic drift, and the size and 
severity of the epidemic will depend on the degree to which the virus is different from 
viruses already experienced by the population. 
Figure 5. Origin of human pandemic influenza A viruses. (Reproduced with permission from
Fields Virology, third edition, 1996, Lippincott Williams and Wilkins, Philadelphia). 
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Swine influenza and public health implications 
Swine influenza was first observed at the time of the pandemic in humans in 1918 and 
the virus was isolated and identified in 1930 by Shope [126])(Table 2). This H1N1 virus 
was the prototype strain of a group of viruses now known as classical swine influenza 
viruses. Serological studies have shown that classical swine H1N1 is prevalent 
throughout the major pig populations world-wide, with 25% of animals demonstrating 
evidence of infection [12,58]. In the USA they have remained antigenically conserved 
[81,125]. In Europe, these viruses disappeared, reappeared in 1976 [98], but have been 
replaced since 1979 by avian-like swine H1N1 viruses antigenically distinguishable 
from classical swine H1N1 viruses (Fig. 6). Around 1970, following the human Hong 
Kong flu pandemic, the human H3N2 virus was transmitted to pigs. This human-like 
swine H3N2 virus continued to circulate, particularly in Europe and Asia, but only 
sporadically caused clinical signs. It only started causing clinical disease since 1984 
probably as a result of a reassortment with the avian-like swine H1N1 virus. This 
reassortment resulted in a reassortant human-like swine H3N2 with the HA and NA of 
the human and all internal proteins of the avian virus (Fig. 6) [16]. This reassortant 
H3N2 virus has since replaced the original H3N2 virus in Europe. In the US, H3N2 
viruses only started to circulate recently, causing serious illness in sows, and 
reproductive losses. These viruses evolved from reassortments involving classical H1N1 
and human H3N2 viruses and are antigenically and genetically distinct from the 
European human-like H3N2 viruses [153]. 
In recent years a reassortant human-like swine H1N2 seems to become of 
increasing importance in Europe. It was first described in the United Kingdom [14] and 
subsequently also in Belgium [140]. This virus resulted from a reassortment involving a 
human H1N1 left over from the 1980s and a reassortant human-like H3N2 virus. Only 
the HA of the reassortant human-like H3N2 was replaced. Similarly, in the US, shortly 
after appearance of the reassortant H3N2 viruses, an H1N2 virus was isolated, which 
resulted from a reassortment involving a classical swine H1N1 virus and a reassortant 
H3N2 virus [64].  
All of the modern husbandry systems provide easy pig-to-pig transmission. 
Together with the high frequency of contact with other species, particularly humans, it 
provides an opportunity for co-circulation of viruses and genetic reassortment. Whereas 
reassortment and antigenic shifts occur frequently in pigs, antigenic drift is less 
pronounced in pigs than in humans. The availability of new susceptible piglets produces 
relatively low immune pressure and therefore may explain the reduced antigenic drift 
[32]. 
 15
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Origin of swine influenza A viruses currently circulating in pigs in Europe. In 1968, a
H3N2 Hong Kong influenza virus was transmitted from humans to pigs and started to circulate.
In 1979, a H1N1 virus was transmitted from ducks to pigs. In 1984, a reassortment occurred by
which the H3N2 virus acquired all proteins from the H1N1 virus, except for the HA and NA. In
1994, an H1N2 virus was isolated in the UK and subsequently in Belgium. This virus has become
of increasing importance in the UK and maybe in Europe. The virus was shown to have arisen
from a reassortment of a human Russian H1N1 virus with a reassortant human-like swine H3N2
virus. Only the HA was derived from the human H1N1 virus and phylogenetic analysis of this HA
suggested that the H1N1 virus had been circulating in pigs ever since the early 1980s. It is
possible that it is still circulating (?). The three viruses that resulted from these events are shown
on the right. These viruses regularly cause outbreaks of respiratory disease on pig farms in Europe,
today.  
Swine influenza is a zoonosis and pigs have been suggested to be an intermediate host 
and a mixing vessel in which genetic reassortment between human and avian viruses 
takes place [122]. The evidence supporting this role of pigs is as follows. i) Pigs are 
often in close contact with both poultry and humans. Especially in China, the influenza 
epicentre where new virus strains originate from, pigs are often kept close to people and 
ducks. ii) The same virus strains can infect and spread in both humans and pigs. Both the 
1918 H1N1, and 1968 H3N2 human pandemic strains continued to circulate in pigs. iii) 
Although humans can be infected with true avian viruses they were never shown to be 
able to spread among humans, unlike swine viruses (Fort Dix, New Jersey, 1976, [39]). 
iv) Genetic reassortment occurs frequently in pigs [14,16,153]. v) Pigs have cell surface 
receptors for both human and avian viruses [60], and pigs appear to host a broader range 
of NP genes in reassortant viruses, than both humans and birds [121]. vi) It was indeed 
reported that an avian-human reassortant from pigs in Europe caused disease in two 
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children [18]. The involvement of reassortment in at least the human pandemics of 1957, 
and 1968 shows that it is a successful event from the virus point of view and that it can 
be expected to also underlie a possible next human pandemic. In this respect, the 
presence in pigs of H9N2 subtype influenza viruses similar to those transmitted from 
birds to humans [54] is a potential threat to humans. 
In addition to being a possible source of reassortant influenza viruses, pigs could 
also be involved in direct transfer of avian viruses. Influenza in swine was first 
observed in the U.S. during the catastrophic 1918 to 1919 human influenza pandemic. 
Genetic analysis suggests that the influenza virus that caused the Spanish flu of 1918 
was not a reassortant, but a complete avian virus [49,134]. Sequences of gene 
segments of an influenza virus isolated from a soldier who died in 1918 revealed that 
this virus was genetically similar to swine influenza viruses. However, it remains unclear 
whether these viruses appeared first in people and then spread to pigs, or vice versa.  
Finally, pigs could be involved in the re-emergence of a virus, which caused an 
epidemic many years earlier. Pigs can be a reservoir, in which old human influenza 
strains are maintained [8,65,85,97,104]. Human viruses that are maintained in the pig 
population could be re-introduced in the human population when immunity has 
disappeared. After the 1918 human pandemic, H1N1 influenza viruses have continued to 
infect pigs in the United States ever since the 1930s (classical swine influenza H1N1). 
Human infections with swine influenza viruses have been documented in the US at least 
nine times since 1974 [24,146], including fatal infections, [70,105,112,128,137,145], as 
well as in Europe [26,27,109], and in New Zealand [35]. In 1976, several hundred U.S. 
military recruits were infected with an influenza virus A/NJ/8/76(H1N1), closely related 
to swine influenza viruses [48,67]. Consequently, a national program to vaccinate 
humans against A/NJ/8/76(H1N1) virus, and a surveillance program was initiated to 
investigate pigs and their human contacts. In addition, data suggest that zoonotic swine 
influenza infections occur more often among people in regular contact with pigs than the 
number of documented cases indicate [100,119]. Influenza viruses of the H3N2 subtype 
also persist in pigs many years after their antigenic counterparts caused the Hong 
Kong flu [55,127]. Thus, pigs provide a reservoir of influenza viruses and viral gene 
segments, which may in the future be transmitted to a susceptible human population.  
 
Clinical signs 
The disease caused by influenza viruses in pigs is essentially similar to that in humans, 
although generally somewhat milder. It consists of an acute febrile, respiratory disease 
characterised by fever (usually in the range 40.5-41.7 ºC), apathy, anorexia, and laboured 
breathing. Coughing may be apparent during the later stages of disease. Clinical signs 
seen less frequently include sneezing, nasal discharge, and conjunctivitis. 
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Table 2. Salient points in the history of swine influenza (adapted from [32]) 
1918 
 
 
1930 
 
1941 
1970 
1976 
1979 
 
1984 
 
 
1986 
 
1987 
 
1989 
1992-1993 
1993 
 
 
1994 
 
1992-1998 
 
1998 
 
1998 
 
 
 
1999 
 
2001 
Swine influenza H1N1 described in north central USA, Hungary, and China. 
May have been cause of human pandemic [62], causing 20-40 million human 
deaths. 
Shope isolated influenza virus from pigs [126]. The prototype classic swine 
influenza H1N1strain (A/Swine/Iowa/30) transmitted experimentally to pigs. 
Recognised in Europe and disappeared.  
Transmission of human H3N2 virus to pigs. Avian-like H3N2 in pigs in Asia. 
Classical H1N1 reappears in European pigs [98]. 
Introduction of whole H1N1 virus from birds to pigs. Antigenically 
distinguishable from classical strains. Still circulating today (2001). 
Reassortment between human H3N2 and avian H1N1 in swine resulting in 
reassortant H3N2 virus with avian internal gene segments [16]. H3N2 strains 
first associated with respiratory epizootics. Still circulating today (2001). 
Classical H1N1 reappears in UK, similar to classical H1N1 in continental 
Europe [111]. 
Reassortant H3N2 associated with respiratory epizootics in UK [107]. Related 
to A/Port Chalmers/73(H3N2) [107]. 
Avian-like swine H1N1 is dominant and widespread in Europe [4]. 
Avian-like H1N1 strains widespread in UK. 
Infection of children with reassortant H3N2 virus from pigs and isolation of 
avian-like swine H1N1 virus from a pneumonia patient in the Netherlands 
[18,109]. 
H1N2 first isolated in pigs in UK, and later also in Belgium. Human-avian 
reassortant virus [14,140].  
H3N1 (H3 human, N1 swine) [32] and H1N7 (H1 human, N7 equine) [32] 
also occurred in swine in the UK but failed to spread. 
H9N2 in pigs and humans in Asia [54]. Apparently an avian virus that has 
adapted to pigs. 
For the first time, H3N2 viruses cause severe disease in N. America. Viruses 
are triple (avian-human-classical swine) reassortants, distinct from earlier 
strains and European strains [153,154]. H1N2 identical to H3N2, but with 
H1HA from classical swine H1N1, also isolated [64]. 
Single case of isolation of avian H4N6 from pigs with pneumonia in Canada 
[63]. 
Current situation in Europe: avian-like H1N1, and reassortant human-like 
H3N2 and H1N2. In North America: classical swine H1N1, triple reassortant 
H3N2. 
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Morbidity may be up to 100%, with a low mortality rate and rapid recovery, usually five 
to seven days after the onset of clinical signs [40,98,126] (Loeffen, personal 
communication, 2001). Secondary bacterial infections can increase the severity of illness 
and may result in complications such as pneumonia. The gross lesions found in 
uncomplicated swine influenza are mainly those of a viral pneumonia. They are most 
often limited to the apical and cardiac lobes of the lungs, but in severe cases more than 
half of the lung may be affected. The altered lung areas are depressed and consolidated, 
dark red or purple red in colour, and contrast sharply with normal tissue. The airways are 
likely to be dilated and filled with blood-tinged, fibrinous exudate. The associated 
bronchial and mediastinal lymph nodes are usually enlarged.  
The extremely high morbidity has serious economic consequences due to the 
increased time needed to attain slaughter weight as a result of the infection. The cost has 
been estimated at up to £7 per pig, accounting for a financial loss to the pig industry in 
the UK of approximately £65 million each year [66].  
 
Epizootiology 
Swine influenza is widespread and endemic in pig populations world-wide and is 
responsible for one of the most prevalent respiratory diseases in pigs. Serologic 
examination of finishing pigs has shown the prevalence of the H1N1 and H3N2 strains 
to be 92% and 57%, respectively, in Belgium (1996, [82]), 73 and 62% in Spain (1992, 
[152]), 55 and 51% in Germany (1993, [51]), and 60% and 30% (1990, [42]), or 54 and 
13%, in the Netherlands (2001, Loeffen, personal communication). Although many 
infections may be subclinical, a field survey performed in the winter of 1995-96 in the 
Netherlands revealed that swine influenza virus is indeed a major cause of outbreaks of 
acute respiratory disease in finishing pigs [80]. Swine influenza H1N1 and H3N2 
infections were responsible for half of the cases of acute respiratory disease, and this was 
confirmed in a follow-up study that took place between 1996 and 2000 (2001, Loeffen, 
personal communication). 
Swine influenza is related to movement of pigs from infected to susceptible herds 
and clinical disease generally appears with the introduction of new pigs into the herd. 
Once a herd is infected, the virus is likely to persist through the production of young 
susceptible pigs and the introduction of new stock. Outbreaks of disease occur 
throughout the year but usually peak in the colder months [41]. Infection is often 
subclinical and typical signs are seen in only 25 to 30% of a herd. The primary route of 
transmission is through direct transmission by the nasopharyngeal route by aerosols 
formed either directly during coughing or sneezing or indirectly after physical contact. 
Nasal secretions are laden with virus during the acute febrile stages of infection, and pigs 
excrete virus for approximately 6 days. The severity of clinical disease is influenced by 
many factors, most importantly, maternal immunity, virus strain, route of inoculation, 
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and secondary bacterial infections. Maternal colostrum derived antibodies decrease the 
severity, and typical clinical signs are generally limited to seronegative pigs [41]. 
Of the viruses circulating in the UK, avian-like H1N1 seemed to cause more 
severe clinical disease outbreaks than the classical H1N1 and the reassortant human-like 
H3N2 viruses [10], and this has been confirmed experimentally. Classical H1N1 and 
reassortant H3N2 produced minimal gross lesions and mild interstitial pneumonia [33], 
while avian-like H1N1 produced marked gross lesions and more severe histopathological 
changes [11]. The amount of virus that reaches the deeper airways and the resulting 
production of infectious virus in the lungs determine the severity of illness. Although 
influenza virus replicates throughout the respiratory tract, the lungs seem to be the major 
target organ for virus replication. It has been reported that experimental inoculation of 
pigs with high virus quantities via the nasal route results in subclinical infections while 
intratracheal or aerosol inoculation produces typical clinical signs [83]. In humans, the 
infectious dose administered intranasally is 127 to 320 [22,23], and by aerosol 0.6 to 3 
TCID50 [1]. 
 
Immune responses 
Much of our knowledge about immune mechanisms operating against influenza is 
gained from studies in humans and rodents. However, the importance of swine in 
agriculture has resulted in a substantial increase in research efforts on the swine immune 
system during the past few years. Since many reagents used to study immunity in 
humans and rodents have also been developed for pigs, the roles of antibodies and T-
lymphocytes in immunity against many viral, bacterial, and parasitic infections could be 
better investigated in pigs (reviewed in [15,116]). Although limited differences may 
exist between immune responses in pigs and humans, the general mechanisms are the 
same. Also, the course of infection with influenza A virus in pigs is similar to that in 
humans [139], and the same influenza virus strains naturally infect both pigs and 
humans. In contrast, rodents are not natural hosts, and infection of rodents typically leads 
to lethal pulmonary infection. The pig, therefore, also seems a highly valuable model 
animal to study pathogenesis of, and immunity to, influenza in humans. 
Immune responses to infectious agents can be divided in non-specific innate 
responses and specific acquired responses. Non-specific immune responses to influenza 
virus infection include the production of cytokines, particularly interferons, and the 
activation of natural killer (NK) cells. NK cells kill infected cells, and thus limit 
replication and spread of the virus. Interferons are produced early in infection and may 
reduce viral spread by inducing an antiviral state in host cells and by activation of CTLs 
and NK cells, thereby contributing to recovery from infection.  
In addition to these non-specific immune mechanisms, influenza specific 
antibody responses and cellular immune responses are needed, to ultimately clear the 
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virus. Antibodies can contribute to the elimination of the infection, in principle in two 
ways by: (1) binding to infected cells and thereby reducing the production of progeny 
virus, termed cell-targeting (CT) activity, and 2) by binding with released progeny virus 
and thereby inhibiting the spread of the infection, termed virus neutralising (VN) activity 
[94]. Most antibodies produced, are directed against the HA, NA, NP and M proteins. 
Neutralising antibodies against the HA of influenza virus are highly effective in 
clearance of infection and resistance to infection and/or illness, whereas antibodies to NP 
and M1 are not [2,3,20,43,95,130]. However, non-neutralising antibodies to the HA and 
NA as well as to the extracellular part of the M2 also contribute. The synergism between 
CT and VN activity was suggested to underlie the high efficacy of HA-specific VN 
antibodies in combating influenza infection [94]. Not surprisingly, epitopes on the HA 
recognised by virus neutralising antibodies, are the most variable epitopes. 
After primary viral infection, antibodies of the IgM isotype are first produced 
followed by antibodies of the IgA and IgG isotype. IgM antibodies are highly efficient in 
aggregating virions and in mediating lysis of infected cells by complement via the 
classical pathway. IgA antibodies function mainly by binding to released virions 
(reviewed in [25]). Aggregated IgA, promotes phagocytosis by binding to 
polymorphonuclear neutrophils (PMN). In addition, IgA can mediate cellular lysis by 
complement via the alternative pathway. IgG antibodies can bind to released virions, 
promoting phagocytosis by PMN and macrophages, and mediate cellular lysis by 
complement via the classical pathway. In addition, IgG mediates antibody dependent 
cellular cytotoxicity (ADCC) by NK cells.  
Antibodies are transferred from the sow to the newborn piglets by means of 
colostrum. This passively acquired maternal immunity protects the piglets from clinical 
signs when infected during the first months of their life. The antibodies are mainly of the 
IgG isotype and generally do not prevent infection with influenza [9,91-93,108]. 
Maternal immunity is beneficial to the piglet as it allows the piglet to acquire active 
immunity without developing disease. However, for vaccination it is disadvantageous as 
it inhibits the induction of active immunity and can greatly reduce vaccine efficacy. 
The cellular immune response to influenza infection includes influenza virus-
specific T helper (Th) cells. They contribute to the clearance of the infection primarily 
by stimulating antibody production and proliferation of cytotoxic T lymphocytes 
(CTLs), and by production of cytokines [74,75,151]. It has been reported that Th cells 
specific for NP or M proteins can stimulate B-cells specific for HA [73,74,114,118]. 
Although a subset of CD4+ cells has been shown to have a cytotoxic effect on cells 
infected with influenza virus, Th cells by their own cannot clear virus infection 
[118,138,151]. CTLs kill virus infected cells when they recognise the viral peptides that 
are presented to them via MHC class I. They contribute to clearance of virus from the 
respiratory tract and accelerate recovery from infection [6,89,90]. CTL epitopes are less 
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abundant than B and Th cell epitopes and are mainly concentrated in the more conserved 
influenza virus proteins, like the NP [30,31,90]. CTLs directed against conserved 
antigens have been shown to confer protection against heterosubtypic influenza A 
viruses [79,124,150]. In addition numerous experiments in mice have demonstrated that 
CTLs can clear as well as protect against virus infection, in the absence of B and Th cells 
[44,50,135,148,149]. Moreover, a recent study showed that like mutations in HA and 
NA, allowing escape from antibody-mediated immunity, mutations in CTL epitopes 
occur to escape from CTL-mediated immunity, which gives credence to the belief that 
CTLs have a significant protective role [141]. However, despite the fact that 
heterosubtypic CTLs are induced following infection, they do not confer long-lived 
immunity against infection in humans [88]. 
After recovery from primary infection a long-lived immunity against the infecting 
virus is established. The immune system has adapted its effectors to optimally combat 
the virus and part of the effectors will continue to circulate for a considerable time. 
Especially antibodies of the IgG isotype will continue to circulate for a long time, while 
the quantity of IgA antibodies in the respiratory tract, and the number of Th and CTL 
will gradually drop. However, virus-specific IgA (and IgG) antibody producing cells 
(ASC), as well as Th and CTLs will now be present in the tissues lining the respiratory 
tract, and in local lymph nodes. Thus, the immune system has now built up a memory, 
which will immediately recognise the influenza virus upon secondary contact, leading to 
a faster, stronger, more localised and more accurate secondary response. Probably the 
individual, human or pig is life-long protected from clinical signs of a secondary 
infection with the same strain. When in 1977 the H1N1 virus reappeared in humans, 
people 20 years previously infected with H1N1 were still resistant to infection or disease 
[45]. Vaccination strives to establish long-lived immunity by artificially exposing 
individuals to the influenza virus without causing the clinical signs of a natural infection. 
However, as discussed above, influenza viruses gradually or abruptly change by 
antigenic drift or shift, respectively. While immunity will protect against re-infection 
with the same or a closely related virus, it will be less protective or absent when a more 
distant virus is encountered. In other words, immunity to influenza wanes over time, 
depending on the speed of antigenic drift of the virus, and little, if any, immunity exists 
to a virus of another subtype. The fact that heterosubtypic immunity appears weak in 
humans, as became clear during influenza pandemics of the last century, indicates that 
long lasting protective immunity after natural infection is primarily mediated by 
responses, particularly VN antibodies, to the surface glycoproteins. Possibly, infection 
induces responses, which are optimal in protection against homologous infection but not 
against heterologous or heterosubtypic infection. However, by surveillance and by 
determining the cross-reactive antigens, we may be able to guide the immune response in 
the right direction. The cross-reactivity of post-infection immune responses might be 
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improved upon by developing vaccines, which target epitopes other than those 
recognised by VN antibodies.  
Because of their continuous antigenic change and the ample availability of naive 
individuals in their natural hosts, influenza viruses, unlike most other pathogens, have 
not evolved mechanisms to evade specific acquired immunity. The immunity induced by 
the virus is highly effective, both in clearing the virus after primary infection as well as 
protecting against a secondary infection. However, the influenza virus may have an 
escape mechanism for innate immunity. An important function of NS1 seems to be to 
prevent induction of interferon α and β, thus escaping their early inhibitory effect on 
viral replication [7,142]. The absence of evasion mechanisms for specific immunity 
makes the influenza virus an ideal virus to study the proper function of acquired immune 
mechanisms. 
 
Diagnosis 
Influenza can be diagnosed by virus isolation, or by detection of viral antigen, viral 
RNA, or specific antibody. Virus can be isolated by inoculating embryonated chicken 
eggs or cell cultures with nasal mucus or pharyngeal mucus collected by swabbing the 
nasal passages or throat. The cytopathic effect can be observed in cell culture, and 
allantoic fluid or cell lysates can be tested for their ability to agglutinate chicken red 
blood cells, which is presumptive evidence for the presence of an influenza virus. The 
haemagglutinin subtype is determined by the haemagglutination-inhibition (HI) assay, 
and the neuraminidase subtype by the neuraminidase-inhibition (NI) assay [68].  
Other methods for detection of virus or viral components are: 
immunofluorescence on lung tissue [5], on nasal epithelial cells [101], or on 
bronchioalveolar lavage contents [113], immunohistochemical detection in fixed tissue 
[56], enzyme linked immunosorbent assay (ELISA) [77,78], polymerase chain reaction 
(PCR)[123], cell culture and immunoperoxidase staining for typing and subtyping [155], 
and a rapid enzyme-immunoassay membrane test (Directigen FLU-A)[115]. 
The most common serologic assay for diagnosis of swine influenza is the HI 
assay. An advantage of the HI assay is that it can discriminate between different 
subtypes and antigenic variants within a subtype. However, it also holds several 
disadvantages. It is relatively insensitive and may not detect a response if the infecting 
strain is antigenically different from the virus used in the assay. Thus, infections with 
new subtypes or antigenic variants within the subtype will not be detected. Therefore, 
the virus strains used in the assay need to be regularly updated. Also, it requires the use 
of paired serum samples, one obtained during the acute phase of the disease and the 
second 3-4 weeks later, to demonstrate an increase in antibody titre. In addition, the 
assay is very laborious, needs many standardised reagents, and is therefore prone to 
variation. 
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Diagnosis of the disease by virologic and serologic means is complicated in 
piglets with maternal antibodies. The virus recovery and severity of signs of disease are 
inversely related to the level of maternal antibody, and depending on the level of 
antibody, it may be very difficult to isolate virus [36,37,108]. Maternal antibodies also 
inhibit the active antibody production by the piglets and the serologic response may not 
be detected [36,108]. 
 
Vaccines 
Influenza vaccines currently in use for pigs are based on inactivated and disrupted 
(split) virus in an oil-adjuvant. In humans, inactivated whole or split virus, or purified 
preparations containing the surface glycoproteins HA and NA are used, and no adjuvant 
is licensed. The vaccines for pigs are bivalent, i.e. they contain representatives of both 
influenza A viruses (H1N1 and H3N2), while the human vaccines additionally contain 
influenza B virus. The composition of the human vaccine is reconsidered bi-annually by 
the WHO, for the Northern and Southern hemispheres, respectively. The WHO is 
advised by influenza centres all over the world, which monitor circulating viruses. 
Representative viruses are selected as vaccine strains and propagated in the allantoic 
cavity of embryonated chicken eggs.  
In pigs, antigenic drift of influenza viruses seems to be more limited than in 
humans [8,13,17]. This is probably because pigs have a short life span, which does not 
cover more than one influenza epidemic, and vaccines are not widely applied. 
Nevertheless, antigenic drift of the swine influenza A H3N2 viruses was demonstrated in 
the Netherlands and Belgium. This drift has led to a loss of cross-reactivity of recent 
field isolates with the human A/Port Chalmers/1/73 (H3N2), which is the current strain 
in the swine influenza vaccine. Therefore, replacement of this strain by a more recent 
swine H3N2 isolate has been recommended [29].  
In humans, live-attenuated virus vaccines have been extensively tested, as an 
alternative to the currently used vaccines, but are still not licensed. An advantage of 
these vaccines is that, when administered intranasally, they mimic natural infection and 
thus induce local secretory IgA (and local IgG), as well as CTLs, in addition to serum 
antibodies. In pigs however, injection is, at least currently, the only practical way of 
immunising. Moreover, a disadvantage of these live-attenuated vaccines is that it cannot 
be excluded that attenuated viruses reverse to wild-type virus. In addition, the segmented 
genome of the virus, makes it possible that if an individual is vaccinated while at the 
same time being naturally infected with an influenza virus, the attenuated vaccine strain 
can acquire wild-type gene-segments of the other virus strain, and at the same time many 
other reassortant viruses can also arise. 
In addition to vaccination, antivirals can be used for the control of influenza in 
humans. Amantadine and rimantadine, which inhibit viral replication by blocking the 
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M2 ion channel, and the neuraminidase inhibitors, zanamivir and oseltamivir are 
effective against all influenza A virus subtypes. However, vaccination will remain the 
major means to control influenza in humans [102], and the only means in pigs as 
antiviral treatments are not licensed for use against influenza in swine, and are probably 
not economically profitable. 
 
Aims and outline of this thesis 
The increasing economic importance of swine influenza, its zoonotic risk, and the 
unexpected antigenic drift observed, prompted us to intensify research on swine 
influenza virus infections in the field and on vaccine development. The studies described 
in this thesis deal with the factors that are relevant to the development of swine influenza 
vaccines, and hence, may be relevant to the development of human influenza vaccines. 
 They have the following objectives: investigate whether the observed antigenic 
drift in recent swine H3N2 viruses [29] is also observed in H1N1 viruses; develop a 
swine influenza challenge model and immunological assays; analyse the effect of 
maternal immunity on the active immune response to influenza infection; evaluate 
immunity after vaccination with a current commercial vaccine, and after infection with a 
homologous and heterosubtypic virus to attempt to correlate immune mechanisms with 
protection; and investigate how influenza vaccines could possibly be improved to induce 
longer, better and broader immunity.  
Chapter 2 describes the analysis of the antigenic and genetic variation in swine 
influenza H1N1 viruses. In chapter 3.1 the development of ELISAs for NP-specific IgM, 
IgG, and IgA, and their use in analysing systemic and mucosal isotype-specific antibody 
responses is described. In chapter 3.2 the quality of protection conferred by a 
commercial porcine influenza A vaccine or a previous infection is discussed in relation 
to the observed immune responses. Then, chapter 4 describes a study to investigate the 
effect of maternally derived antibodies (MDA) on clinical signs and on the immune 
response of piglets after a primary influenza infection, and on the subsequent protection 
against a secondary infection. Because a possible improvement to current vaccines 
would be to broaden the spectrum of protection to influenza A viruses, the immune 
mechanisms operating in broad-spectrum protection were investigated in the following 
study (Chapter 5.1). Finally, a study is described, in which the protection conferred by 
antibodies against the extracellular domain of the influenza M2 protein (M2e) only, or in 
conjunction with T-helper cells and CTLs was tested (Chapter 5.2). Pigs were 
immunised with a protein resulting from the fusion between the M2e and the Hepatitis B 
core protein, or were immunised with a DNA plasmid expressing an influenza M2e-
nucleoprotein fusion protein. The results of all studies described in this thesis are 
integrated and discussed in Chapter 6.  
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Heterogeneity in swine influenza H1N1 viruses 
 
Summary 
In order to explore the occurrence of antigenic drift in swine influenza A(H1N1) viruses 
and the match between epidemic and vaccine strains, 26 virus isolates from outbreaks of 
respiratory disease among finishing pigs in the Netherlands in the 1995/1996 season and 
reference strains from earlier outbreaks were examined using serological and molecular 
methods. In contrast to swine H3N2 viruses, no significant antigenic drift was observed 
in swine H1N1 viruses isolated from the late 1980s up to 1996 inclusive. However, a 
marked antigenic and genetic heterogeneity in haemagglutination inhibition tests and 
nucleotide sequence analyses was detected among the 26 recent swine H1N1 virus 
strains. Interestingly, the observed antigenic and molecular variants were not randomly 
distributed over the farms. This finding indicates independent introductions of different 
swine H1N1 virus variants at the various farms of the study and points to a marked 
difference between the epidemiologies of human and swine influenza viruses. The 
observed heterogeneity may hamper the control of swine influenza by vaccination and 
indicates that the efficacy of current swine influenza vaccines requires re-evaluation and 
that the antigenic reactivity of swine influenza viruses should be monitored on a regular 
basis.  
 
Introduction 
Influenza A(H1N1) and A(H3N2) viruses have been infecting swine for decades. In 
1918, at about the time of the Spanish Influenza pandemic, large epidemics of typical 
influenza were described among pigs in the USA. In 1930, Shope isolated the first swine 
influenza virus strain, A/swine/Iowa/15/30 (H1N1) [27], and similar viruses have been 
isolated from pigs in the USA ever since. Based on his serological studies on humans, 
Shope suggested that a virus closely related to A/swine/Iowa/15/30 (H1N1) had been 
responsible for the great human pandemic of 1918 [27]. That theory received support 
recently from nucleotide sequence data [21,22]. Presumably, therefore, the classical 
swine H1N1 influenza virus has remained an endemic infection of the pig population of 
North America since 1918. In fact, it is still responsible for a large proportion of the 
respiratory illnesses in these animals today [17]. 
Classical swine H1N1 virus remained confined to North America until the 1970s 
when it was introduced to Asia and Europe [25]. This virus started to circulate in Europe 
in 1976, mainly in Italy [18]. Since the late 1970s, however, the classical swine H1N1 
virus has been gradually replaced in Europe by a newly introduced H1N1 virus from 
birds [19]. This avian virus first emerged in pigs in Northern Europe and became 
established as a stable lineage without reassortment with human influenza viruses 
[4,24,26] and with little antigenic change [4]. Serious disease resulting from infections 
of humans with these viruses has been reported [5,7]. In the present paper, we describe a 
study on the antigenic and molecular properties of a number of swine H1N1 virus strains 
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isolated in the Netherlands in 1995/1996 during a field survey [14]. The purpose was to 
detect antigenic changes, possibly necessitating examination of the efficacy of the 
currently used swine influenza vaccine. A similar analysis has already been published 
for the H3N2 viruses isolated during the same study [8]. 
 
Materials and methods 
Virus strains 
In a field survey during the 1995/1996 winter season, 16 outbreaks of acute respiratory 
disease in 11- to 20-week-old piglets on 16 farms in the Netherlands have been 
examined using virological and serological methods [14]. In each outbreak, lung tissue 
was collected from four pigs at necropsy during the acute stage of disease. For virus 
isolation, we used standard procedures to prepare primary cultures of porcine thyroid 
taken from ca. 6-week-old pigs of the specific pathogen-free herd of ID-Lelystad. The 
cells, most of which had an epitheloid appearance, were incubated in Eagles Minimal 
Essential Medium with 0.5% lactalbumin hydrolysate supplemented with 10% foetal 
bovine serum for growth and 3% foetal bovine serum for maintenance of the cells. No 
trypsin was added. Cell cultures were inoculated with a homogenate of inflamed lung 
tissue and inspected for cytopathic effects for seven days.  
Five of the 16 examined outbreaks of 1995/1996 were associated with H1N1 
virus infection, five with Actinobacillus pleuropneumoniae infection, one with 
concurrent infections with H1N1 virus and Actinobacillus pleuropneumoniae, and two 
with H3N2 virus infection, whereas no clear cause could be established for the other 
three outbreaks [14]. Earlier, we analysed the H3N2 viruses isolated in the 1995/1996 
and 1996/1997 seasons [8]. In the present study, we examined, in detail, all 26 H1N1 
virus strains isolated in the period from January 1996 up to April 1996 inclusive, i.e., 
from six herds at six farms. The farms were located in an area with a radius of about 40 
km. Not a single species of pathogenic bacteria, including Mycoplasmata, could be 
isolated from all the affected lungs in any of the six 1995/1996 outbreaks from which 
influenza virus was isolated. No influenza vaccines had been administered on the farms 
with a documented H1N1 influenza outbreak.  
The designation of influenza virus strains in the present paper follows the 
internationally accepted rules and consists of type/animal/place of isolation/sequential 
number/year of isolation (subtype): for example, A/swine/Best/5M/96 (H1N1). No 
animal species is indicated for human isolates. Reference swine and human H1N1 virus 
strains were obtained from various sources (Table 1) and passaged in monkey kidney 
cell culture or Madin-Darby canine kidney (MDCK) cell culture before use in 
haemagglutination inhibition (HI) assays [6]. One of the reference viruses, 
A/Netherlands/386/86 (H1N1), had been isolated from a 29-year-old farmer in the 
Netherlands early in 1986 and proved to be swine-like as demonstrated by serological 
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methods and nucleotide sequence analysis [5,23]. 
 
Sera and antisera 
For each outbreak, paired blood samples were collected in the acute stage and four 
weeks later from ten group mates of the pigs which were killed for necropsy and virus 
isolation. In five of the six herds where H1N1 virus was isolated and found responsible 
for the outbreak, seroconversions occurred in nine or ten out of ten tested group mates, 
confirming H1N1 virus as the main cause of these outbreaks. In the herd on farm 16, 
antibodies against H1N1 virus were already present in nine out of ten tested group mates 
tested, and only one of the pigs seroconverted [14]. No other clinical material was taken 
and no influenza virus isolates were obtained from these group mates, therefore.  From 
each farm, two of the convalescent sera were used in the panel for the antigenic 
characterisation of the influenza virus strains. 
Ferret antisera were prepared by intranasal infection and bleeding 14-18 days 
later. The chicken antiserum to A/swine/England/195852/92 (H1N1) was a gift from Dr 
I. Brown, Weybridge, UK. Pigs were vaccinated with a commercial influenza vaccine 
that contained, among others, strain A/swine/Netherlands/25/80 as the H1N1 virus 
component. After four weeks, the animals got a booster immunisation with the same 
vaccine. The immune sera used in the present study were obtained four weeks after the 
booster. All sera were treated with receptor-destroying enzymes (RDE) present in locally 
prepared cholera bacterium filtrate before use in HI assays.  
 
Antigenic characterisation 
The HI reactivities of the various H1N1 strains were examined in three different sessions 
with standard HI assays [6] in microplates using turkey erythrocytes. The variance of the 
three paralel determinations with the same serum samples was 1.25. Some antisera in 
low dilutions agglutinated the erythrocytes by unknown mechanisms, thus precluding the 
detection of serum HI activity at these dilutions against the viruses being tested. The 
antigenic reactivities of the neuraminidases (NAs) were assessed in biochemical 
neuraminidase inhibition tests (NI) as described [7]. In short, NA activities of the virus 
strains were determined by measuring the quantity of N-acetyl neuraminic acid liberated 
after incubation of dilutions of the virus with the substrate fetuin, using a colorimetric 
method. Subsequently, virus dilutions yielding an OD value at 549 nm between 0,45 and 
0,85 were treated with Triton-X-100 to release the NA from the virus particles and (also 
in three different sessions) incubated with 3-fold antiserum dilutions starting at a dilution 
of 1:5. Serum NI titres were expressed as the reciprocal of the serum dilution giving a 
50% reduction of the OD value of the virus control. 
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Virus strain (a) Abbreviation Isolated in Supplier Accession number (b)
A/swine/Iowa/15/30 ("S15") (H1N1) Iowa/30 USA Fort Dodge (c) AF091308 (HA)
A/swine/Hong Kong/1/74 (H1N1) HK/74 China, SAR Mill Hill (d) X57491 (HA)
A/New Jersey/8/76 (H1N1) NJ/76 USA Mill Hill (d) not used
A/swine/Italy/1443/76 (H1N1) Ital/76 Italy Mill Hill (d) not used
A/swine/Netherlands/25/80 (H1N1) N25/80 the Netherlands authors AF320067 (HA) (e)
A/swine/France/3614/84 (H1N1) France Lyon (f) AF320056 (HA) (e)
A/swine/Netherlands/12/85 (H1N1) the Netherlands authors AF320061 (HA) (e)
A/Netherlands/386/86 (H1N1) N386/86 the Netherlands authors AF320065 (HA) (e)
A/swine/Geneva/5175/86 (H1N1) Gen/86 Switzerland Geneva (g) not used
A/swine/Netherlands/711/89 (H1N1) N711/89 the Netherlands authors not used
A/swine/Belgium/V233/91 (H1N1) Bel/91 Belgium Ghent (h) not used
A/swine/England/195852/92 (H1N1) Eng/92 United Kingdom Weybridge (i) L40332 (NP)
A/swine/France/525/94 (H1N1) France Lyon (f) AF320059 (HA) (e)
A/swine/Best/5C/96 (H1N1) 5C (j) the Netherlands authors AY038349 (HA)
AF393516 (NA), AF393530 (NP) (e)
A/swine/Best/5J/96 (H1N1) 5J the Netherlands authors AY038350 (HA) (e)
A/swine/Best/5K/96 (H1N1) 5K the Netherlands authors AY038351 (HA) (e)
A/swine/Best/5M/96 (H1N1) (Best/)5M the Netherlands authors AY038352 (HA) (e)
A/swine/Best/5R/96 (H1N1) 5R the Netherlands authors AY038353 (HA) (e)
A/swine/Best/5T/96 (H1N1) 5T the Netherlands authors AY038354 (HA) (e)
A/swine/Dongen/6B/96 (H1N1) 6B the Netherlands authors AY038355 (HA)
AF393518 (NA), AF393529 (NP) (e)
A/swine/Dongen/6D/96 (H1N1) 6D the Netherlands authors AY038356 (HA) (e)
A/swine/Dongen/6J/96 (H1N1) 6J the Netherlands authors AY038357 (HA) (e)
A/swine/Dongen/6T/96 (H1N1) 6T the Netherlands authors AY038358 (HA) (e)
A/swine/Nederweert/13A/96 (H1N1) 13A the Netherlands authors AY038333 (HA)
AF393513 (NA), AF393528 (NP) (e)
A/swine/Nederweert/13G/96 (H1N1) 13G the Netherlands authors AY038334 (HA) (e)
A/swine/Nederweert/13H/96 (H1N1) 13H the Netherlands authors AY038335 (HA) (e)
A/swine/Nederweert/13I/96 (H1N1) 13I the Netherlands authors AY038336 (HA) (e)
A/swine/Nederweert/13O/96 (H1N1) 13O the Netherlands authors AY038337 (HA) (e)
A/swine/Someren/14A/96 (H1N1) 14A the Netherlands authors AY038338 (HA)
AF393514 (NA), AF393527 (NP) (e)
A/swine/Someren/14C/96 (H1N1) 14C the Netherlands authors AY038339 (HA) (e)
A/swine/Someren/14J/96 (H1N1) 14J the Netherlands authors AY038340 (HA) (e)
A/swine/Someren/14M/96 (H1N1) 14M the Netherlands authors AY038341 (HA) (e)
A/swine/Leende/15C/96 (H1N1) 15C the Netherlands authors AY038342 (HA) (e)
A/swine/Leende/15E/96 (H1N1) 15E the Netherlands authors AY038343 (HA) (e)
A/swine/Leende/15Q/96 (H1N1) 15Q the Netherlands authors AY038344 (HA) (e)
A/swine/Leende/15R/96 (H1N1) 15R the Netherlands authors AY038345 (HA) (e)
A/swine/Leende/15S/96 (H1N1) 15S the Netherlands authors AY038346 (HA) (e)
A/swine/St. Anthonis/16B/96 (H1N1) 16B the Netherlands authors AY038347 (HA)
AF393515 (NA), AF393526 (NP) (e)
A/swine/St. Anthonis/16F/96 (H1N1) 16F the Netherlands authors AY038348 (HA) (e)
A/swine/Boxtel/144-15/97 (H1N1) the Netherlands authors AF393517 (NA), AF393525 (NP) (e)
A/swine/Ommel/152-15/97 (H3N2) the Netherlands authors AF393519 (NP) (e)
A/swine/Mierlo/155-15/97 (H3N2) the Netherlands authors AF393520 (NP) (e)
A/swine/Breugel/2511-13/97 (H3N2) the Netherlands authors AF393521 (NP) (e)
A/swine/Haaksbergen/2767-13/97 (H3N2) the Netherlands authors AF393522 (NP) (e)
A/swine/Heino/2627-11/97 (H3N2) the Netherlands authors AF393523 (NP) (e)
A/swine/St. Oedenrode/7C/96 (H3N2) the Netherlands authors AF393524 (NP) (e)
/swine/Mariahout/150-12/97 (H3N2) the Netherlands authors AF393531 (NP) (e)
Table 1. Origins of swine and swine-like influenza A(H1N1) viruses examined in the present
study and accession numbers for the nucleotide sequences. 
A
 
(a) Strains coded with swine were isolated from pigs, all other strains originated from humans.
(b) Accession numbers for nucleotide sequences derived from or deposited at GenBank or EMBL
databank. (c) Fort Dodge, Animal Health, Weesp, the Netherlands. d) n.a.: not available. (e) Mill
Hill: Dr. A.J. Hay, World Influenza Centre, Mill Hill, United Kingdom. (f) cDNA of strains with
an accession number marked (f) was sequenced by the authors. (g) Lyon: Professor M. Aymard,
University Claude Bernard, Lyon, France. (h) Geneva: Dr. M.F. Paccaud, National Influenza
Centre, Institute of Hygiene, Geneva, Switzerland. (i) Ghent: Dr. M. Pensaert, Faculty of
Veterinary Medicine, University of Ghent, Belgium. (j) Weybridge: Dr. I.H. Brown, Central
Veterinary Laboratory, Weybridge, United Kingdom. 
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Nucleotide sequence determinations and phylogenetic analyses of the 
haemagglutinin (HA) gene 
Stretches comprising 509 nucleotides and containing the most variable sites of the HA1 
parts of the HA gene fragments of all 26 swine H1N1 virus isolates from the 1995/1996 
outbreaks were amplified directly from the virus preparations by reverse transcription 
and polymerase chain reaction (PCR). Subsequently, the nucleotide sequences of these 
stretches were determined, using the Dyenamic Direct Cycle Sequencing Kit 
(Amersham, Little Chalfont, UK) and a 373 Sequencer (Perkin-Elmer/Cetus, Norwalk, 
CT, USA). Phylogenetic trees were constructed using the Clustal and the DNA-DIST, 
FITCH and DRAWTREE programs ("Phylip", i.e. Phylogeny Inference Package, 
software package, version 3.572, Joseph Felsenstein 1993, University of California, 
Berkeley, CA, USA). Corresponding nucleotide sequences of some influenza viruses, 
marked by asterisks in Fig. 1, were obtained from either GenBank or the data bank of the 
European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. The newly 
determined nucleotide sequences were submitted to the GenBank database. Assigned 
accession numbers of all sequences used in the study are given in Table 1. 
 
Results 
HI assays with post-infection animal sera 
Using a panel of 21 post-infection sera from experimentally infected ferrets and chickens 
and from pigs naturally infected at the farms during the various outbreaks, we observed a 
marked heterogeneity among the 26 swine H1N1 virus strains isolated at six farms in the 
1995/1996 season (Table 2). Applying the definition that strains showing HI titres that 
differed at most by a factor of two with each of the 21 sera belong to the same variant, 
we could discern ten variants. When according to this criterion different groupings could 
be made, the grouping resulting in the smallest intra-variant differences was chosen. The 
differences in median HI titres between the ten variants ranged from 2-fold to 48-fold. 
The ferret antisera had the largest discriminatory power, but also the swine sera revealed 
significant antigenic differences among the 26 isolates. When we arranged the strains 
according to the farms of origin, the variants proved not to be distributed randomly over 
the farms (Table 2). Most of the variants occurred only at one farm except HI variant 5, 
which was detected on two farms (13 and 15). On the other hand, most farms had more 
than one HI variant circulating. In general, the swine sera randomly taken after the 
outbreak, displayed HI titres to the virus isolates from the same farm which are higher 
than or equal to the HI titres to strains from other farms. This finding confirms that the 
virus strains given in the first column of Table 2 are generally responsible for the 
majority of the infections occurring at the concerning farm. 
Exceptions are sera S278 and S280, originating from farm 14, that showed higher 
titres to strains S16B and S16F isolated from farm 16 than to strains S14A, S14M, S14C,  
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Footnotes table 2. Twenty-six swine H1N1 influenza virus strains were isolated on six farms,
numbered 5, 6, 13, 14, 15, and 16, which experienced an influenza outbreak in the 1995/96 season.
The letters of the virus strain codes mentioned in the second column refer to the individual animals
from which the concerning strains were isolated. The full names of the viruses used for the
preparation of ferret antisera can be found in Table 1. Sera indicated by "S" followed by a number
were obtained from naturally infected pigs at the farm indicated above the serum number. No
isolates were available from these animals and, therefore, no homologous titres can be given for
these sera. Within a variant, the differences in HI titre of each of the (anti)sera are not more than
twofold. Reference HI titres calculated as the means of the values for variant 1 are presented in row
5 of the table. Differences of a factor of 2 or 3 between a given HI titre and the corresponding
reference titre are printed in a light grey field, those of a factor of ≥4 in a dark grey field. 
 
and S14J from farm 14 (Table 2). Whether this exception could be explained by a higher 
avidity for antibodies of the S16 virus strains compared with the S14 strains, or by the 
circulation of several virus variants on farm 14 (including the variant found on farm 16) 
is not known. The ferret antiserum to A/swine/Netherlands/25/80, one of the current 
H1N1 swine vaccine strains [11], showed HI titres to the 26 isolates which in most cases 
were more than fourfold lower than to the homologous strain. Table 3 presents a 
summary of the cross-reactivities of reference swine H1N1 viruses isolated between 
1930 and 1992, and representative strains from each of the swine H1N1 virus variants 
isolated in the present study. The first four virus strains listed in the table are classical 
swine H1N1 viruses, whereas all the other swine strains belong to the avian-like swine 
lineage. In line with earlier observations [28], these data reveal little antigenic drift in the 
avian-like swine H1N1 viruses. Only the antiserum to A/swine/Best/5M/96 showed 
evidence of antigenic drift during the 1980s. 
 
Antibody response of swine after vaccination with a commercial influenza vaccine  
In order to address the question whether the described findings are relevant for the 
efficacy of swine influenza vaccines, we titrated in HI tests sera from eleven vaccinated 
and three unvaccinated pigs against one of the current vaccine strains, namely  
A/swine/Netherlands/25/80, and six swine H1N1 virus isolates from the present study, 
each representing one of the ten variants defined in section 3.1. Apart from one of the 
vaccinated pigs (no 252) which had not significantly responded, the vaccinated pigs 
showed titres against strain 16B that were equal to those against 
A/swine/Netherlands/25/80 (Table 4). The titres against the other five strains, however, 
were on average between 6 and 12-fold below the titres against the vaccine strain. Sera 
from the three non-vaccinated control pigs were negative against all seven viruses tested.  
 
Nucleotide sequence analyses of the haemagglutinin gene (HA)  
For the same 26 virus strains, the nucleotide sequences of a fragment of 509 basepairs 
representing a variable portion of the HA1 domain were determined and compared (Fig. 
1). The sequence differences ranged from 0 to 3.8% at the nucleotide level and  
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Figure 1. Phylogenetic tree of part of the HA1 genes of 26 swine influenza A(H1N1) virus strains
isolated in the Netherlands in 1995/1996. The strain codes are explained in Table 1. Compared
nucleotide sequences range from position 301 to 809 (numbering corresponding to the positions in
the HA1 of A/swine/Schleswig-Holstein/1/93 as derived from GenBank), comprising 509
nucleotides. The horizontal scale bar represents a difference of 1%. 
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Figure 2. Phylogenetic tree of part of the HA1 genes (sequence fragment as in Fig.1) of influenza
A(H1N1) virus strains. The figure shows the relationships of six swine strains isolated in the
Netherlands in 1995/1996 (printed in bold italic type) and 16 reference strains. Sequences of
strains marked with an asterisk were derived from either GenBank or the databank of the
European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. The horizontal scale
bar represents a difference of 10%. 
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Table 3. Haemagglutination inhibition (HI) assays with post-infection ferret antisera to swine and
human influenza A(H1N1) viruses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virus strain Passage HI titres (a) of sera from ferrets (F) infected with 
history (b) Iowa/30 Ital/76 N25/80 N386/86 N711/89 Bel/91 Eng/92 Best/5M
F96 F124 F89027 F562/3 F89013 F93001 F588/9 F571
A/swine/Iowa/15/30 (c) XMK2 5120 20 80 40 <10 40 40 <10
A/swine/Hong Kong/1/74 (c) XMK1 1280 640 40 40 <10 40 20 <10
A/New Jersey/8/76 (c) XtMK3 640 2560 640 320 <10 160 320 <10
A/swine/Italy/1443/76 (c) XMK3 <10 1280 320 1280 <10 80 160 <10
A/swine/Netherlands/25/80  XtMK1 160 160 2560 1280 40 640 320 <10
A/swine/Geneva/5175/86  XtMK1 <10 160 640 1280 40 640 640 40
A/Netherlands/386/86  tMK3 <10 160 320 1280 40 320 640 80
A/swine/Netherlands/711/89  XtMK1 40 80 320 1280 160 640 320 640
A/swine/Belgium/V233/91 XtMK1 <10 80 320 1280 80 1280 640 320
A/swine/England/195852/92  XtMK3 80 80 320 1280 160 1280 640 640
A/swine/Best/5M/96  Pthyr2 <10 40 80 5120 320 2560 1280 5120
A/swine/Best/5T/96  Pthyr2 (b) 20 80 320 40 320 640
A/swine/Dongen/6D/96  Pthyr2 <10 80 320 1280 160 1280 640 1280
A/swine/Dongen/6J/96 Pthyr2 40 40 2560 320 1280 1280
A/swine/Nederweert/13A/96 Pthyr2 80 320 2560 320 2560 1280
A/swine/Nederweert/13H/96 Pthyr2 20 80 2560 320 1280 2560
A/swine/Nederweert/13I/96 Pthyr2 20 80 2560 320 1280 2560
A/swine/Someren/14A/96 Pthyr2 <10 40 160 640 80 640 320 640
A/swine/Someren/14C/96 Pthyr2 20 40 1280 80 640 1280
A/swine/St. Anthonis/16B/96 Pthyr2 320 1280 320 80 1280 320
A/Netherlands/1/93 XtMK3 <10 <10 <10 <10 <10 <10 <10 <10
 
 
 
 
(a) Homologous titres in bold print. Blank entry means not done. 
(b) X is passage history at receipt, MK is primary and tMK is tertiary cynomolgus monkey kidney
cell culture, Pthyr is primary porcine thyroid cell culture. 
(c) The strains in the four top rows are classicalswine H1N1 virus strains. 
confirmed the farm-bound heterogeneity observed in HI assays. Five viruses were 
isolated on farm 15 and all five belonged to a single variant that was not observed on the 
other farms. Each of the other five farms had various sequence variants circulating that 
differed, however, in most cases only at 1-2 nucleotide positions. When these small 
differences are disregarded and a threshold of 1% difference is used, five clusters can be 
distinguished, comprising - arranged in the order of Fig.1 from top to bottom - the strains 
from farm 16, 6, 14, 5, and 13+15, respectively. On each farm, only one cluster was 
found and each cluster occurred on only one farm, except for the 13+15 cluster, which 
was isolated on both the farms 13 and 15. The results of the HI tests are in agreement 
with our nucleotide sequence data: strains with different HI reactivities display different 
HA1 sequences, whereas strains with similar HI reactivities are found on the same 
branch in the phylogenetic tree constructed on the basis of 509 nucleotides of the 
variable part of the HA1 fragment (Fig. 1). For each of the ten antigenic variants, the 
partial amino acid sequence of the HA1 molecule as deduced from the nucleotide 
sequences differs from those of the other nine variants by one to ten amino acid residues. 
Thirty-six of these 45 comparisons between the amino acid sequences showed at one or 
more positions different amino acids that were located at or were adjacent to positions 
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for which in human H1N1 viruses a relation to antigenic change has been made probable 
[20].  
By comparing corresponding nucleotide sequences of the HA1 gene, the recently 
isolated swine H1N1 viruses appeared to fit roughly in chronological order into the 
group of other European swine H1N1 viruses which have an avian origin (Fig. 2). They 
are less closely related to the classical swine H1N1 viruses circulating in other parts of 
the world. 
 
Neuraminidase inhibition (NI) assays 
Three swine H1N1 virus strains representing three different HI variants proved only 
marginally different in NI assays (Table 5). For example, using anti-A/swine/Best/5M/96 
antiserum, the difference in NI titres between A/swine/Best/5M/96 and 
A/swine/Someren/14A/96 was 2.7-fold (in three tests: 2.3, 2.3, and 3.5-fold, 
respectively). The same antiserum distinguished A/swine/Someren/14A/96 and 
A/swine/Leende/15C/96 only by a factor 2.0 (in three tests: 2.0, 1.3, and 2.6, 
respectively).  
 
Nucleotide sequence analyses of the neuraminidase (NA) and nucleoprotein genes  
In agreement with the serological data and similar to the HA genes, the nucleotide 
sequences of the NA genes of five strains representing five different HI variants proved 
to be closely related (Fig. 3). The differences range from 2.7 to 6.0%. Also the sequences 
of the nucleoprotein genes of the same five strains showed differences, which range from 
1.1 to 3.3% and are, therefore, of the same magnitude as those found among the various 
HA and NA genes (Fig. 4). In line with the common avian origin of the nucleoprotein, 
sequences of this gene of the 13 examined swine H1N1 and H3N2 strains from the 
1995/1996 and 1996/1997 surveillance did not cluster according to the subtype of the 
HA and NA (Fig. 4). 
 
Discussion 
In contrast to swine H3N2 virus strains [8], the recently isolated swine H1N1 virus 
strains displayed a marked antigenic heterogeneity in HI tests, even though they 
originated from a small region and in a single season (Table 2). Moreover, the ten 
described HI variants were not randomly distributed over the six farms of the study. 
Nucleotide sequencing showed the potential molecular basis of the antigenic 
heterogeneity by revealing five clusters which differed among each other at ≥1% of the 
nucleotide positions (Fig. 1). Each of these sequence clusters was confined to a single 
farm, with the exception of one cluster, that was found on two farms. As mentioned 
above, the amino acid sequences of the HA1 molecule of each of the ten antigenic 
variants differ from those of the other nine variants by one to ten amino acid residues.  
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 Figure 3. Phylogenetic tree of part of the NA genes of influenza A virus strains of subtype N1.
The figure shows the relationships of five swine influenza A(H1N1) virus strains isolated in the
Netherlands in 1995/1996 (printed in bold italic type) and one in 1996/1997, and six reference
strains of various HA subtypes, marked with an asterisk. The reference sequences were derived
from either GenBank or the databank of the European Molecular Biology Laboratory (EMBL),
Heidelberg, Germany. Compared nucleotide sequences range from position 21 to 357 (numbering
corresponding to the positions in the HA1 of A/goose/Guangdong/1/96*), comprising 337
nucleotides. The horizontal scale bar represents a difference of 10%. 
 
 
 
 
 
 
The majority of these amino acid substitutions occurred in, or in close proximity to, 
variable positions of the HA1 that are potentially associated with antigenic drift of 
human H1N1 viruses [20] and could therefore play a role in determining the antigenic 
heterogeneity. This finding contrasts with a paper reporting that among avian-like swine 
H1N1 viruses the mutations were distributed randomly across HA1 and not associated 
specifically with regions that have been determined or proposed to influence antigenic 
properties of the influenza virus [3]. Nucleotide sequencing of the nucleoprotein genes 
of five strains, each representing one of five different farms, confirmed the 
epidemiological unrelatedness of strains isolated on different farms (Fig. 4).  
Our observations indicate that the introduction of the swine H1N1 viruses at the 
various farms generally occurred along epidemiologically independent routes and that 
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Figure 4. Phylogenetic tree of part of the nucleoprotein genes of five swine influenza A(H1N1)
virus strains isolated in the Netherlands in 1995/1996 (printed in bold italic type) and one in
1996/1997, seven swine influenza A(H3N2) virus strains isolated in the Netherlands in
1995/1996 and 1996/1997 (de Jong 1999), and six reference strains, marked with an asterisk. The
reference sequences were derived from either GenBank or the databank of the European
Molecular Biology Laboratory (EMBL), Heidelberg, Germany. Compared nucleotide sequences
range from position 12 to 376 (numbering corresponding to the positions in the HA1 of
A/swine/Italy/839/89*), comprising 365 nucleotides. The horizontal scale bar represents a
difference of 1%. 
 49
Heterogeneity in swine influenza H1N1 viruses 
 
transmission of these viruses between the farms was minimal or absent. In agreement 
with this conclusion, inquiries at the concerning farms about the origin of their pigs in 
the period of 1993 to 1996 showed that all farms had different suppliers. Although we 
were unsuccessful in obtaining swine H1N1 virus strains from the same farm in different 
seasons, the observed sequence micro-heterogeneity within the clusters suggests that the 
clusters had maintained themselves at the various farms or their suppliers for more than 
one year, allowing the emergence of several micro-variants. As far as we know, no 
comparable epidemiological behaviour has been reported for human influenza viruses. 
Interestingly, virological researchers of swine influenza had already proposed the same 
hypothesis 25 years ago on epidemiological grounds, stating: The fact that disease 
commonly occurs only once a year on a given farm and tends to recur annually on that 
same farm suggests that virus might be resident on the farm itself. [10]. In line with this 
hypothesis, 80 to 90% of the sows in the Netherlands have HI antibodies to either or 
both swine H1N1 and H3N2 virus [12]. Because of their low numbers and long stay of 
the sows at the farm, it seems unlikely that influenza viruses can be maintained among 
these animals. Virus circulation, therefore, probably depends on infection of piglets, 
which are frequently born or newly introduced at the farms. When they are growing 
older, maternal antibodies are waning and the animals become susceptible to influenza 
virus. 
The few studies providing information on the genetic changes in the HA of avian 
swine H1N1 viruses indicate a considerable evolutionary rate over the time period of 
1979-1993 [3,15]. To our knowledge, no data for genetic heterogeneity among these 
viruses isolated in a single country during a single season has been published. Reports on 
antigenic reactivity in HI tests do not produce clear evidence for antigenic drift of avian 
swine H1N1 viruses during the period 1981-2000 [9,16]. Marked differences between 
their HI profiles, however, were observed among such viruses isolated in Brittany, 
France, in a single year (1999) [16]. The latter finding is in line with the antigenic 
heterogeneity detected in the 26 swine H1N1 viruses examined in the present study, and 
contrasts with the antigenic homogeneity of 13 swine H3N2 virus strains obtained during 
the same field survey [8]. On the other hand, we found a systematic antigenic drift of 
swine H3N2 viruses during the 1990s [8], but not in swine H1N1 viruses isolated 
between 1989 and 1996 (Table 3). The latter observation recalls the antigenic stability of 
the human H1N1 viruses circulating in Europe between 1986 and 1998 [1,2], whereas 
considerable cumulative genetic changes occurred in the same period. 
Our findings may have implications for the influenza vaccination policy for 
swine. The results of the HI tests on sera from vaccinated pigs (Table 4) confirm the 
antigenic heterogeneity detected in assays with the sera from post-infection animal sera. 
When updating influenza vaccines for human use, one of the important criteria of the 
WHO for the replacement of an existing vaccine strain is that ferret antiserum to that 
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strain shows - compared with the titre to the vaccine strain itself - at least a fourfold 
lower HI titre to an emerging strain of probable epidemiological importance [2]. One of 
the viruses incorporated in current swine influenza vaccines is 
A/swine/Netherlands/25/80 [11]. Ferret antiserum prepared with this strain showed HI 
titres against most of the 26 strains examined in the present study which were fourfold or 
more below the homologous HI titre (Table 2). Post-vaccination swine sera showed titres 
against a selection of the recent isolates, which were on average sixfold lower than those 
against the vaccine strain (Table 4).  
If the WHO criterion, developed for human vaccinees, would also apply to pigs, 
these observations throw doubts on the efficacy of current vaccines in protecting pigs 
against presently circulating swine H1N1 viruses, at least in the Netherlands. Antigenic 
differences between vaccine virus and challenging virus do not necessarily reduce the 
efficacy of the vaccine. For example, evidence has been obtained that the antigenic drift 
recently observed in swine influenza virus subtype H3N2 [8] did not lead to impairment 
of the protection rendered by the current vaccine against an experimental challenge six 
weeks after the booster with a recently isolated antigenically different porcine H3N2 
virus strain [13]. Nevertheless it may be expected that better matching vaccines will 
induce higher antibody titres to the epidemic strains that will result in a longer period of 
protective antibody levels after vaccination. The observed antigenic heterogeneity 
among swine H1N1 viruses, however, may interfere with attempts to select such a well-
matching vaccine strain. Although swine sera seem to be more broadly reactive 
compared with the ferret antisera (Table 2), post-infection as well as post-vaccination 
swine sera (Table 4) still display fourfold or higher differences between the HI titres 
against some strains.  
In conclusion, our findings appear to justify the evaluation of the ability of 
current porcine influenza vaccines in protecting pigs against disease from presently 
circulating swine H1N1 viruses. The study also shows that, in order to check whether the 
vaccine strains used still match the circulating strains, a regular influenza surveillance 
among pigs is recommendable.  
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Chapter 3.1 
 
Summary 
The immunoglobulin isotype-specific responses in serum and at the respiratory mucosa 
of pigs after a primary infection with influenza virus were studied. To do this, we 
developed an aerosol challenge model for influenza in specified pathogen-free (SPF) 
pigs and isotype-specific enzyme-linked immunosorbent assays (ELISAs). Ten-week-old 
pigs were inoculated without anaesthesia into the nostrils with an aerosol of the field 
isolate influenza A/swine/Neth/St. Oedenrode/96 (H3N2). The infection caused acute 
respiratory disease that closely resembled the disease observed in some outbreaks of 
influenza among finishing pigs, which were not complicated by bacterial infections. Pigs 
showed clinical signs characterised by fever, dyspnoea and anorexia. At necropsy on 
post-infection days 1 and 2, an exudative endobronchitis was observed throughout the 
lung. Viral antigen was present in the epithelial cells of the bronchi and bronchioli and 
virus was isolated from bronchioalveolar and nasal lavage fluids and from pharyngeal 
swabs until 5 days after infection. With the isotype-specific ELISAs, viral nucleoprotein-
specific IgM, IgG1, and IgA antibody responses were measured in serum and 
bronchioalveolar and nasal lavage fluids. To determine whether the antibodies were 
produced and secreted at the respiratory mucosa or were serum-derived, the specific 
activity (i.e., the ratio of antibody titre to Ig concentration) was calculated for each 
isotype. The IgA and interestingly also a substantial part of the IgG1 antibody response 
in pigs upon infection with influenza virus were shown to be mucosal responses. Local 
production of specific IgA in the nasal mucosa, and of specific IgA and IgG1 in the lung 
was demonstrated. These results indicate that protective efficacy of vaccination can be 
improved by an immunisation procedure that preferentially stimulates a mucosal 
immune response. The aerosol challenge model in SPF pigs and the isotype-specific 
ELISAs that we developed can be useful for evaluating various strategies to improve 
efficacy of porcine influenza vaccines and to study the immune mechanisms underlying 
the observed protection. 
 
Introduction 
A field survey performed in the winter of 1995-96 in the Netherlands revealed that swine 
influenza virus is a major cause of outbreaks of acute respiratory disease in finishing 
pigs [14]. This finding indicated that influenza is a bigger problem amongst pigs than 
was commonly thought and prompted us to intensify research on swine influenza virus 
infections in the field and on vaccine development to prevent disease and spread of the 
virus. 
Moreover, influenza is a potential zoonotic disease, because pigs can be a source 
of new influenza strains that can be a threat for humans. Human influenza viruses are 
believed to have arisen from genetic reassortment between genes of human and avian 
influenza viruses which requires simultaneous infection of a host animal with both avian 
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and human influenza viruses. Pigs could possibly function as a mixing vessel in which 
that reassortment takes place, creating new human pandemic strains [19,27]. In addition, 
swine influenza viruses can occasionally infect humans causing respiratory disease and 
sometimes death [6,7]. 
Influenza virus infection and immunity have been extensively studied in small 
laboratory animals and humans, but only a few infection and vaccination studies have 
been performed in pigs. Moreover, these studies were performed in conventional pigs, 
which are often co-infected with other pathogens complicating the interpretation of the 
test results [1]. Because use of specified pathogen-free (SPF) pigs reduces the chance of 
interfering co-infections, an infection and challenge model in SPF pigs appears a 
valuable experimental model to study swine influenza infection and vaccination. 
Moreover, because pigs, unlike mice and ferrets, are natural influenza virus hosts, and 
their lungs resemble those of humans in many physiological aspects they have also been 
suggested to represent a highly valuable experimental model to study pathogenesis and 
immunity of influenza in humans [23].  
Vaccination of pigs is currently performed intramuscularly with a disrupted (split) 
virus vaccine containing an adjuvant. Such vaccines induce high serum IgG antibody 
titres but only a poor mucosal IgA response and were shown to protect less than a 
previous infection [13,17]. Moreover, vaccination experiments in pigs have shown that 
such conventional vaccines confer only little or no protection against challenge with an 
antigenically different strain of the same subtype [9]. Vaccination with a conventional 
vaccine protects less than a previous natural infection, probably because they induce 
different immunological effector mechanisms. However, little is known about the 
correlation between the different effector mechanisms and protection against influenza. 
Knowledge about this correlation is of great importance for the development of effective 
vaccines. 
A reason for the limited efficacy of conventional vaccines can be that they do not 
induce the same isotype-specific antibody response at the mucosa of the respiratory tract 
as a natural infection does. To study the systemic and mucosal antibody responses after 
infection with influenza virus, we developed a challenge model for influenza in SPF pigs 
and isotype-specific ELISAs. 
   
Materials and methods 
Propagation of virus 
Madin Darby canine kidney cells (MDCK, ECACC No.: 84 121 903) were cultured in 
Dulbeccos modification of Eagles medium (DMEM; BRL Life Technologies/Gibco, 
the Netherlands) containing 10% foetal calf serum, penicillin (200 IU/ml) and 
streptomycin (200 µg/ml).  
The influenza virus strain A/swine/Neth/St. Oedenrode/96 (H3N2) was isolated 
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from pneumonic lung tissue of a pig from an outbreak of influenza during a recent field 
survey [14]. This virus was isolated in primary cultures of porcine thyroid cells, then 
passaged three times in these cells, and then passaged twice in MDCK cells to obtain 
virus for the inoculation of pigs. Monolayers of MDCK cells were washed with 
phosphate buffered saline (PBS, pH 7.2), inoculated with virus (0.001 TCID50/cell) and 
cultured in McCoys medium (BRL Life Technologies/Gibco, the Netherlands) without 
serum and supplemented with trypsin (5 µg/ml) as described previously [20]. After a 24 
h incubation, cultures were freeze-thawed twice and the cell lysate was clarified by 
centrifugation at 1000 g for 15 min. Thereby, a virus stock was produced, which 
contained 108 TCID50/ml. This virus stock was stored at -70°C and was used to inoculate 
pigs.  
 
Experimental pigs and aerosol infection 
Six 10-week-old Dutch Landrace pigs were obtained from the SPF herd of the Institute 
for Animal Science and Health. The pigs were born to unvaccinated sows and before the 
start of the experiment pigs had no antibodies against influenza. At 10 weeks of age, pigs 
were inoculated into the nostrils with an aerosol produced by nebulization of 2 ml 
culture medium containing 108 TCID50/ml virus, using an air brush device (Badger, No.: 
100LG, Franklin Park, IL, USA). The experiment was approved by the Institutes ethical 
committee for experiments in animals. 
 
Clinical observations and sampling of the animals 
Clinical observation was performed daily and body temperature was measured daily 
until post-infection day (PID) 7. At PID 1 and 2 one pig was slaughtered for pathological 
examination and pieces of tissue from all lung lobes were taken for virus isolation and 
detection of viral antigen by immunoperoxidase staining. Oropharyngeal fluid, 
bronchioalveolar lavage fluid (BALF)[22], and nasal lavage fluid (NLF) of the 4 
remaining pigs were collected at various time points until PID 45. For this purpose, 
animals were anaesthetised by inhalation of nitrous oxide and halothane. Erythrocytes in 
the BALF samples were counted in a haemocytometer and only samples containing less 
than 3000 erythrocytes per µl of sample (i.e. less than 0.1% blood) were used for 
antibody detection. BALF samples used for virus isolation and antibody detection, were 
centrifuged for 10 minutes at 1000 g to remove cells. NLF was obtained by injecting 16 
ml PBS deep into the nasal cavity and collecting fluid dropping out of the nostrils. For 
the determination of antibody titres, NLF was clarified by filtration over a 200 nm filter 
and 10-fold concentrated by freeze-drying. The number of BALF and NLF samples 
analysed on each day varied (n=1 to 3) because not all pigs were sampled on each day 
and some BALF samples were discarded because they contained more than 0.1% blood. 
Blood was collected on PID 0, 4, 7, 10, 17, 24 and 43 from all pigs (n=4) to determine 
antibody titres in isotype-specific ELISAs and in a haemagglutination inhibition test.  
 61
Mucosal antibody response to infection 
 
Immunohistochemistry 
An indirect immunostaining method was used to detect viral antigens in the lungs of 
infected pigs. Cryostat sections of lung tissue from all lung lobes were fixed with 
acetone and incubated with monoclonal antibody (MAb) HB65, against a conserved 
antigenic determinant of the nucleoprotein (NP) of influenza A virus. The hybridoma 
that produces the MAb was obtained from the American Type Culture Collection 
(ATCC No.: HB 65, H16-L10-4R5)[29]. Sections were subsequently incubated with a 
peroxidase conjugate specific for mouse immunoglobulin and then with a 
chromogen/substrate solution (3,3-diaminobenzidine/H2O2) to detect viral antigens.  
 
Virus isolation 
At post mortem examination on PID 1 and 2, pieces of lung tissue were collected from 
the right apical and cardiac lung lobes, from the proximal, medial and distal part of the 
diaphragmatic lobe, and from the accessory lobe. The volume of these pieces was 
measured and then pieces were homogenised in a mortar with sand and PBS. A 10% 
(v/v) suspension in PBS was prepared and centrifuged at 1000 g for 10 min. Ten-fold 
serial dilutions of the supernatant were prepared in cell culture medium (McCoys 
medium without serum, supplemented with 5 µg/ml trypsin). Dilutions were inoculated 
on MDCK cells in microtitre plates, which were incubated at 37°C and examined for a 
cytopathic effect after 4 days. Infectious virus in oropharyngeal swab samples, BALF, 
and NLF was titrated in a similar way. Virus titres were calculated by the method of 
Spaerman Kärber and were expressed as TCID50/cm3 of lung tissue. 
 
Nucleoprotein-specific and isotype-specific ELISAs 
The MAbs specific for IgM (28.4.1), IgG1 (23.49.1), and IgA (27.9.1b) that were used in 
the isotype-specific ELISAs have been previously analysed for their isotype specificity 
[25] and have been used successfully to monitor isotype specific antibody responses 
against other pathogens of pigs: PRV [11] and E. coli K88 [4]. MAb HB65 was purified 
from hybridoma cell culture medium by affinity chromatography on protein G sepharose 
and was used for coating of microtitre plates and for conjugation with HRPO [28]. In 
previous studies, an antibody capture assay (ACA) format of the ELISA performed 
better for the detection of virus-specific IgM and IgA, and an indirect double antibody 
sandwich assay (IDAS) format performed better for the detection of virus-specific IgG1 
[24]. Therefore, we developed an ACA-ELISA for the detection of influenza NP-specific 
IgM and IgA, and an IDAS-ELISA for the detection of influenza NP-specific IgG1. 
Positive reference sera for each isotype were obtained from a previous influenza 
infection-experiment. To optimise our ELISAs several variables were tested such as the 
use of various proteins (i.e. BSA, foetal bovine serum and non-fat milk powder) as a 
 62
Chapter 3.1 
 
blocking agent for aspecific binding, the dilution of antigen, dilutions of MAbs used for 
coating, and dilution of the conjugates. 
 
Antigen preparation 
A virus pool of influenza A/swine/Neth/St. Oedenrode/96 (H3N2) containing 107.5 
TCID50/ml and with a haemagglutination titre of 1:1000 was 40-fold concentrated by 
centrifugation at 100,000 g for 1 h at 4 °C, and the pellet was resuspended in 1% NP-40 
in PBS. This virus suspension was centrifuged twice for 15 min at 1000 g to remove 
coarse particles and the supernatant was stored in small aliquots at -70°C. This virus 
preparation was used as antigen in all ELISAs. 
 
Nucleoprotein-specific IgM and IgA 
MAbs specific for porcine IgM (28.4.1) and IgA (27.9.1b) were purified from mouse 
ascites fluid by ammonium sulphate precipitation, followed by dialysis overnight against 
PBS. Immunoglobulin concentration was determined by measuring optical density at 
280 nm. ELISA plates (Costar EIA/RIA, Cat. no. 3590, Costar, USA) were i) coated 
overnight at 4°C with 200 ng of Mab per well for IgM and 800 ng of MAb per well for 
IgA in 50 mM sodium bicarbonate buffer, pH 9.6; ii) blocked with 0.3% non-fat milk 
powder in PBS by shaking on a microplate shaker (Vari-shaker, Dynatech Laboratories, 
Sussex, UK) for 2 h at 37°C; iii) incubated with 2-fold serial dilutions of serum samples, 
BALF or NLF; iv) incubated with a 1:200 dilution of antigen preparation; v) incubated 
with HRPO conjugated MAb HB65 against the NP of influenza virus; and vi) incubated 
at room temperature with chromogen/substrate solution (0.1 mg/ml tetramethylbenzidin 
(TMB), 0.006% H2O2 in 0.1 M sodium acetate buffer). Coloration was stopped after 30 
min with 0.5 M H2S04. All dilutions of reagents were made in ELISA buffer (0.5 M 
NaCl, 0.05% (w/v) Tween 80 in PBS, pH 7.4) to which 0.3% non-fat milk powder was 
added, and plates were shaken for 1 hour at 37 °C in each step. In each step, 100 µl of 
reagent was added per well and between each step plates were washed 5 times (10 times 
before adding chromogen/substrate) with 0.05% (w/v) Tween 80 in tap water. The 
absorbance at 450 nm was read with an ELISA reader (Spectra Reader, SLT 
labinstruments, Salzburg, Austria). Antibody titres were expressed as the reciprocal of 
the sample dilution still giving optical density (OD) values of ½ the maximum OD (1/2 
ODmax) of the positive control sample. 
 
Nucleoprotein-specific IgG1 
In the IDAS-ELISA for NP specific IgG1, plates were i) coated with 50 ng per well of 
MAb HB65 specific for influenza NP; ii) blocked with 1% BSA in PBS; iii) incubated 
with a 1:200 dilution of antigen preparation; iv) incubated with 2-fold serial dilutions of 
serum samples, BALF or NLF; v) incubated with a MAb against IgG1 (23.49.1) 
conjugated to HRPO; and vi) incubated at room temperature with chromogen/substrate 
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solution. Coloration was stopped after 30 min with 0.5 M H2S04. In each step, 100 µl of 
reagent was added per well, and all dilutions of reagents were made in ELISA buffer to 
which 1% BSA was added. Between each step plates were washed, and titres were 
determined as described for the NP specific IgM and IgA ELISAs. 
 
Haemagglutination inhibition assay 
The haemagglutination inhibition assay was performed essentially as described 
previously [10], using 0,5 % chicken erythrocytes for haemagglutination and four 
haemagglutinating units of A/swine/Neth/St. Oedenrode/96. 
 
ELISAs for total concentrations of IgM, IgG and IgA 
Double antibody sandwich ELISAs to determine total concentrations of IgM, IgG, and 
IgA were performed essentially as previously described [3]. In the IgM and IgA ELISAs 
the quantity of MAbs for coating and the dilution buffer were kept the same as was 
found optimal for the detection of NP specific antibodies. In the IgM and IgA ELISA, 
the same MAb was used for coating and detection (for detection the MAb was 
conjugated with HRPO). For IgG, a different MAb was used for coating (23.7.1) than for 
the conjugate (23.3.1a). In short, plates were i) coated with MAbs specific for each 
isotype; ii) blocked with 0.3% non-fat milk powder in PBS for the IgM and IgA ELISA, 
and with 1% BSA in PBS for the IgG ELISA; iii) incubated with 2-fold serial dilutions 
of serum, BALF or NLF in ELISA buffer with 0.3% non-fat milk powder for IgM and 
IgA or 1% BSA for IgG; iv) incubated with conjugates specific for each isotype; and v) 
incubated at room temperature with chromogen/substrate solution. Isotype 
concentrations were determined by using a reference sample with known isotype 
concentrations [3]. The reference sample was a mixture of sera from thirty 10-week-old 
SPF pigs. For both the antigen-specific and total Ig ELISAs positive control samples 
were included to enable correction for plate differences. Although batches of plates were 
coated at different days, the results were highly reproducible and differences in titres of 
control samples did not exceed more than one dilution step. Therefore, no correction was 
needed for any of the titres measured. For a comparison of antibody responses in blood 
and mucosal secretions, the specific activity (i.e., the ratio of influenza specific antibody 
titre to total Ig concentration) was calculated for each isotype. 
 
Results 
Experimental infection 
Inoculation of 10-week-old pigs with an aerosol of 108 TCID50/ml of A/swine/Neth/St. 
Oedenrode/96 (H3N2) virus into the nostrils caused acute disease, which was 
characterised by fever (> 40°C) on PID 1 and 2, dyspnoea, and anorexia in all pigs. Only 
a few atelectatic lesions were observed in the apical and cardiac lung lobes at necropsy 
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on PID 1 and 2, but at microscopic examination a suppurative bronchiolitis and mild 
interstitial pneumonia were observed throughout the lung. Bronchioli were filled with 
exudate consisting of necrotic cells, polymorphonuclear granulocytes, macrophages, and 
mononuclear cells.  
By immunoperoxidase staining, viral antigen was observed in epithelial cells of 
the nasal cavity, trachea, bronchi, and bronchioli, but much less or no antigen was 
observed in alveolar epithelium. Inflammation and presence of viral antigen were 
observed far into the caudal part of the diaphragmatic lung lobe. Virus titres were 107.3 to 
107.6 TCID50/cm3 of lung tissue in all lobes on PID 1 and were about 100 fold lower on 
PID 2. From the four remaining pigs, virus was isolated from oropharyngeal swabs, 
BALF, and NLF from PID 1 till 5.  Maximum titres found were 104.8, 104.8, and 101.9 
TCID50/ml, respectively.  
 
Evaluation of NP- and isotype-specific antibody responses 
The detection limit of the ELISAs to determine the Ig isotype concentrations appeared to 
be 0.05 µg/ml for IgM, 0.17 µg/ml for IgG, and 0.19 µg/ml for IgA. By ELISA, the IgM, 
IgG, and IgA concentration was determined in all blood, BALF, and NLF samples (Fig.1 
and Table 1). It was not possible to determine the absolute immunoglobulin content of 
nasal secretion and epithelial lining fluid of the lung due to the unknown dilution by the 
lavage technique used to collect the mucosal secretions. The mucosal IgM : IgG and IgA 
: IgG ratios could be determined, however, and were compared with ratios in blood 
(Table 1). Although the technique of sampling was standardised as much as possible, 
immunoglobulin concentrations varied more in the lavages than in blood.  
Using the isotype-specific ELISAs, IgM, IgG1, and IgA antibody responses 
specific for the NP of influenza A virus were determined in serum, BALF, and NLF. The 
kinetics of the IgM, IgG1, and IgA antibody responses and of the specific activity of 
each isotype are presented (Fig. 2). 
IgM IgG IgA Ratio
(µg/ml ± SD) N (µg/ml ± SD) N (µg/ml ± SD) N IgM : IgG IgA : IgG
serum  1,572 ± 85 28 12,717 ± 2,476 28  165 ± 36 28 0.12 0.01
BALFa 6 ± 10 21 41 ± 19 24 6 ± 5 30 0.15 0.15
NLFb 5 ± 1 30 4 ± 5 30 8 ± 6 26 1.25 2.0
Mean quantities of all samples of 4 pigs during the experimental period. 
N = number of samples 
a Bronchioalveolar lavage fluid 
b Nasal lavage fluid 
Table 1. Comparison of IgM, IgG, and IgA content in blood and in secretions of the respiratory
tract of 10  16 week old pigs. 
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Figure 1. Concentration of IgM, IgG, and IgA in serum (●), bronchioalveolar lavage fluid (❍),
and nasal lavage fluid (!) measured over a period of 45 days after a primary infection with
influenza virus. Mean values in serum of four pigs (n=4), and in bronchioalveolar lavage fluid
and nasal lavage fluid of a variable number of pigs (n=1 to 3) at each time point are shown. 
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Figure 2. Kinetics of nucleoprotein specific IgM, IgG1, and IgA antibodies in serum (●),
bronchioalveolar lavage fluid (❍), and nasal lavage fluid (!) after a primary infection with
influenza virus. At the bottom HI antibody titres in serum are shown (graphs on the left). For a
comparison of titres in blood and mucosal secretions, specific activity is also presented for each
isotype (graphs on the right). The graphs only show data above the lower detection limit. Mean
values in serum of four pigs (n=4), and in bronchioalveolar lavage fluid and nasal lavage fluid of
a variable number of pigs (n=1 to 3) at each time point are shown. 
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A sharp rise in IgM antibody titre specific for influenza virus in blood and mucosal 
secretions was detected between PID 4 (negative) and PID 7 (maximum titre). Specific 
activity of IgM was approximately 8 and 4 times higher in BALF and NLF than in 
serum. After reaching a peak on PID 7, the IgM antibody titre decreased and IgM 
antibodies were detectable in blood and BALF until PID 25. In NLF this decrease was 
slightly slower (Fig. 2). 
IgG1 antibodies specific for influenza virus were first detected in blood and 
BALF on PID 10. The titre reached its maximum on PID 15 and remained on this level 
until the end of the experiment. Kinetics of the IgG1 antibody responses were similar in 
serum, BALF, and NLF but the specific activity of IgG1 was approximately 14 times 
higher in BALF than in serum. In NLF, titres of IgG1 antibodies specific for influenza 
virus were low and specific activity of IgG1 was the same as in serum. 
IgA specific for influenza virus was first detected on PID 7 in blood and mucosal 
secretions and reached its maximum titre around PID 15. Interestingly, the kinetics of 
the IgA response in BALF and NLF clearly differed from that in serum. Whereas in 
serum the IgA titre dropped after reaching a peak on PID 17, in the mucosal secretions it 
remained at a constant level until PID 44. Specific activity of IgA was much higher in 
BALF and NLF than in serum. On PID 44, specific activity of IgA was 280 times higher 
in NLF and 570 times higher in BALF than in serum (Fig. 2). 
In all four pigs, the titre of haemagglutination inhibiting (HI) antibodies in the 
blood increased rapidly to maximum levels on PID 7, and remained on this level until 
the end of the experiment at PID 45 (Fig. 2). The high HI titres at PID 7 corresponded 
with the high titres of anti NP IgM antibodies in serum on PID 7 in the isotype specific 
ELISA, and the response curve for HI antibodies corresponded with the summation of 
the three isotype-specific anti NP responses. 
 
Discussion 
In this paper, we describe the development of ELISAs for the detection of IgM, IgG1, 
and IgA antibodies specific for the nucleoprotein of influenza virus. Isotype specific 
ELISAs have been described previously, but these were based on Ig isotype specific 
polyclonal sera, which are often poorly reliable for the pig and show a large badge-to-
badge variation. In contrast, the ELISAs developed in this study are entirely based on 
monoclonal antibodies, assuring a reliable test for unlimited time. Because the 
nucleoprotein is highly conserved, the ELISAs can be used to measure and compare 
antibody responses of pigs against all subtypes of influenza A from pigs, and other hosts. 
The usefulness of the ELISAs was assessed by monitoring antibody responses in serum 
and at the respiratory mucosa of pigs after experimental infection with swine influenza 
virus (H3N2 field isolate). To determine whether IgM, IgG1, and IgA antibodies in 
mucosal secretions were locally produced, the influenza virus specific activity (i.e., the 
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ratio of influenza specific antibody titre to total Ig concentration) for each isotype in 
NLF and BALF was compared with that in serum. If mucosal antibodies were derived 
merely from serum, the specific activities in NLF, BALF and serum should be the same. 
Specific activity has been previously used to determine mucosal production of IgG 
antibodies in humans [26] and of IgM, IgG and IgA in mice [21].  
The antibody response to infection was characterised by high IgA antibody titres 
in nasal and bronchioalveolar secretions. Moreover, substantial titres of IgG1 were 
detected in bronchioalveolar secretions, and less in nasal secretions. The specific activity 
of IgA was much higher in NLF and BALF than in serum. On PID 43, specific activity 
of IgA was even 280 times higher in NLF and 570 times higher in BALF than in serum. 
These results indicate a local production of IgA and suggest a predominant role of IgA in 
mucosal defence against re-infection. 
The specific activity of IgG1 was approximately 14 times higher in BALF than in 
serum suggesting a local production of this isotype in the lung too. Concentrations of 
IgG1 in NLF were so low that specific antibodies could only just be detected. The 
influenza virus specific activity of IgG1 was higher in BALF than in NLF, and this is 
consistent with the finding that in the lung 63 % of the IgG was produced locally and in 
the nose only 21% [15]. Our data indicate that a much larger proportion of influenza 
specific IgG is produced locally, in the lung. Therefore we can assume that of the 63% 
IgG which is produced locally a large proportion is directed against antigens which enter 
via the respiratory route like influenza. A substantial amount of IgG antibody-secreting 
cells (IgG2a isotype) in the lungs was observed in mice after primary infection with 
influenza virus [8] and production of serum IgG close to the viral challenge site was 
suggested. Our study supports this suggestion. 
The IgM, IgG, and IgA content of serum, BALF and NLF was measured, and 
IgM : IgG and IgA : IgG ratios were compared (Table 1). IgA was the predominant 
immunoglobulin in NLF and IgG in BALF. Although precise IgA : IgG ratios in NLF 
and BALF in our study were different from ratios reported by Morgan et al. [15], a 
characteristic feature of both studies is that IgA : IgG ratios were lower in 
bronchioalveolar than in nasal secretions. The higher IgG content in BALF in our study 
could be the result of more transudation of IgG by tissue damage during inluenza 
infection, but could also be caused by a difference in age of the pigs or difference in 
sampling techniques. 
The appearance of influenza specific IgM between PID 4 and 7 coincides with the 
clearance of virus from the oropharyngeal tract on PID 5. This finding suggests that IgM 
is responsible for viral clearance after a primary infection, but in contrast to IgA, IgM 
has probably a minor role in long lasting immunity to a secondary infection. However, in 
young pigs, IgM was shown to partially take over the role of IgA at the mucosae [2], and 
in humans IgM producing cells increase in number in IgA immunodeficient patients 
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[18]. Moreover, a recent study demonstrated that IgM like IgA, behaves more like a 
mucosal isotype in the pig than in other species [5]. 
The temporary character of influenza virus specific serum IgM (PID 6-25) and 
IgA (PID 10-50) may make the presence of these isotypes in serum indicative for a 
recent infection with influenza virus. Monitoring of IgM in serum could provide an 
alternative for examining paired sera as a diagnosis of recent influenza virus infections 
in the field. Moreover, the ELISA for IgM and IgA could possibly distinguish influenza 
virus infected pigs from pigs with passively acquired antibodies, because these 
antibodies are mainly of the IgG isotype [3]. 
The advantage of the nucleoprotein specific ELISAs is that the nucleoprotein is 
highly conserved so that the ELISAs can be used to measure and compare responses 
against all subtypes of influenza A from swine, and other hosts. However, antibodies 
against NP are thought to have a minor role in clearance of virus compared to 
haemagglutinin specific antibodies. Therefore, we compared the kinetics of the anti NP 
antibody response with the haemagglutination inhibiting (HI) antibody response in the 
serum (Fig. 1). The kinetics of the HI antibody response corresponded with the 
summation of the three isotype specific responses suggesting that the kinetics of the HI 
antibody response does not differ essentially from the anti-NP response. 
Inoculation into the nostrils with an aerosol of influenza virus was shown to be an 
effective method of inducing clinical signs of influenza in SPF pigs. Clinical signs and 
lung lesions after inoculation of A/swine/Neth/St. Oedenrode/96 resembled those 
observed in outbreaks of influenza among finishing pigs in a field survey in the winter of 
1995-96 [14]. Exposure to aerosols was shown to be a more reliable method of inducing 
clinical influenza in ponies than intranasal inoculation and would be more suitable for 
challenge studies [16]. Moreover, anaesthesia was shown to interfere with the course of 
an influenza infection in mice [12]. Because aerosol inoculation of pigs resembles a 
natural infection and can be performed without anaesthesia, it can be considered an 
optimal inoculation to study natural infection. 
The present study shows that the antibody response upon infection with influenza 
virus is mainly a mucosal response, characterised by local production of specific IgA in 
the nasal mucosa, and specific IgA and IgG1 in the lung. These mucosal antibodies will 
contribute to protection of pigs against secondary infection with influenza virus. 
Moreover, the IgA and IgG1 antibody secreting cells can be activated or mobilised 
during the memory response. Vaccination of pigs is currently performed intramuscularly 
with a disrupted (split) virus vaccine containing an adjuvant. This vaccine will provoke 
mainly a systemic IgG antibody response, which will protect against a pneumonia, but it 
is reasonable to suggest that protective efficacy of vaccination can be improved by an 
immunisation procedure that also stimulates a mucosal immune response. In ponies, 
parenteral vaccination with inactivated virus induced no mucosal IgA response and 
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incomplete protection of a few months duration only. However, a natural infection 
induced a mucosal IgA response and protective immunity for at least 12 months [17]. 
The failure of current vaccines to induce a good local IgA and IgG1 response could 
explain their limited efficacy when compared to a previous infection. However, the 
correlation of the local IgA and IgG1 response and other immune mechanisms with 
protection needs further investigation. The aerosol challenge model in SPF pigs and the 
influenza and isotype-specific ELISAs described here will be useful tools to study this 
correlation. 
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Summary 
Antigenic drift of swine influenza A (H3N2) viruses away from the human A/Port 
Chalmers/1/73 (H3N2) strain, used in current commercial swine influenza vaccines, has 
been demonstrated in the Netherlands and Belgium. Therefore, replacement of this 
human strain by a more recent swine H3N2 isolate has to be considered. In this study, 
the efficacy of a current commercial swine influenza vaccine to protect pigs against a 
recent Dutch field strain (A/Sw/Oedenrode/96) was assessed. To evaluate the level of 
protection induced by the vaccine it was compared with the optimal protection induced 
by a previous homologous infection. Development of fever, virus excretion, and viral 
transmission to unchallenged group mates were determined to evaluate protection. The 
vaccine appeared efficacious in the experiment because it was able to prevent fever and 
virus transmission to the unchallenged group mates. Nevertheless, the protection 
conferred by the vaccine was sub-optimal because vaccinated pigs excreted influenza 
virus for a short period of time after challenge, whereas naturally immune pigs appeared 
completely protected. The immune response was monitored, to investigate why the 
vaccine conferred a sub-optimal protection. The haemagglutination inhibiting and virus 
neutralising antibody responses in sera, the nucleoprotein-specific IgM, IgG, and IgA 
antibody responses in sera and nasal secretions and the influenza-specific 
lymphoproliferation responses in the blood were studied. Vaccinated pigs developed the 
same or higher serum haemagglutination inhibiting, virus neutralising, and 
nucleoprotein-specific IgG antibody titres as infected pigs but lower nasal IgA titres and 
lymphoproliferation responses. The lower mucosal and cell-mediated immune responses 
may explain why protection after vaccination was sub-optimal.  
 
Introduction 
Swine influenza is a highly contagious acute viral disease of the respiratory tract in pigs, 
which is distributed world-wide. It is characterised by fever, apathy, anorexia, coughing, 
sneezing, nasal discharge, conjunctivitis, a low mortality rate and a rapid recovery. 
Secondary bacterial infections can increase the severity of the illness and may result in 
complications such as pneumonia. The disease causes considerable economic damage 
primarily due to reduced weight gain in finishing pigs and reduced reproductive 
performance of sows [3].  
A field survey performed in the winters of 1996 and 1997 in the Netherlands 
revealed that swine influenza virus H3N2 and H1N1 infections are a major cause of 
outbreaks of acute respiratory disease in finishing pigs [10]. Moreover, sera from 
infected pigs showed a markedly lower haemagglutination inhibition (HI) titre against 
A/Port Chalmers/1/73 (H3N2) than against a recent field isolate, indicating that antigenic 
drift had occurred. Indeed, further antigenic analysis of the isolates using ferret post-
infection antisera showed that there has recently been considerable antigenic drift within 
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the swine influenza A (H3N2) viruses in the Netherlands and Belgium. This drift has led 
to a loss of cross-reactivity of recent field isolates with the human A/Port Chalmers/1/73 
(H3N2), which is used as the current vaccine strain. Therefore, replacement of this strain 
by a more recent swine H3N2 isolate was recommended [4].  
In the present study, the efficacy of a commercial swine influenza vaccine to 
protect pigs against infection with a recent swine influenza strain (A/Sw/Oedenrode/96 
(H3N2)) was investigated. Because a homologous infection is expected to induce the 
best quality of protection, the performance of the vaccine was compared to that of a 
previous homologous infection. This study was performed using an aerosol challenge 
model for influenza in specified pathogen free (SPF) pigs and recently developed 
ELISAs to measure influenza nucleoprotein (NP)-specific IgM, IgG and IgA antibodies 
[6]. Development of fever, virus excretion, and viral transmission to unchallenged group 
mates were determined to evaluate protection. Antibodies in serum were measured in HI 
and virus neutralisation (VN) assays against the vaccine virus and challenge virus, and 
IgM and IgG antibodies in serum, and IgA antibodies in nasal secretion were measured 
using the ELISAs. To measure the cellular immune response a lymphoproliferation assay 
was used. The humoral and cellular responses of pigs to vaccination and infection were 
compared and the differences were evaluated as to whether they were due to antigenic 
variance between vaccine and challenge strain, and whether they could explain 
differences in protection. The quality of protection in relation to the underlying immune 
responses observed in the vaccinated and infected pigs is discussed. 
  
Materials and methods 
Propagation of virus  
The influenza virus strain A/Sw/Oedenrode/96 (H3N2) was isolated from pneumonic 
lung tissue of a pig from an outbreak of influenza during a recent field survey [10]. This 
virus was isolated in primary cultures of porcine thyroid cells, then passaged three times 
in these cells, and then passaged twice in Madin Darby canine kidney cells (MDCK, 
ECACC No.: 84 121 903). The virus strain A/Port Chalmers/1/73 was obtained (World 
Influenza Centre, UK) and passaged twice in MDCK cells. Virus stocks were produced, 
and were stored at -70°C until used as inoculum or as antigen in HI and VN assays, 
ELISAs and T-cell proliferation assays.  
 
Immunisation and challenge 
Thirty-six Dutch Landrace pigs were obtained from the SPF herd of the Institute for 
Animal Science and Health. The pigs were born to unvaccinated sows and had no 
antibodies against influenza before the start of the experiment. The pigs were randomly 
assigned to 3 groups of 12 pigs and each group was housed in a separate room. At 10 
weeks of age, pigs in one group were immunised into the nostrils with an aerosol 
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produced by nebulisation of 2 ml culture medium containing 108 TCID50/ml of the field 
isolate A/Sw/Oedenrode/96 (H3N2), using an air brush device (Badger, No.: 100LG, 
Franklin Park, IL, USA). Pigs in a second group were immunised by i.m. injection of a 
commercial disrupted (split) virus vaccine (Griporiffa, Rhône Mérieux, The 
Netherlands) containing A/Port Chalmers/1/73 (H3N2) formulated in an oil-adjuvant, 
followed by a second injection 3 weeks later (Post-immunisation day (PID) 21). Pigs in a 
third group were left non-immunised to be used as a challenge control. At PID 63, 9 
weeks after immunisation of pigs in the group immunised by aerosol of live virus and 6 
weeks after second i.m. vaccination of pigs in the vaccine group, 7 of the pigs in each 
group were challenged with an aerosol of the field isolate A/Sw/Oedenrode/96 (H3N2). 
Thus, pigs in the group immunised by aerosol of live virus were challenged with the 
same virus strain that was used for immunisation (homologous challenge), whereas pigs 
in the i.m. vaccine group were challenged with a virus strain different from the strain 
used for immunisation (heterologous challenge). The other 5 pigs of each group were 
kept apart for 24 hours and then reunited with their challenged group mates to determine 
whether viral transmission occurred. Of the 7 challenged pigs, one pig was euthanised at 
24 and one at 48 hours for pathological examination. The experiment was approved by 
the Institutes ethical committee for experiments in animals. 
 
Clinical observations and sampling 
Body temperature of all pigs was measured and oropharyngeal fluid was collected daily 
for 8 days following immunisation (PID 0-8) and challenge (PID 63-71). On day 1 and 2 
post-challenge, one pig of each group was killed for pathological examination and pieces 
of tissue from all lung lobes were taken for virus isolation. Of the other 5 challenged 
pigs and of the 5 contact pigs, blood and nasal lavage fluid (NLF) were collected at PID 
0, 3, 7, 10, 17, 24, 31, 38, 59, 66, 70, 73, 80, and 84. To collect NLF, animals were 
anaesthetised by intra-muscular injection of 4.2 mg/kg Ketamine (Aescoket, Aesculaap, 
the Netherlands), 0.022 mg/kg medetomidine (Domitor, Pfizer Animal Health), and 0.18 
mg/kg midazolam (Dormicum, Roche), and NLF was obtained by injecting 16 ml PBS 
deep into the nasal cavity and collecting fluid dropping out of the nostrils. Blood was 
collected from the superior vena cava. Serum was collected to determine antibody titres 
in HI and VN assays, and isotype-specific anti-NP ELISAs [6]. Heparinized blood was 
collected for the isolation of PBMC to be used in a T-cell proliferation assay.  
 
Virus isolation 
On days 1 and 2 after challenge inoculation (PID 64 and 65) one pig was killed and 
pieces of lung tissue were collected from all lung lobes. The volume of these pieces was 
measured and then pieces were homogenised in a mortar with sand and PBS. A 10% 
(v/v) suspension in PBS was prepared and centrifuged at 1000 g for 10 min. Ten-fold 
serial dilutions of the supernatant were prepared in cell culture infection medium 
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(McCoys medium without serum, supplemented with 5 µg/ml trypsin). Dilutions were 
inoculated on MDCK cells in microtitre plates, which were incubated at 37°C and 
examined for a cytopathic effect after 4 days. Infectious virus in oropharyngeal swab 
samples was titrated in a similar way. Of the samples that were negative in the microtitre 
assay, 1 ml was tested for the presence of virus by inoculating a monolayer in 25 ml 
tissue culture flasks. Virus titres were calculated by the method of Spearman-Kärber.  
 
Haemagglutination inhibition (HI) and virus neutralisation (VN) assay  
The HI assay was performed essentially as described previously [7], using 0,5 % chicken 
erythrocytes for haemagglutination and four haemagglutinating units of 
A/Sw/Oedenrode/96 or A/Port Chalmers/1/73.  
The VN assay was performed essentially as described previously [17]. Briefly, 50 
µl containing 100 TCID50 of A/Sw/Oedenrode/96 or A/Port Chalmers/1/73 was mixed 
with 50 µl of 2-fold serial dilutions of serum, starting at a dilution of 1:10. After 
incubation for 1 h at 37°C the mixture was tested for residual virus infectivity on MDCK 
cell monolayers prepared in 96-well tissue culture plates (655180, Greiner, The 
Netherlands). Cultures were incubated at 37°C and examined for a cytopathic effect after 
4 days. 
 
Nucleoprotein-specific and isotype-specific ELISAs 
The ELISAs to measure influenza NP-specific IgM, IgG, and IgA antibodies in pigs 
were described recently [6]. An antibody capture assay format of the ELISA was used to 
detect IgM and IgA. In short, ELISA plates (Costar EIA/RIA, Cat. no. 3590, Costar, 
USA) were coated with MAbs specific for porcine IgM (28.4.1) or IgA (27.9.1b). 
Subsequently, they were incubated with 2-fold serial dilutions of serum samples or NLF, 
antigen (complete virus disrupted in 1% NP-40 in PBS), a horseradish peroxidase 
(HRPO) conjugated MAb (ATCC No.: HB 65, H16-L10-4R5) against the NP of 
influenza virus, and chromogen/substrate solution. An indirect double antibody 
sandwich format of the ELISA was used for the detection of specific IgG. Plates were 
coated with the MAb against the NP. Subsequently, they were incubated with antigen, 2-
fold serial dilutions of serum samples, a MAb against IgG (23.49.1) conjugated to 
HRPO, and chromogen/substrate solution. The absorbance at 450 nm was read with an 
ELISA reader (Spectra Reader, SLT labinstruments, Salzburg, Austria), and antibody 
titres were expressed as the reciprocal of the sample dilution still giving an OD value of 
1.0. In each ELISA, positive control samples obtained from a previous influenza 
infection experiment were included to enable correction for plate differences. However, 
differences in titres of control samples on different plates and measured on different days 
were never more than one dilution step. Therefore, no correction was needed for any of 
the titres measured. 
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T-cell proliferation assay 
The T-cell proliferation assay to measure influenza-specific T-cell responses of pigs was 
developed essentially as described for pseudorabies virus [8]. Briefly, PBMC were 
isolated from heparinised blood samples by centrifugation onto Lymphoprep (Nycomed 
Pharma A., Oslo, Norway), and were washed twice with PBS. The isolated PBMC were 
seeded in 96-well flat-bottom plates (M29, Greiner, The Netherlands) at a density of 5 x 
105 cells per well in 100 µl medium (RPMI 1640 containing 10% porcine serum (a pool 
from 2 euthanised SPF pigs that did not have antibodies to influenza), 2 mM L-
glutamine, 50 µM β-mercaptoethanol, 200 U/ml penicillin, 200 µg/ml streptomycin, and 
100 U/ml mycostatin). To the PBMC, 100 µl medium containing 400 haemagglutinating 
units and 5 x 105 TCID50 of influenza A/Sw/Oedenrode/96 or A/Port Chalmers/1/73, a 
control sample prepared from non-infected cells (mock control) or 5 µg/ml of Con A 
(vitality control) were added in quadruplicate. After 4 days incubation at 37 °C in a 5% 
CO2 atmosphere, the cultures were pulsed with 0.4 µCi [3H]-thymidine (Amersham, The 
Netherlands). After 4 h of incubation, cells were harvested and the incorporated 
radioactivity was measured in a Betaplate scintillation counter (Wallac, EG&G 
Instruments, The Netherlands). Proliferation was expressed as the number of counts 
(mean of quadruplicate) of influenza-stimulated PBMC minus the number of counts of 
the mock control-stimulated PBMC (delta counts).  
 
Statistics 
Comparisons of LPT responses and nasal IgA responses in the three groups were 
evaluated by two-sided Students t-tests. Comparison of T-cell proliferation when 
PBMC were stimulated with the homologous or heterologous virus strains was evaluated 
by a paired-sample Students t-test. Probability (p) values <0.05 were considered 
significant. 
 
Results 
Protection against challenge infection and transmission  
Primary inoculation of pigs with an aerosol of 108 TCID50/ml of A/Sw/Oedenrode/96 
(H3N2) virus into the nostrils caused acute disease. All pigs after immunisation (PID 0) 
in the group immunised by aerosol of live virus and after challenge (PID 63) in the 
control group, developed fever (≥ 40°C) for at least 1 day between day 1 and 6, and 
excreted virus from day 1 to 6 after inoculation. Moreover, in the control group 
challenged pigs transmitted virus to their unchallenged group mates and all contact pigs 
developed fever between PID 3 and 7 and excreted virus from PID 3 to 7. In these 
aspects, and also in the development of immunity, contact pigs reacted very similarly to 
challenged pigs and these results show the validity of the aerosol challenge and 
transmission model for influenza in pigs. 
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Figure 1a. Mean temperatures of pigs after challenge by aerosol with 108 TCID50
A/Sw/Oedenrode/96. Pigs were immunised by intramuscular vaccination with killed A/Port
Chalmers/1/73 (●), by aerosol with live A/Sw/Oedenrode/96 (▲), or were non-immunised (■). 
Figure 1b. Mean temperatures of contact pigs in the three groups. Contact pigs were separated
before their group mates were challenged and were then reunited after 24 hours. Results are
presented as the mean ± SD (n=5). 
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In the group immunised by aerosol of live virus but not in the group immunised by i.m. 
vaccination, pigs were completely protected against challenge infection. In the infection 
group, none of the challenged (Fig. 1a) or contact pigs (Fig. 1b) developed fever and no 
virus was isolated from oropharyngeal swabs, nor from lung tissue at 24 and 48 hours 
after challenge (Table 1). However, in the i.m. vaccine group reduced virus titres were 
detected in lung tissue of both pigs killed on PID 1 and 2, and in oropharyngeal swabs of 
two pigs. Nevertheless, i.m. vaccination protected most pigs from fever (although one of 
the pigs that excreted virus developed fever on one day (PID 3)) and prevented 
transmission of virus to unchallenged pigs of the same group. In none of the contact pigs 
fever or virus could be detected and prevention of viral transmission was confirmed by 
the complete absence of a secondary HI, IgG or IgA antibody response in the contact 
pigs after challenge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Virus titres in oropharyngeal swabs (log10TCID50 /ml) of all pigs and in lung tissue
(log10TCID50 /cm3) of 2 pigs per group, after challenge by aerosol with 108 TCID50
A/Sw/Oedenrode/96. Pigs were immunised by aerosol with A/Sw/Oedenrode/96, by intramuscular
vaccination with A/Port Chalmers/1/73, or were non-immunised.  
 
Aerosol of live virus Intramuscular vaccine Non-immunised control
challenged contactc
Pig 1 2 3 4 5 6b 7 b 1 2 3 4 5 6 b 7 b 1 2 3 4 5 6 b 7 b 1 2 3 4 5
PCDa
1         < <  < 3.7 3.6 3.1 3.6 2.9 6.9     
2            1.9 1.6 2.1 1.6 1.6 1.6 6.2 1.6 1.6 1.6 1.6 1.6
3        <   1.7 2.6 1.9 1.8 1.6 1.6 1.8 1.7 2.7 2.7
4        < <  2.3 3.2 2.4 1.7 1.8 1.6 1.6 2.5 1.6 1.6
5           1.7 < 2.6 2.8  3.1 2.2 2.9 2.2 2.4
6              1.6  1.6 1.6 1.7 2.1 2.2
7                < < < 2.3 <
8                    
 
aPost-challenge day 
bThese pigs were killed on PCD 1 and 2, and virus was isolated from lung tissue. 
cThe 5 contact pigs were separated before their group mates were challenged and were then
reunited after 24 hours. Virus was only detected in contact pigs in the non-immunised control
group, and not in contact pigs in the other groups. 
< : Virus detected in 1 ml sample 
- : No virus detected 
HI and VN antibody responses 
HI antibody responses in the three groups were determined against the homologous and 
heterologous virus strains A/Sw/Oedenrode/96 and A/Port Chalmers/1/73. Sera taken 
from pigs in the group immunised by aerosol of live virus and from pigs in the i.m. 
vaccine group at PID 10, 38, 59 and 80 were chosen to determine the VN antibody titres. 
In the group immunised by aerosol of live virus, a quick rise in HI antibody titres to a 
maximum level on PID 7 was observed and in the i.m. vaccine group a maximum was 
reached on PID 31, 10 days after the second vaccination. Serum HI and VN antibody 
titres against the A/Sw/Oedenrode/96 challenge strain were approximately 3-fold higher 
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Aerosol of live virus Intramuscular vaccine
PIDb A/Sw/
Oedenrode/96
A/Port
Chalmers/1/73
specificityc A/Sw/
Oedenrode/96
A/Port
Chalmers/1/73
specificityd
HI VN HI VN HI VN HI VN HI VN HI VN
10 1152 223 58 <10 20 - <10 <10 29 <10 3 -
38 416 128 20 <10 21 - 1408 794 4864 1497 4 2
59e 288 107 17 <10 17 - 1152 640 3840 1050 3 2
80 f 944 1274 118 25 8 50 6656 19456 13824 8192 2 0.4
a Immunisation by aerosol of live virus and first i.m. vaccination were performed on day 0,
second i.m.vaccination on day 21 and challenge infection with A/Sw/Oedenrode/96 on day 63. 
b Post-immunisation day 
c Specificity is the ratio of titre with A/Sw/Oedenrode/96 to titre with A/Port/Chalmers/1/73.   
d Specificity is the ratio of titre with A/Port/Chalmers/1/73 to titre with A/Sw/Oedenrode/96.  
e 4 days pre-challenge 
f 17 days post-challenge 
Table 2. Comparison between mean haemagglutination (HI) and virus neutralisation (VN) titres
and the specificity of HI and VN antibodies in serum of pigs immunised by intramuscular
vaccination with A/Port Chalmers/1/73, or by aerosol with A/Sw/Oedenrode/96 a. 
after i.m. vaccination than after immunisation by aerosol of live virus, at PID 59, 4 days 
pre challenge (Fig. 2a,b and Table 2). 
The specificity of the antibodies induced by i.m. vaccination and immunisation 
by aerosol of live virus, was expressed as the ratio (homologous:heterologous) of the 
mean HI and VN titres (Fig. 2c, Table 2). Specificity of antibodies in the pigs immunised 
by aerosol of live virus is the mean titre with A/Sw/Oedenrode/96 : mean titre with 
A/Port/Chalmers/1/73. Specificity of antibodies in the pigs immunised by i.m. 
vaccination is the mean titre with A/Port/Chalmers/1/73 : mean titre with 
A/Sw/Oedenrode/96. As expected, in the group immunised by aerosol of live virus, HI 
and VN titres were much higher (18-fold for HI and >30-fold for VN antibodies, at the 
moment of challenge) against the homologous A/sw/Oedenrode/96 virus than against the 
heterologous A/Port Chalmers/1/73 virus, and before challenge no VN titre was detected 
with A/Port Chalmers/1/73 in the infection group. Surprisingly however, in the i.m. 
vaccine group HI and VN antibody titres were only slightly higher (3-fold for HI and 2-
fold for VN antibodies, at the moment of challenge) against the homologous A/Port 
Chalmers/1/73 virus than against the heterologous A/Sw/Oedenrode/96 virus. 
After challenge, a low HI and VN titre was detected with A/Port Chalmers/1/73 
in the group immunised by aerosol of live virus. The specificity of the VN antibodies 
could be calculated and was higher than of the HI antibodies after challenge (50 and 8, 
respectively). In conclusion, the titres with the homologous virus were comparable in the 
HI assay and the VN assay but the specificity of the antibodies after immunisation by 
aerosol of live virus was even higher in the VN assay than in the HI assay. After 
challenge infection on PID 63 a rise in HI and VN titre was observed in both the group 
immunised by aerosol of live virus and the i.m. vaccine group, in the challenged pigs but 
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Figure 2. HI titres against the virus strains A/Sw/Oedenrode/96 (a) and A/Port Chalmers/1/73 (b),
and mean specificity of HI antibodies expressed as the ratio of mean antibody titres
(homologous:heterologous) (c) in serum of pigs. Pigs were immunised by intramuscular
vaccination with killed A/Port Chalmers/1/73 (●), by aerosol with live A/Sw/Oedenrode/96 (▲),
or were non-immunised (■). Open symbols represent contact animals in the three groups.
Immunisation by aerosol of live virus and first vaccination were performed on day 0, second
vaccination on day 21 (arrow) and challenge infection on day 63 (dashed line). Results are
presented as the mean ± SD (n=5). 
Chapter 3.2 
 
not in the contact pigs, confirming the absence of virus transmission.  
 
Evaluation of NP and isotype-specific antibody responses 
The quality of the antibody responses after i.m. vaccination and immunisation by aerosol 
of live virus was further analysed by measuring the isotype-specific antibody responses. 
Using the isotype-specific ELISAs, IgM and IgG antibodies specific for the NP of 
influenza A virus were determined in serum and IgA antibodies in serum and NLF (Fig. 
3). In the group immunised by aerosol of live virus (PID 0) as well as in the control 
group (PID 63) the kinetics of the IgM, IgG and IgA antibody responses were similarly 
to those previously described [6]. These results confirm the validity of the aerosol 
challenge and transmission model in SPF pigs and of the isotype-specific ELISAs. 
In the group immunised by aerosol of live virus, a sharp rise in serum IgM 
antibody titre specific for influenza virus was detected between PID 3 (negative) and 
PID 7 (maximum titre). In contrast, no IgM response was detected in the i.m. vaccine 
group. After challenge infection on PID 63, no IgM response was observed in any of the 
challenged or contact pigs in the group immunised by aerosol of live virus, nor in the 
i.m. vaccine group (Fig. 3). 
IgG antibodies specific for the NP of influenza virus were first detected on PID 
10 in both the group immunised by aerosol of live-virus and in the i.m. vaccine group 
(Fig. 3). In the group immunised by aerosol of live virus, the titre reached its maximum 
on PID 24 and remained on this level until challenge. In the i.m. vaccine group, the titre 
reached its maximum on PID 31, 10 days after second vaccination. After challenge 
infection a secondary IgG response was observed in the i.m. vaccine group but not in the 
group immunised by aerosol of live virus. This secondary IgG response indicates that 
virus replication occurred after challenge in the i.m. vaccine group but not in the group 
immunised by aerosol of live virus. No secondary IgG response was observed in the 
contact pigs of either group indicating that viral transmission did not occur. 
IgA specific for influenza virus was first detected on PID 7 in blood and nasal 
secretion of pigs in the group immunised by aerosol of live virus (Fig. 3). A weak IgA 
response could also be detected in nasal secretion after first and second vaccination in 
the i.m. vaccine group, but titres were not significantly higher than in the control group 
and significantly lower (p<0.05) than in the group immunised by aerosol of live virus. 
After challenge infection, a secondary IgA response was observed in the group 
immunised by aerosol of live virus. However, in the i.m. vaccine group the IgA response 
was similar to that seen in the non-immunised control group. No secondary IgA response 
was observed in the contact pigs of either group, again indicating that viral transmission 
did not occur. 
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Figure 3. Mean anti-influenza nucleoprotein specific IgM, IgG, and IgA antibody responses in
serum and nasal lavage fluid. Pigs were immunised by intramuscular vaccination with killed
A/Port Chalmers/1/73 (●), by aerosol with live A/Sw/Oedenrode/96 (▲), or were non-
immunised (■). Open symbols represent contact animals in the three groups. Immunisation by
aerosol and first intramuscular vaccination were performed on day 0, second intramuscular
vaccination on day 21 and challenge infection on day 63. Results are presented as the mean ± SD
(n=5). * The nasal IgA titre in the vaccine group was significantly lower than in the infection
group (p<0.05) on these days. The nasal IgA titre in the vaccine group was not significantly
higher than in the control group on any day. 
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Influenza specific T-cell response 
In both the group immunised by aerosol of live virus as well as in the i.m. vaccine group 
an influenza specific T-cell response of PBMC was measured in the lymphoproliferation 
assay (Fig. 4a). In both groups the response was measured from PID 7 onwards. The 
kinetics of the responses was very similar but the response was lower in the i.m. vaccine 
group than in the group immunised by aerosol of live virus. Like the HI antibody 
response, the T-cell proliferation response was more specific after immunisation by 
aerosol of live virus than after i.m. vaccination. PBMC of pigs in the group immunised 
by aerosol of live virus showed a higher response (p<0.05) when stimulated with the 
homologous influenza A/Sw/Oedenrode/96 than with A/Port Chalmers/1/73. PBMC of 
pigs in the i.m. vaccine group showed an equal response to both strains (Fig. 4b). At PID 
3 after challenge infection the specific response dropped dramatically in the i.m. vaccine 
group but not in the group immunised by aerosol of live virus. The vitality of PBMC was 
the same throughout the immunisation and challenge period in all groups. 
 
Discussion 
Due to antigenic drift, recent swine influenza virus strains have been shown to be 
antigenically different from the A/Port Chalmers/1/73 (H3N2) strain currently used in 
commercial vaccines [4]. In the present study, the efficacy of a commercial swine 
influenza vaccine to protect pigs against infection with a recent swine influenza field 
strain (A/Sw/Oedenrode/96 (H3N2)) was investigated. The quality of protection induced 
by the i.m. vaccine was evaluated using a previous homologous infection as a reference 
for optimal protection. In our experiment, the vaccine protected pigs from fever and viral 
transmission to unchallenged group mates and therefore still seems rather efficacious. 
However, it remains uncertain whether the vaccine is effective when used in the field. 
First, the vaccine was shown to induce a lower level of protection than a previous 
infection, because it did not completely prevent viral replication whereas a previous 
infection did. Second, pigs used in this study did not have maternal antibodies, which are 
known to inhibit the active immune response to vaccination. Third, bacterial co-
infections often increase the severity of clinical signs of influenza infections in the field. 
In this study SPF pigs were used in which these secondary infections do not occur. And 
fourth, pigs were vaccinated twice and then challenged 6 weeks later when immunity is 
still optimal. In horses, the time-period of protection after conventional vaccination has 
been shown to be of shorter duration than after previous infection [13]. Furthermore, the 
absence of an IgM response in vaccinated pigs and the subsequently delayed HI antibody 
response further decrease the time-period within which pigs will be well protected. 
Indeed, clinical outbreaks of swine influenza H3N2 do occur in fattening pig herds that 
are vaccinated twice [4]. 
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Figure 4a. Mean influenza specific lymphocyte proliferation responses of PBMC of pigs. Pigs were
immunised by intramuscular vaccination with killed A/Port Chalmers/1/73 (●), by aerosol with live
A/Sw/Oedenrode/96 (▲), or were non-immunised (■). PBMC were stimulated with
A/Sw/Oedenrode/96. Primary infection and first vaccination were performed on day 0, second
vaccination on day 21 and challenge infection on day 63. Results are presented as the mean ± SD
(n=5). * Proliferation in the vaccine group was significantly different from that in the infection group
(p<0.05). 
Figure 4b. Specificity of influenza specific lymphocyte proliferation responses of PBMC of pigs.
PBMC of pigs (n=5) taken at PID 59, were stimulated with A/Sw/Oedenrode/96 or A/Port
Chalmers/1/73. * Proliferation with these viruses was significantly different in the infection group
(p<0.05) 
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In a previous study, a change of the virus strain used in the vaccine was recommended 
because a loss of cross-reactivity of the vaccine strain with ferret and porcine post-
infection antisera was observed in HI assays [4]. The results of the present study indicate 
that such loss of cross-reactivity does not have to mean a loss of cross-reactivity of post-
vaccination antisera with current field viruses. HI and VN antibodies induced by the 
vaccine were more cross-reactive than those induced by infection, and titres after 
vaccination were almost the same against the field strain A/Sw/Oedenrode/96 as against 
the vaccine strain A/Port Chalmers/1/73. 
The observation that vaccination induces more cross-reactive antibodies than 
infection is in line with previous studies. Serum samples from humans, naturally infected 
with influenza showed a strong and specific avidity increase to the infecting strains, but 
not to other virus strains and this avidity increase was not observed after vaccination [2]. 
The antibody affinity maturation was found to depend on the time period of antigen 
stimulation [19] and on antigenic dose [15]. The antigenic load of the vaccine might be 
too high and/or the time period of antigen stimulation too short for affinity maturation, 
even though the antigen is administered in an oil-adjuvant. In addition, since it is a non-
replicating vaccine, it may not have stimulated all the accessory cells that are required 
for affinity maturation. A recent study suggested that live virus is transported and 
released by dendritic cells in secondary lymphoid tissues to induce optimal anti-viral 
neutralising B-cell responses [11]. Because this mechanism would be operative after 
infection but not after vaccination, it could well explain why antibodies induced by 
infection have a higher specificity and affinity. High quantities of serum IgG antibodies 
of low specificity and affinity probably account for the high HI titres induced by 
vaccination, as was previously suggested [2]. The differences in the way antigen is 
presented could also partly explain the unexpected absence of a detectable IgM response 
after vaccination. In addition, the oil-adjuvant in the vaccine may accelerate the 
induction of T-cells to produce interleukins, which stimulate the IgM to IgG isotype 
switching in B-cells.  
The porcine influenza vaccine was shown to confer a sub-optimal protection, 
because it did not completely prevent viral replication whereas a previous infection did. 
Protection from influenza virus infection is thought to depend primarily on secretory IgA 
and transudated IgG antibodies at mucosal surfaces, with IgA being the principal 
mediator of nasal immunity and IgG contributing more to immunity in the lung. IgG and 
CTLs prevent progression and eliminate virus during the recovery phase [1,16,22,23]. 
The results of our study do not rule out that the antigenic variance between the vaccine 
strain and the challenge strain contributes to the observed difference in level of 
protection. However, our study does show that there are also clear differences in the 
induction of specific immune mechanisms that can explain why a previous infection 
confers a better protection than vaccination.  
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The difference in quantity of antibodies induced does not seem to explain a difference in 
protection because HI and VN antibody titres in the serum were higher after vaccination 
than after infection. However, the serum antibody titres do not reflect the local situation 
at the site of infection, and local titres are probably still lower after vaccination than after 
infection. In a previous study we showed that IgG antibodies, although less than IgA 
antibodies, are also produced locally in the lung after infection [6]. The ratio of influenza 
specific IgG antibody titre : total IgG concentration after infection, was approximately 
14 times higher in the lung than in serum. Therefore, it is still possible that increasing the 
serum IgG antibody titre, or inducing a mucosal IgG antibody response, by vaccination 
could lead to better protection.  
The absence of a local IgA response after vaccination will be partly responsible 
for the difference in protection. In this study we showed that the antibody response to 
primary infection was characterised by high IgA antibody titres in nasal secretion and in 
a previous study we showed the same for bronchioalveolar secretions [6]. Moreover, the 
antibody response to secondary infection seems merely a local IgA response. Some nasal 
IgA could also be detected after vaccination, but this is not locally produced. 
Presumably, it is produced systemically and then selectively transported to mucosal 
sites. The kinetics of the IgA response in nasal secretion after challenge of vaccinated 
pigs is similar to that observed in the naive control pigs which suggests that vaccinated 
pigs are not primed for a mucosal immune response. Because IgA is the principal 
mediator of nasal immunity, vaccinated pigs will be especially susceptible to viral 
replication in the nose. 
Whereas IgG antibodies after infection become highly specific, mucosal IgA 
antibodies probably take care of cross-reactivity after infection. Secretory IgA was found 
to have a wider spectrum of activity against type A influenza viruses than circulating 
antibodies [18,25] and cross-protection in mice was correlated with local IgA rather than 
serum antibody [9,20,21]. In our study, the cross-reactivity of IgA antibodies seems 
responsible for the drop in specificity of HI antibodies seen after challenge at PID 63 in 
the infection group. IgA seems the only isotype produced after secondary infection when 
measured in the nucleoprotein specific ELISAs and this is probably also true for 
haemagglutinin specific antibodies. In mice, secondary challenge only increased the 
number of IgA and not of IgG secreting cells in the lung and lymph nodes draining the 
site of infection [5]. If the role of IgA is to prevent viral infection and of IgG to arrest an 
established infection than IgA seems to be more effective for cross-protection. Any 
replication in the presence of immunity can result in antigenic drift and would accelerate 
the race of host immunity against virus.  
A lower cellular immune response will also contribute to a difference in 
protection after vaccination and after infection. Virus specific T-cell responses of PBMC 
were lower after vaccination than after infection. Again, this was not due to the strain 
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used in the proliferation assay because in analogy to HI antibodies, proliferation was 
more cross-reactive after vaccination than after infection. This analogy is possibly due to 
a role of B-cells as antigen presenting cells. T-cell proliferation of PBMC from 
vaccinated pigs was the same when stimulated with the heterologous or with the 
homologous strain. Moreover, like the humoral response, the cellular response after 
infection is probably largely a local response and the proliferation response of PBMC 
does not fully reflect the protective response at the site of infection. A study in mice 
showed that protective virus-specific CD8+ cytotoxic T-cell (CTL) responses were only 
induced in mucosa-associated tissues after infection and not after vaccination, even 
though after vaccination high CTL responses were detected in the spleen and cervical 
lymph nodes [14]. In the present study, the local character of the cellular response is 
possibly reflected by the strong drop in the T-cell response seen after challenge, in the 
vaccinated pigs. This drop could be caused by a recruitment of influenza specific T-cells 
from the blood to the respiratory tract.   
In conclusion, the present study shows that the current vaccine induces a strong 
serum IgG response, which protects pigs against clinical signs, greatly reduces virus 
replication and prevents viral transmission. However, it induces a lower local IgA and 
cellular response, which can explain why it confers a lower level of protection than a 
previous infection. In addition, the IgG antibodies induced by i.m. vaccination probably 
have a lower affinity than the IgG antibodies induced by a previous infection and this 
can also cause a difference in protection. The systemic IgG antibody response and 
cellular response after i.m. vaccination were highly cross-reactive in the in vitro assays 
used, but can be expected to be less effective in vivo. These observations emphasize the 
need to develop vaccination strategies that can induce local and systemic immune 
responses typical of those resulting from natural infection. 
The level of protection conferred by a vaccine should especially be high in the 
case of influenza, when it is based on antibodies reactive with the variable glycoproteins 
haemagglutin and neuraminidase. Such a vaccine should not only prevent clinical signs 
but also viral replication in the host. If the vaccine allows the virus to replicate in the 
presence of immunity, escape variants of the virus will quickly arise leading to an 
acceleration of antigenic drift and loss of vaccine efficacy. Human vaccines are updated 
yearly based on extensive world-wide surveillance, but at least for veterinary 
application, it might be more practical to try to develop broad-spectrum vaccines. Recent 
studies in mice have shown that protective antibodies can be induced with a vaccine 
based on the conserved influenza M2 protein [12], and heterosubtypic immunity 
associated with mucosal cytotoxic T-cells was observed after previous infection [14]. 
Pigs, unlike mice and ferrets, are natural influenza virus hosts and like humans, pigs host 
both the subtypes H1N1 and H3N2. Moreover, their lungs resemble those of humans in 
many physiological aspects and they have therefore been suggested to represent a highly 
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valuable experimental model to study pathogenesis and immunity of influenza in 
humans [24]. The results of the present study indicate that the aerosol challenge model in 
SPF pigs and the influenza and isotype-specific ELISAs are valuable tools to evaluate 
vaccines. Vaccines based on the conserved proteins M2 and nucleoprotein are currently 
investigated. 
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Summary 
The aim of this study was to determine the role of maternally derived antibodies (MDA) 
against an influenza H1N1 virus in the clinical protection of piglets and especially their 
effect on the development of the active immunity after an infection with a homologous 
influenza H1N1 virus. Twenty piglets with MDA and ten piglets without MDA were 
housed together and inoculated twice with influenza H1N1 virus, at 7 and 15 weeks of 
age. Nine piglets without MDA were added to these groups at 12 weeks of age to be 
inoculated at 15 weeks of age only. Clinical signs, body temperature, growth 
performance, virus excretion, antibody responses, and influenza-specific T-cell response 
were monitored. It was shown that MDA protect piglets against the clinical 
consequences of a primary influenza infection, but that this protection is not complete. A 
short but significant rise in body temperature was observed and growth seemed to be 
inhibited due to the infection. Piglets with MDA shed virus for a longer period after an 
infection than piglets without MDA. Piglets with and without MDA were protected 
against the clinical consequences of a secondary infection. However, both after primary 
and secondary infection significant differences in immune responses were observed that 
indicated that pigs with MDA developed a weaker immunity than pigs without MDA. 
Furthermore, overall growth performances from weaning to slaughter show a trend in 
favour of pigs without maternal antibodies, compared to pigs with maternal antibodies, 
mainly caused by a significant better performance in the second half of the finishing 
period. The results of this study provide us insight in the role of MDA in clinical 
protection and their influence on active immunity after an influenza virus infection of 
pigs. Furthermore it leads us to the discussion about the profitability of massive sow 
herd vaccinations in an attempt to increase MDA levels in piglets, taking into account 
the overall performance of these piglets and the possible effects on antigenic drift. 
 
Introduction 
In 1995/96 a field survey was carried out in swine in the Netherlands to examine which 
infectious agents were involved in acute respiratory disease in finishing pigs. Influenza 
virus turned out to be the most important agent involved. It was isolated from nine out of 
sixteen outbreaks of acute respiratory disease. In seven of these outbreaks, among 
finishing pigs 15 to 20 weeks old, no other infectious agents were consistently isolated 
from all investigated pigs, indicating that influenza virus was the primary agent related 
to the clinical signs. The important role of influenza virus in acute respiratory disease 
was confirmed in a follow-up study of another 37 outbreaks (Loeffen, unpublished data). 
In outbreaks not related to influenza but occurring at a comparable age, 
haemagglutination inhibiting (HI) antibodies against one subtype of influenza virus or 
even against both H1 and H3 were often already present. These antibodies must have 
been the result of infections earlier in life. The absence of clinical signs related to these 
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infections suggests that many influenza infections remain subclinical but do result in 
immunity at least for the rest of the finishing period. This is also in agreement with 
studies in which high seroprevalences were observed in finishing pigs, even in herds 
without a history of respiratory disease [7,8,13,14,23]. Protection by maternally derived 
antibodies (MDA) during early infections may have accounted for the absence of clinical 
signs. 
Studies from the early seventies show that MDA protect up to a certain level 
against clinical disease after infection [2] although other studies find no protection 
[15,16] or a level of protection depending on the level of MDA [20]. Besides differences 
in levels of MDA, the age at the moment of infection or the influenza strain used may 
also have influenced the results of these studies. There is a certain consensus about the 
fact that influenza infections in the presence of MDA do not cause any rise in HI 
antibody levels [2,15,16,20]. 
The aim of this study was to determine the role of MDA in the clinical protection 
of piglets and especially their effect on the development of active immunity against a 
homologous influenza H1N1 virus. For this, virus excretion, HI antibody titres, IgM, 
IgA, IgG titres against influenza nucleoprotein, and influenza-specific T-cell responses 
after both the primary and secondary inoculation were analysed in pigs with and without 
MDA. 
. 
Materials and methods 
Housing 
The experiment took place in a small, conventional pig stable. The stable consisted of 
two identical compartments (A and B) that were completely separated from each other, 
including a separate airflow. Each compartment consisted of 5 separate pens that could 
house either one sow with piglets or up to 9 finishing pigs. Pens were separated with 
fully closed dividing boards and no direct contact between pigs from adjacent pens was 
possible. In another part of the building, accessible only through another outside door 
and separate hygiene lock, a small compartment (C) with one pen was available to 
temporarily separate 10 piglets from the other piglets in compartments A and B. 
 
Experimental pigs 
For the experiment 40 piglets were needed: 20 with maternal antibodies against the same 
H1N1 influenza strain they would be inoculated with, and 20 without maternal 
antibodies. To obtain these piglets, eight pregnant sows were bought from a conventional 
sow herd in the Netherlands. This herd had been closed for over eight years, without any 
import of animals and was situated in a region with a low pig density. Serological testing 
of the herd showed that no influenza infections had occurred in the last two-and-a-half 
years because all sows under that age were seronegative for both subtypes present in the 
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Netherlands (H1N1 and H3N2). All eight sows were tested again individually, both in a 
haemagglutination inhibition (HI) assay as well as in an ELISA for influenza 
nucleoprotein-specific IgG, just before they were transported to the experimental 
facilities. 
Five of the eight sows were transported to the experimental facilities seven weeks 
before farrowing and housed in compartment B. They were allowed to acclimatise for 
one week and were then inoculated with an influenza virus, subtype H1N1. The 
remaining three sows were transported to the experimental facilities ten days before 
farrowing and were housed in compartment A. 
All sows farrowed within a period of two days. Piglets received an injection with 
iron and penicillin on day three. Boars were not castrated. At 4 weeks of age, piglets 
were weaned by removing the sows. Blood samples from all sows and piglets were 
collected at the same day and tested for antibodies against influenza subtypes H1N1 and 
H3N2. At 6 weeks of age all test results were available and 40 piglets were assigned to 
the experimental groups. Piglets showing signs of disease were excluded from the 
experiment. All piglets not assigned to any of the groups were removed from the stable. 
Twenty piglets with the highest levels of maternal antibodies from compartment 
B were selected and designated group MDA+7 (MDA positive, first inoculation at 7 
weeks of age). Ten piglets were randomly selected from compartment and were 
designated group MDA-7 (MDA negative, first inoculation at 7 weeks of age). Ten other 
piglets were randomly selected from the remaining piglets in compartment A and were 
designated group MDA-15 (MDA negative, first inoculation at 15 weeks of age). 
Piglets from groups MDA+7 and MDA-7 were randomly (although stratified by 
sex as much as possible) assigned to the ten available pens in compartments A and B, 
resulting in one piglet of group MDA-7 and two piglets of group MDA+7 in each pen. 
By allocating pigs this way, effects of pen or compartment are for the most part 
eliminated in comparisons between the experimental groups. Piglets from group MDA-
15 were relocated to compartment C, where they were kept separated from groups 
MDA-7 and MDA+7 for the next 6 weeks. No contact with these piglets in compartment 
C was allowed for any person, unless at least 12 hours had passed since their last contact 
with other pigs (including those in compartments A and B), and they had showered and 
changed to clean clothing. Separate clothing, boots, feed storage and other supplies were 
used for these piglets. These measures were carried out to prevent these piglets from any 
infection with an influenza virus, including spread of the inoculation strain to 
compartment C. The same hygienic measures were applied for compartments A and B 
although previous contact with pigs in compartment C was allowed. 
Groups MDA+7 and MDA-7 were inoculated with an influenza virus, subtype 
H1N1, for the first time (day 0) when they were 7 weeks of age. Piglets from group 
MDA-15, housed in compartment C, were tested for antibodies against both influenza 
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subtypes when they were 11 weeks of age. They all tested seronegative and at 12 weeks 
of age they were regrouped with groups MDA+7 and MDA-7 by randomly assigning 
one piglet to each pen in compartments A and B. Because one of the piglets in 
compartment C had suddenly died, one pen contained only three piglets, while the others 
all contained four piglets. Cause of death was Mulberry heart disease. 
All pigs were inoculated with an influenza virus, subtype H1N1, when they were 
15 weeks of age (day 56), either for the first time (group MDA-15) or for the second 
time (groups MDA+7 and MDA-7). 
 
Virus and experimental inoculation 
The influenza strain A/swine/Neth/Best/96 (H1N1) was isolated form pneumonic lung 
tissue of a pig from an outbreak of influenza during a recent field survey [12]. The virus 
was isolated on primary porcine thyroid cells and passaged three times in these cells, 
after which it was passaged twice on Madin Darby canine kidney (MDCK) cells. A virus 
stock containing 108 TCID50/ml was produced as described before [9] and stored at         
-70°C. This same batch was used for inoculation of the sows, the piglets at 7 weeks of 
age (day 0) and the pigs at 15 weeks of age (day 56). All pigs were inoculated into the 
nostrils with an aerosol produced by nebulization of 1.5 ml of the culture, using an 
airbrush device (Badger, No.: 100LG, Franklin Park, IL, USA). 
 
Clinical observations and sampling 
Clinical observations and measurements of rectal body temperatures were carried out 
from day -1 to 8 and from day 55 to 67. On the day of the inoculation and the following 
4 days, pigs were observed twice a day, on the other days only once. Clinical scoring 
was carried out by one and the same veterinarian during the whole experiment. This 
veterinarian did not know to which group each pig belonged at the time he was scoring 
them. Pigs were always observed and scored at rest, before body temperatures were 
measured. The clinical signs that were scored were: overall activity, breathing frequency, 
abdominal breathing, and coughing (Table 1). Scores for each observation were 
accumulated to obtain a clinical score for each moment, ranging from 0 to 7. Pigs were 
weighed at 4 weeks of age (day -20, at the time of weaning), and again at day 0, 7, 21, 
56, 63, 77 and 105. 
Pharyngeal swabs for virus isolation were taken on day 1, 2, 4, 6, 8, and 10, as 
well as on day 57, 58, 60, 62 and 64. Multi-layered gauze dressings in a pair of tweezers 
were used to scrape the dorsal pharyngeal wall, behind the soft palate. Tools used for 
sampling were disinfected, rinsed with water and dried between sampling each pig. 
Swabs were stored in 2 ml Eagles minimal essential medium (EMEM) (Flow 
Laboratories) at -70°C until analysis. 
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Table 1. Scores for clinical signs in pigs, experimentally infected with an influenza H1N1 virus. For
a total clinical score all scores per topic are accumulated. 
 
 
 
 
 
 
 
 
 
 
 
Topic Scores Description
Activity 0 Active, alert
1 Diminished activity, not fully alert, gets up after little urge, but tends to lie
down again after a moment
2 Apathy, unwilling to get up, immediately lying down after getting up
under heavy pressure
Breathing frequency 0 Normal
1 Slightly elevated
2 Clearly elevated
Abdominal breathing 0 Normal
1 Slight abdominal breathing
2 Distinct abdominal breathing, jerking
Coughing 0 Absent
1 Present, at rest or during exertion
 
Nasal swabs for detection of IgA antibodies and blood samples for detection of IgM, IgG 
and haemagglutination inhibiting (HI) antibodies were taken on day -20 (HI assay only), 
-3, 4, 7, 14, 21, 28, 53, 60, 63, 70, 77, 84, and 105. Nasal swabs were stored in 1.5 ml 
EMEM at -70°C and serum samples at -20°C until all samples were analysed at the same 
time. Heparinised blood samples for the T-cell proliferation test were taken on day -3, 7, 
14, 53, 60, 63, 70, and 84. These samples were transported to the laboratory for 
immediate analysis. 
 
Virus isolation 
Oropharyngeal swab samples were centrifuged at 1000 g for 10 min. Ten-fold serial 
dilutions of the supernatant were prepared in cell culture infection medium (McCoys 
medium without serum, supplemented with 5 mg/ml trypsin). Dilutions were inoculated 
on MDCK cells in microtitre plates, which were incubated at 37°C and examined for a 
cytopathic effect after 4 days. Of the samples that were negative in the microtitre assay, 
1 ml was tested for the presence of virus by inoculating a monolayer in 25 ml tissue 
culture flasks. Virus titres were calculated by the method of Spearman-Kärber. 
 
Haemagglutination inhibition (HI) assay 
The HI assay detects antibodies against the haemagglutinin (HA) and was performed 
essentially as described previously [10], using 0.5% chicken erythrocytes for 
haemagglutination and strains A/swine/Neth/Best/96 (H1N1) and A/swine/Neth/St 
Oedenrode/96 (H3N2) to test for antibodies against H1 and H3 respectively. All sera 
were tested in serial twofold dilutions, starting at 1:9. Titres ≥18 were considered 
positive. 
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Nucleoprotein (NP)-specific and isotype-specific ELISAs 
The ELISAs to measure influenza NP-specific IgM, IgG, and IgA antibodies in pigs 
were described recently [9]. An antibody capture assay (ACA) format of the ELISA was 
used to detect IgM and IgA. In short, ELISA plates (Costar EIA/RIA, Cat. no. 3590, 
Costar, USA) were coated with monoclonal antibodies (MAbs) specific for porcine IgM 
(28.4.1) or IgA (27.9.1b). Subsequently, they were incubated with 3-fold serial dilutions 
of serum samples or nasal swab samples, antigen (complete virus disrupted in 1% NP-40 
in phosphate-buffered saline (PBS)), a horseradish peroxidase (HRPO) conjugated MAb 
(ATCC No.: HB 65, H16-L10-4R5) against the NP of influenza virus, and a 
chromogen/substrate solution. 
An indirect double antibody sandwich (IDAS) format of the ELISA was used for 
the detection of specific IgG. Plates were coated with the MAb against the NP. 
Subsequently, they were incubated with antigen, 3-fold serial dilutions of serum 
samples, a MAb against IgG (23.49.1) conjugated to HRPO, and chromogen/substrate 
solution. 
The absorbance at 450 nm was read with an ELISA reader (Spectra Reader, SLT 
labinstruments, Salzburg, Austria), and antibody titres were expressed as the reciprocal 
of the sample dilution still giving an optical density (OD) value of 1.0. In each ELISA, 
positive control samples obtained from a previous influenza infection experiment were 
included to enable correction for plate differences. However, differences in titres of 
control samples on different plates were never more than one dilution step. Therefore, no 
correction was needed for any of the titres measured. 
 
T-cell proliferation assay 
The T-cell proliferation assay to measure influenza-specific T-cell responses of pigs was 
developed essentially as described for pseudorabies virus [11]. Briefly, peripheral blood 
mononuclear cells (PBMC) were isolated from heparinised blood samples by 
centrifugation onto Lymphoprep (Nycomed Pharma A., Oslo, Norway), and were 
washed twice with PBS. The isolated PBMC were seeded in 96-well flat-bottom plates 
(M29, Greiner, The Netherlands) at a density of 5 x 105 cells per well in 100 µl medium 
(RPMI 1640 containing 10% porcine serum (a pool from 2 euthanised SPF pigs that did 
not have antibodies to influenza)), 2 mM L-glutamine, 50 µM ß-mercaptoethanol, 200 
U/ml penicillin, 200 µg/ml streptomycin, and 100 U/ml mycostatin). To the PBMC, 100 
µl medium containing 400 haemagglutinating units and 5 x 105 TCID50 of influenza 
A/swine/Neth/Best/96, a control sample prepared from non-infected cells (mock control) 
or 5 µg/ml of Con A (vitality control) were added in quadruplicate. After 4 days 
incubation at 37°C in a 5% CO2 atmosphere, the cultures were pulsed with 0.4 µCi [3H]-
thymidine (Amersham, The Netherlands). After 4 hours of incubation, cells were 
harvested and the incorporated radioactivity was measured in a Betaplate scintillation 
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counter (Wallac, EG&G Instruments, The Netherlands). Proliferation was expressed as 
the number of counts (mean of quadruplicate) of influenza-stimulated PBMC minus the 
number of counts of the mock control-stimulated PBMC (delta counts). 
 
Statistics 
Comparisons of growth rates, body temperatures, virus isolation, IgM, IgA, IgG, and HI 
antibody titres, and T-cell proliferation in all three experimental groups were evaluated 
in an analysis of variance with pen as a block variable, allowing for comparison of 
treatment within blocks. Comparisons of clinical scores were evaluated by a non-
parametric analysis on ranks (Wilcoxon rank-sum test). All comparisons were made by 
comparing two groups at a time. 
 
Results 
Clinical signs 
The first clinical signs were noticed within 24 hours after inoculation and the clinical 
score peaked at approximately 30 hours after the inoculation (Fig. 1). Only minor or no 
signs were noticed in groups MDA+7 after both inoculations and MDA-7 after the 
secondary inoculation at 15 weeks of age. The course of the clinical signs was similar 
after primary inoculation at 7 or 15 weeks of age in groups MDA-7 and MDA-15 
respectively. However, the peak score in group MDA-15 seemed a little higher, 
indicating slightly more severe clinical signs. In general, coughing was a rare symptom, 
noticed in a few pigs and for a few days only. 
Body temperature curves showed a course similar to that of the clinical score. In 
groups MDA-7 and MDA-15 after primary inoculation at 7 and 15 weeks of age 
respectively, a rise in body temperature was noticed within 24 hours after the inoculation 
and peaked at approximately 30 hours after the inoculation (Fig. 1). A second peak, 
much lower but lasting longer, was observed, most notably in group MDA-15, after the 
inoculation at 15 weeks. Piglets from group MDA+7 showed a very short rise in body 
temperature approximately 30 hours after the inoculation at 7 weeks of age (Fig. 1). On 
the other hand, most pigs with antibodies due to a previous inoculation showed no 
increase of body temperature at all after the secondary inoculation at 15 weeks of age. 
In the first week after the primary inoculation at 7 weeks of age, growth rates in 
the MDA-7 group were significantly lower than in the MDA+7 group (Table 2). In the 
second and third week however, there was some compensation in the MDA-7 group and 
overall, growth performance from day 0 to day 21 was not significantly different 
between both groups. Much higher growth rates between day 7 and 21 suggested that the 
first inoculation also reduced the growth rate in group MDA+7 in the first week after 
inoculation. 
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Table 2. Growth performances in pigs, experimentally infected with an influenza H1N1 virus, 
before and after inoculations at 7 (D0) and 15 (D56) weeks of age (group MDA-15 only 
inoculated at the age of 15 weeks). Different letters in a column are significant differences 
between values (P<0.05). 
 
 
 
 
 
 
 
 
 
 
 Group n Growth performance after inoculation at 7 weeks of age
D-20/0 D0/7 D7/21 D0/21
g/day SD g/day SD g/day SD g/day SD
 MDA+7 20 378a 66 513a 103 784a 95 694a 66
 MDA-7 10 379a 64 397b 182 807a 129 670a 92
 Group n Growth performance after inoculation at 15 weeks of age
D38/56 D21/56 D56/63 D63/77 D56/77
g/day SD g/day SD g/day SD g/day SD g/day SD
 MDA+7 20 - - 818a 93 764a 160 903a 164 856ab 148
 MDA-7 10 - - 873a 92 825a 128 1087b 150 975a 134
 MDA-15 9 912 110 - - 41b 422 1158b 255 786b 110
 
 
n=number of pigs in each group, SD=standard deviation. 
In the first week after the inoculation at 15 weeks of age, growth rates in the primary 
inoculated group MDA-15, were severely reduced, compared to the secondary 
inoculated groups MDA+7 and MDA-7 (Table 2). Again, in the second and third week 
after inoculation, growth rates were partly compensated. Both groups MDA+7 and 
MDA-7 showed a minor reduction in growth during the first week after secondary 
inoculation, compared to growth rates right before and after that week. 
Right before slaughter, at day 105 of the experiment, pigs from group MDA-7 
were significantly heavier than pigs from group MDA+7 (Table 3). In the overall growth 
performance from weaning until slaughter (day -20 to 105) there was a trend in favour of 
group MDA-7 (P=0.07), mainly caused by a significantly higher growth rate between 
day 56 and 105, after the second inoculation (P=0.02). Group MDA-15, although 
included in table 3, was not included in these comparisons because these pigs were kept 
under different circumstances for a part of their life. 
 
Virus isolation 
After the primary inoculation at 7 weeks of age, there was no significant difference 
between groups MDA+7 and MDA-7 in virus isolation from pharyngeal swabs during 
the first 4 days (Fig. 1). However, piglets with MDA excreted virus longer than pigs 
without MDA. On day 6 post-inoculation virus could be isolated from only 2 out of 10 
piglets from group MDA-7, against 13 out of 20 piglets from group MDA+7. After the 
secondary inoculation at 15 weeks of age, low amounts of virus were isolated from only 
3 pigs from group MDA+7 at day 1 post-inoculation, and no virus was isolated from 
pigs in group MDA-7. Virus isolation from group MDA-15 was similar to group MDA-7 
after the primary inoculation at 7 weeks of age (Fig. 1). 
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Table 3. Live body weights (at weaning, before second inoculation and before slaughter) and
growth performances (weaning to second inoculation, second inoculation to slaughter and overall)
in pigs, experimentally infected with an influenza H1N1 virus, once (group MDA-15, at 15 weeks
of age) or twice (groups MDA+7 and MDA-7, at 7 and 15 weeks of age). Different letters in a
column are significant differences between values (P<0.05). Only groups MDA+7 and MDA-7
are compared with each other because group MDA-15 was housed under different circumstances
between day -4 and day 38. 
 
 
 
 
 
 
 
 
 
 
 
 
 Group n Live body weight
Day -20 Day 56 Day 105
kg SD kg SD kg SD
 MDA+7 20 8.7a 0.30 59.5a 1.1 103.0a 2.1
 MDA-7 10 9.9b 0.74 62.1a 1.4 112.2b 2.9
 MDA-15 9 9.8 0.58 65.7 1.8 109.9 2.6
 Group n Growth performance
D-20/56 D56/105 D-20/105
g/day SD g/day SD g/day SD
 MDA+7 20 668a 62 887a 130 754a 76
 MDA-7 10 687a 63 1022b 123 818a 81
 MDA-15 9 735 61 901 135 800 66
 
n=number of pigs in each group, SD=standard deviation 
Antibody response 
IgM antibody titres were highest at 7 days after inoculation and persisted longer in pigs 
inoculated at a later age (MDA-7 vs. MDA-15, both after primary inoculation) (Fig. 2). 
IgM antibody titres were almost completely suppressed after inoculation in the presence 
of either MDA or actively produced antibodies. The IgG response was initially also 
inhibited in the presence of MDA (MDA+7 after primary inoculation), but in time, titres 
in groups MDA+7 and MDA-7 after the primary inoculation became comparable. The 
secondary inoculation however resulted in a booster effect in group MDA+7, but not in 
group MDA-7. The IgG response in group MDA-15 was comparable to that in group 
MDA-7 after the primary inoculation at 7 weeks of age (Fig. 2). 
The IgA response was also suppressed after inoculation in the presence of MDA. 
However, when the same pigs (MDA+7) were inoculated again, the IgA response was 
faster than in naive pigs (MDA-15) (Fig. 2), although the antibodies were detectable for 
a shorter period of time. 
The formation of HI antibodies was almost completely suppressed after 
inoculation in the presence of MDA. However, secondary inoculation at 15 weeks of age 
in that group (MDA+7) resulted in antibody titres significantly higher than in the other 
two groups (Fig. 2). 
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Figure 1. Mean clinical scores, body temperatures, and virus titres in pharyngeal swabs, after
inoculation of pigs at the age of 7 and 15 weeks with an influenza H1N1 virus. Pigs were either MDA
positive (MDA+7) or MDA negative (MDA-7 and MDA-15). At the age of 15 weeks, group MDA-15
was inoculated for the first time, while the other two groups were inoculated for the second time with
the same influenza virus strain. 
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Figure 2. Mean influenza nucleoprotein-specific serum IgM, serum IgG, and nasal IgA, and
mean serum HI antibody titres after inoculation of pigs at 7 and 15 weeks old with an influenza
H1N1 virus. Groups MDA+7 and MDA-7 were MDA positive and MDA negative respectively
and were inoculated with the same influenza virus strain at 7 and 15 weeks of age. Group
MDA-15 was MDA negative and was inoculated at 15 weeks of age only. 
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Figure 3. Mean influenza-specific lymphoproliferation response of PBMC after inoculation of
pigs at 7 and 15 weeks old with an influenza H1N1 virus. Groups MDA+7 and MDA-7 were
MDA positive and MDA negative respectively and were inoculated with the same influenza virus
strain at 7 and 15 weeks of age. Group MDA-15 was MDA negative and was inoculated at 15
weeks of age only. 
T-cell response 
After the inoculation at 7 weeks of age, an influenza specific T-cell response of PBMC 
was measured in groups MDA+7 and MDA-7. Kinetics of the responses were similar, 
although the early response at day 7 was significantly higher in group MDA-7 than in 
group MDA+7 (Fig. 3). 
After the inoculation at 15 weeks of age, kinetics of the responses were quite 
different. In group MDA+7 there was a sharp drop 4 days after the inoculations, before it 
went up to be the highest response of all groups. In group MDA-7 the response remained 
more consistent, and the response in group MDA-15 was similar to that of group MDA-7 
after the primary inoculation at 7 weeks of age. 
 
Discussion 
Maternally derived antibodies (MDA) against an influenza H1N1 virus protect piglets 
against the clinical effects of an influenza infection with the same virus strain. However, 
protection is not complete, at least not at the levels of antibodies present at challenge in 
our study. In piglets protected by MDA a small peak of fever was noticed approximately 
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30 hours after the infection. Also, growth rates during the first week after the infection, 
compared to the two weeks following, indicate a minor growth retardation due to the 
infection. Moreover, the virus excretion was not significantly reduced by the presence of 
MDA, but lasted even longer than in piglets without MDA. 
MDA mainly consist of IgG antibodies, which predominantly protect the lungs 
against virus replication and invasion. Local antibodies of the IgA isotype on the other 
hand are important in the inhibition of virus replication in the upper airways 
[1,19,21,22]. Observations in the present study confirm the inhibition or at least delay of 
the active antibody response to primary infection (including IgA, but also IgM, IgG, and 
HI antibody response) in the presence of MDA. Moreover, MDA not only inhibited the 
antibody responses, but also affected the proliferative T-cell response after primary 
infection. Although the response was ultimately comparable to that of piglets without 
MDA, the response was initially inhibited in the presence of MDA, resulting in a 
significantly lower response at 7 days after primary infection. The inhibition of the 
immune response and the inability of the MDA to counter virus replication in the upper 
airways may explain why the virus is excreted for a longer period in piglets with MDA. 
Prolonged virus excretion, as well as an initial reduction of the 
lymphoproliferation response in piglets with MDA was found in pseudorabies virus 
infections as well [4]. In addition, Renshaw described several experiments, which 
suggested that influenza virus excretion from piglets with low levels of MDA lasted at 
least as long as from MDA-negative piglets [20]. Higher levels of MDA however 
resulted in a much shorter period of excreting influenza virus. Because these 
experiments were performed using piglets from different ages and different inoculation 
protocols, interpretations have to be made with caution, but the level of MDA may be an 
important factor determining the duration of virus excretion. 
The implications of the extended virus excretion in MDA positive piglets are hard 
to assess. Vaccinating sows, thereby increasing levels and duration of MDA, may not 
affect virus circulation among piglets. Therefore, the only effect would be a clinical 
protection of influenza virus infections in young piglets, also resulting in a less than 
optimal active immunity, as discussed further on. However, transmission of virus is not 
only affected by virus excretion, but by susceptibility of the host as well. Transmission 
experiments with pseudorabies virus in MDA positive piglets showed that, possibly 
depending on the levels of MDA, MDA can significantly inhibit transmission of the 
virus [3], even though under certain circumstances excretion of virus may be extended 
compared to piglets without MDA. 
Antigenic drift of influenza viruses in pigs is less pronounced then in humans, 
although limited antigenic drift has been reported to occur for influenza subtypes H1N1 
[6] and H3N2 [5]. This limited antigenic drift is likely to be caused by immune pressure, 
either in sows that live long enough to be infected more than once with the same 
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subtype, or in young piglets in the presence of MDA. Excretion, and therefore 
replication of virus seems not to be inhibited in the presence of MDA. It is however 
conceivable that the extensive replication in the presence of antibodies results in 
antigenic drift. Transmission experiments wherein influenza virus is passaged several 
times in MDA-positive piglets and antigenetically compared to the original strain would 
show the effect of MDA on virus transmission and in how far they can cause antigenic 
drift. This information would be valuable to assess the effect of massive sow vaccination 
in order to increase levels and duration of MDA in piglets. 
The presence of MDA also inhibited the development of immunity against a 
secondary influenza infection. The differences in immune responses after the second 
inoculation at the age of 15 weeks were even more pronounced than after primary 
inoculation. The stronger HI, IgG, IgA, and lymphoproliferation responses in the MDA-
positive than in the MDA-negative pigs after the second inoculation, indicate that the 
immunity of MDA-positive pigs prior to secondary inoculation was weaker. In addition, 
a sharp drop in the proliferative T-cell response upon secondary inoculation in MDA-
positive pigs was observed, which probably resulted from an initial massive relocation of 
T-cells to the lungs, dramatically lowering the presence of influenza-specific T-cells in 
the peripheral blood. This relocation probably compensated for lower protective 
antibody levels in the MDA-positive pigs, rather than for a lower level of cell-mediated 
immunity, because previous studies indicated that MDA do not affect the establishment 
of cell-mediated immunity [17,18]. 
There was a clear difference between the antibody response to the NP measured 
in the IgG ELISA and the HI antibody response. The IgG response to the NP in MDA-
positive piglets was comparable to the response in MDA-negative piglets, after a 
primary inoculation. However, the HI antibody response was much lower in MDA-
positive piglets. This is consistent with the findings of Pertmer et al. who demonstrated 
that the IgG response to the HA, but not the IgG response to the NP was inhibited by 
MDA [17]. It was suggested that the immune response against HA, embedded in the 
virus membrane and thus fully accessible to antibodies, would be blocked by maternal 
antibodies because they neutralise the HA before it is presented to the immune system. 
On the other hand maternal antibodies would not block the response to the NP because 
they have little access to NP, which is either shielded by the viral lipid membrane or 
inside the infected host cell. However, it is also possible that the strong immunogenicity 
is an intrinsic characteristic of the NP. Because antibodies to the NP do not inhibit viral 
replication, the NP may thus act as a decoy to misdirect the antibody response. 
Besides a difference in clinical signs and immune response caused by the 
presence of MDA, some differences also seemed to be caused by age. Fully susceptible 
piglets at the age of 7 weeks showed less growth retardation and less severe clinical 
signs than pigs at the age of 15 weeks. However, because these inoculations were not 
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carried out at the same time, these conclusions can not statistically be accounted for. 
In conclusion it can be stated that maternal antibodies do protect piglets against 
most of the clinical consequences after an influenza virus infection and that this infection 
also leads to an active immunity, protecting the pig probably at least until the end of the 
finishing period. This may explain why so many infections in the field are subclinical 
and pass unnoticed for most farmers. Both clinical protection and development of active 
immunity however are sub-optimal in MDA-positive pigs as several parameters showed. 
Furthermore, it may be that the overall growth performance in MDA-positive pigs is 
lower than in MDA-negative pigs in cases where there is repeated contact with influenza 
virus. In our experiment this difference was mainly caused by a highly significant 
difference in growth performances in the period from the second inoculation until 
slaughter. Thus it remains to be seen whether massive vaccination of sow herds will be 
profitable in terms of performance of piglets and finishing pigs, to say nothing of the 
possible effects on antigenic drift and its attendant necessity to update influenza vaccines 
regularly [5,6]. Depending on the rate of transmission of influenza virus among MDA 
positive piglets, this effect on genetic drift may or may not be a problem, but should 
certainly be investigated in detail. 
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Heterosubtypic immunity after infection 
 
Summary 
The level of heterosubtypic immunity (Het-I) and the immune mechanisms stimulated by 
a heterosubtypic infection were investigated in pigs. Pigs are natural hosts for influenza 
and, like humans, they host both the subtypes H1N1 and H3N2. Marked Het-I was 
observed when pigs were infected with H1N1 and subsequently challenged with H3N2. 
After challenge with H3N2, pigs previously infected with H1N1, did not develop fever 
and showed reduced virus excretion compared to non-immune control pigs. In addition, 
viral transmission to unchallenged group mates could be shown by virus isolation in the 
non-immune control group but not in the group previously infected with H1N1. Pigs 
previously infected with homologous H3N2 virus were completely protected. After 
challenge with H3N2, pigs previously infected with H1N1 showed a considerable 
increase in serum IgG titre to the conserved extracellular domain of M2 but not to the 
conserved NP. These results suggest that antibodies against external conserved epitopes 
can have an important role in broad-spectrum immunity. After primary infection with 
both H1N1 and H3N2, a long-lived increase in the percentage of CD8+ T-cells in the 
lungs and in the lymphoproliferation response in the blood was observed. Upon 
challenge with H3N2, pigs previously infected with H1N1 again showed an increase in 
the percentage of CD8+ T-cells in the lungs whereas pigs previously infected with H3N2 
did not, suggesting that CD8+ T-cells also have a role in Het-I. To confer a broad-
spectrum immunity, future vaccines should induce antibodies and CD8+ T-cells against 
conserved antigens. 
 
Introduction 
Influenza A virus expresses on its membrane two immunogenic, but variable proteins: 
the haemagglutinin (HA) and the neuraminidase (NA). In humans, new epidemic strains 
arise every one to two years, as a result of selected point mutations in these two surface 
glycoproteins, a phenomenon known as antigenic drift. Sometimes, an exchange of the 
HA and/or NA gene segment with an animal virus occurs, a phenomenon known as 
antigenic shift, and this may result in a pandemic. Current human influenza vaccines are 
yearly updated to induce immune responses specific for the prevalent strains. 
Antigenic drift is generally ascribed to immune pressure, i.e. the influence of 
antibodies induced by a previous infection, or by vaccination. In pigs, antigenic drift of 
influenza viruses seems to be more limited than in humans [1,3,6]. This is probably 
because pigs have a short life span, which does not cover more than one influenza 
epidemic, and vaccines are only seldom applied. Nevertheless, antigenic drift of the 
swine influenza A H3N2 viruses was demonstrated in the Netherlands and Belgium. 
This drift has led to a loss of cross-reactivity of recent field isolates with the human 
A/Port Chalmers/1/73 (H3N2), which is the current strain in the swine influenza vaccine. 
Therefore, replacement of this strain by a more recent swine H3N2 isolate was 
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recommended [8]. However, the regular updating of influenza vaccines is costly and 
impractical. Antigenic shifts occur frequently in pigs [4,5,46], probably because pigs are 
highly susceptible to infection and have cell surface receptors for viruses of both avian- 
and human origin [17]. Moreover, it is conceivable that if vaccines were to be applied 
more widely, acceleration of antigenic drift and antigenic shifts will soon give rise to 
escape variants. 
Instead of the regular updating of vaccine strains, it might be possible to induce 
broadly reactive immune responses which could provide protection when the vaccine 
does not match circulating strains, perhaps even against a new subtype. Broadly reactive 
responses against influenza A have been studied extensively in mice [20,28,34,42,44]. 
Infection of mice with an influenza A virus of one subtype can induce partial protection 
against an infection with a virus of a different subtype [11,13,21,27,33,43]. However, the 
immune mechanisms responsible for this broad protection, termed heterosubtypic 
immunity (Het-I), are still incompletely defined. 
In this study, the level of Het-I to infection with an H3N2 virus after primary 
infection with an H1N1 virus and the immune mechanisms stimulated, were investigated 
in pigs. The H3N2 virus was transmitted from humans to pigs during the 1968 Hong 
Kong pandemic, and the H1N1 virus from birds to pigs in Northern Europe in 1979. In 
1984 a genetic reassortment between the two subtypes occurred, resulting in an H3N2 
virus carrying all proteins of the avian H1N1 virus, except for the HA and NA [5]. Since 
then, the unchanged avian H1N1 virus and the reassortant human H3N2 virus have 
continued to co-circulate in the swine population in Europe. The fact that all proteins 
except for the HA and NA are very similar between the two subtypes, makes these 
European swine viruses ideal to study heterosubtypic immunity. 
 
Materials and methods 
Propagation of influenza virus  
The influenza virus strains A/Sw/Best/96 (H1N1) and A/Sw/Oedenrode/96 (H3N2) were 
isolated from pneumonic lung tissue of pigs from outbreaks of influenza during a recent 
field survey [22]. These viruses were isolated in primary cultures of porcine thyroid 
cells, then passaged three times in these cells, and then passaged twice in Madin Darby 
canine kidney cells (MDCK, ECACC No.: 84 121 903). Virus stocks were produced, 
and stored at -70°C until used as inoculum or as antigen in haemagglutination inhibition 
(HI) assays, ELISAs, and T-cell proliferation assays.  
 
Pigs, immunisation, and challenge 
Thirty Dutch Landrace pigs were obtained from the specified pathogen free (SPF) herd 
of the Institute for Animal Science and Health. The pigs were divided into three groups 
of 10 pigs and each group was housed in a separate room. At the age of 10 weeks, pigs 
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were inoculated with live virus, in the nostrils, with an aerosol produced by nebulisation 
of 2 ml culture supernatant, using an air brush device (Badger, No.: 100LG, Franklin, IL, 
USA). Pigs in the heterosubtypic immunity (Het-I) group were immunised with 108 
TCID50 of the field isolate A/Sw/Best/96 (H1N1). Pigs in the homologous immunity 
(Hom-I) group were immunised with A/Sw/Oedenrode/96 (H3N2). Pigs in the control 
group were inoculated with uninfected culture supernatant and were used as challenge 
controls. At post-inoculation day (PID) 42, six weeks after primary infection, five of the 
pigs in each group were challenged with an aerosol of the field isolate 
A/Sw/Oedenrode/96 (H3N2). The other five pigs of each group were kept apart for 24 
hours and then reunited with their challenged group mates to determine whether viral 
transmission occurred in the presence of Hom-I and Het-I, and in the absence of 
immunity. The experiment was approved by the institutes ethical committee for 
experiments in animals. 
 
Clinical observations and sampling of pigs 
Rectal temperatures of all pigs were measured with a thermometer (C 402 Terumo 
Digital Clinical, Vetin-Aacofarma, The Netherlands), and oropharyngeal fluid was 
collected daily for eight days following primary infection (PID 0-8) and challenge 
inoculation (PID 42-50). From the five challenged pigs blood was collected at PID 0, 3, 
7, 10, 18, 25, 31, 38, 46, 50, 53, and 59, and from the five contact pigs at PID 38, 46, 50, 
53 and 59. Serum was collected to determine the HI antibody titres in the HI assay, and 
of IgG antibodies specific for the extracellular domain of M2 (M2e) and for the 
nucleoprotein (NP) in ELISAs. Heparinised blood was collected for the isolation of 
peripheral blood mononuclear cells (PBMC) to be used in a T-cell proliferation assay. 
Bronchioalveolar lavage fluid (BALF) and nasal swabs (NS)(Medical Wire & 
Equipment Co., Corsham, UK), of the challenged pigs were collected at PID 0, 2, 4, 8, 
11, 15, 22, 29, 39, 44, 46, 50, 53, and 57. To collect NS and BALF, animals were 
anaesthetised by injection (ketamine, midazolam, medetomidine). To avoid excessive 
interference in viral transmission, no BALF was collected from the contact pigs. NS was 
collected to determine antibody titres in the anti-NP IgA ELISA, and BALF to monitor 
the changes in phenotypes of BALF cells by flow cytometry. 
 
Virus isolation 
Ten-fold serial dilutions, starting at a dilution of 1:10, of oropharyngeal fluid were 
prepared in cell culture infection medium (McCoys medium without serum, 
supplemented with 5 µg/ml trypsin). Dilutions were inoculated on MDCK cells in 
microtitre plates, which were incubated at 37 °C and examined for a cytopathic effect 
after 4 days. Of the samples that were negative in the microtitre assay, 1 ml was tested 
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for the presence of virus by inoculating a monolayer in 25 ml tissue culture flasks. Virus 
titres were calculated by the method of Spaerman-Kärber. 
 
Haemagglutination inhibition (HI) assay 
The HI assay was performed essentially as described previously [18], using 0,5 % 
chicken erythrocytes for haemagglutination and four haemagglutinating units of 
A/Sw/Best/96 (H1N1) or A/Sw/Oedenrode/96 (H3N2). 
 
ELISA for IgG specific for the extracellular domain of M2 (M2e) 
The sequence coding for the complete M2 protein was determined for A/Sw/Best/96 
(H1N1) and A/Sw/Oedenrode/96 (H3N2). The first 25 N-terminal amino acid residues 
that form the extracellular domain of the M2 protein (M2e), were the same for both 
subtypes. A synthetic peptide with the amino acid sequence MSLLTEVETPTRNGWEC 
RY was made and a conjugate of this peptide with keyhole lipid haemocyanin was used 
to coat 96-well ELISA plates (Costar EIA/RIA, Cat. no. 3590, Costar, Cambridge, UK). 
Plates were then blocked with 1% BSA in PBS, incubated with 2-fold serial dilutions of 
serum samples starting at a dilution of 1:20, incubated with a MAb against swine IgG1 
(23.49.1) conjugated to HRPO, and then incubated at room temperature with 
chromogen/substrate solution. The absorbance at 450 nm was read with an ELISA reader 
(Spectra Reader, SLT labinstruments, Salzburg, Austria), and antibody titres were 
expressed as the reciprocal of the sample dilution still giving an optical density (OD) 
value of 1.0. 
 
ELISAs for IgG and IgA specific for the nucleoprotein (NP) 
The ELISAs to measure influenza nucleoprotein (NP) specific IgG, and IgA antibodies 
in pigs were described recently [16]. Absorbance and antibody titres were determined as 
described for the anti-M2e IgG ELISA.  
 
Flow cytometric analysis of BALF cells  
The technique that was used to obtain BALF was previously described [40]. 
Approximately 30 ml of PBS was added to the BALF to render a total volume of 50 ml. 
The BALF cells were collected by centrifugation at 300 x g for 10 min at 4 ºC and 
washed once with 50 ml PBS. Cells were then suspended in 1 ml PBS containing 2% 
heat-inactivated bovine serum and 0.01% sodium-azide (FACS-buffer) and the total 
number of recovered cells was determined. Cells were spun down in 96-well U-
bottomed microtitre plates by centrifugation at 230 x g for 3 min. The supernatant was 
discarded and the cells were incubated for 30 min. on ice with various combinations of 
MAbs to leukocyte differentiation antigens. The MAbs used to differentiate myeloid 
cells were directed against the following cell markers: SWC3 (clone 74-22-15, IgG1), 
MHC II (clone MSA3, IgG2a), CD14 (clone MY4, Ig2b) (Coulter, Hialeah, FL, USA), 
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and CD163 (clone CVI 517.2, IgG2b). The MAbs used to differentiate lymphoid cells 
were directed against: CD2 (clone MSA4, IgG2a), CD3 (clone ppt3, IgG1), CD4 (clone 
74-12-4, IgG2b), CD5 (clone b53b7, IgG1), CD6 (clone a38b2, IgG1), CD8 (clone 
295/33 IgG2a), and γδT-cell receptor (TCR-γδ)(clone ppt16, IgG2b). These MAbs were 
previously used to analyse changes in the phenotype of leukocytes in the BALF of pigs 
infected with porcine reproductive and respiratory syndrome virus [32]. After incubation 
the cells were washed three times with FACS buffer, and then incubated for 30 min on 
ice with the appropriate fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated goat anti-mouse IgG isotype specific antibodies, diluted in FACS buffer. 
Subsequently, the cells were washed three times, re-suspended in FACS buffer, and 
transferred to tubes. Fluorescence was measured using a FACScan flow cytometer 
(Becton Dickinson, Mountain View, CA, USA). 
 
T-cell proliferation assay 
The T-cell proliferation assay to measure influenza specific T-cell responses of pigs was 
performed essentially as described for pseudorabies virus [19]. Briefly, PBMC were 
isolated from heparinised blood samples by centrifugation onto Lymphoprep (Nycomed 
Pharma A., Oslo, Norway), and were washed twice with PBS. The isolated PBMC were 
seeded in 96-well flat-bottom plates (M29, Greiner, The Netherlands) at a density of 5 x 
105 cells per well in 100 µl medium (RPMI 1640 containing 10% porcine serum, 2 mM 
L-glutamine, 50 µM β-mercaptoethanol, 200 U/ml penicillin, 200 µg/ml streptomycin, 
and 100 U/ml mycostatin). To the PBMC, 100 µl medium containing 105 TCID50 of 
influenza A/Sw/Best/96 (H1N1) or A/Sw/Oedenrode/96 (H3N2), a control sample 
prepared from non-infected cells (mock control), or 5 µg/ml of Con A (vitality control), 
were added in quadruplicate. After 4 days incubation at 37 °C in a 5% CO2 atmosphere, 
the cultures were pulsed with 0.4 µCi [3H]-thymidine (Amersham, The Netherlands). 
After 4 h of incubation, cells were harvested and the incorporated radioactivity was 
measured in a Betaplate scintillation counter (Wallac, EG&G Instruments, The 
Netherlands). Proliferation was expressed as the number of counts (mean of 
quadruplicate) of influenza stimulated PBMC minus the number of counts of the mock 
control stimulated PBMC (delta counts). 
 
Results 
Clinical signs and virus excretion  
Primary inoculation of pigs by aerosol with 108 TCID50 of A/Sw/Oedenrode/96 (H3N2) 
or A/Sw/Best/96 (H1N1) virus into the nostrils caused acute disease. Eight out of ten 
H3N2 inoculated pigs and all H1N1 inoculated pigs, developed fever (≥ 40°C) for at 
least one day between day 1 and 6 after inoculation. The infection with the H1N1 virus 
was more severe than with the H3N2 virus, because more pigs had fever during a longer  
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A/Sw/Best/96
(H1N1)
A/Sw/Oedenrode/96
(H3N2) Control
Pig 1 2 3 4 5 1 2 3 4 5
PIDa
1 4.4 2.5 4.6 2.6 2.3 2.5 3.4 2.7 3.3 2.1
2  < <  <   < 2.2 <
3 3.6 < < < 2.3 2.6 < < 2.3 <
4 < 2.5 < < <  2.3 < < 2.6
5 2.1 2.8 3.2 < < 2.6 < < < <
6 < <     <  < 
7          
8          
challenged pigs challenged pigs challenged pigs contact pigsb
1 2 3 4 5 6 7 8 9 10
1(43) 2.6  < < <      < < < 2.7 2.5      
2 < < <  <      < < <        
3           < <  3.7  < < < 2.6 2.6
4           <  <    <    
5           <     <     
6                2.0 <    <
7                     
8                     
 
 
Table 1. Virus titres in oropharyngeal swabs (log10TCID50 /ml) of pigs after primary infection with
A/Sw/Best/96 (H1N1) or A/Sw/Oedenrode/96 (H3N2) and after subsequent challenge of pigs with
A/Sw/Oedenrode/96 (H3N2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: PID = post-inoculation day 
b: Virus was only detected in contact pigs in the non-immunised control group, and not in contact
pigs in the other groups. The 5 contact pigs were separated before their group mates were challenged
and were then reunited after 24 hours. 
< : virus detected in 1 ml sample  
 : No virus detected 
time. Mean temperatures of all pigs are presented (Fig. 1a). In both groups, pigs excreted 
virus for 5 or 6 days after infection (Table 1). 
After challenge inoculation with H3N2 at PID 42, fever was measured in each of 
the 5 challenged pigs in the control group but not in the groups that were previously 
immunised with H1N1 (Het-I group) or H3N2 (Hom-I group) (Fig. 1b). In addition, 
virus excretion and transmission to the contact animals was reduced in the Het-I group 
compared to the control group (Table 1), indicating that infection with H1N1 confers 
heterosubtypic protection to infection with H3N2. Pigs in the Hom-I group did not 
excrete any virus after challenge. 
No fever was detected in the contact pigs in the Hom-I nor in the Het-I group, but 
neither in the contact pigs of the control group (data not shown). 
 
HI responses 
No cross-reactivity of HI antibodies from H1N1 infected pigs with the H3N2 virus, or 
vice versa, was observed after primary infection (Fig. 2a,b). 
After challenge, the challenged pigs in the Het-I group developed an H3N2- 
specific HI response that was very similar, in both kinetics and height, to the response  
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Figure 1a. Mean temperatures of pigs after infection with influenza A/Sw/Best/96 (H1N1) (●)
or A/Sw/Oedenrode (H3N2) (▲), and of control pigs (■)(n=10). Later, of the 10 pigs in each
group, 5 were challenged and 5 were used as contact pigs. Contact pigs were separated before
their group mates were challenged and were then reunited after 24 hours. 
Figure 1b. Mean temperatures of pigs after challenge with influenza A/Sw/Oedenrode (H3N2)
virus, 6 weeks after primary infection with A/Sw/Best/96 (H1N1) (●), or A/Sw/Oedenrode
(H3N2) (▲), and of non-immune control pigs (■). Results are presented as the mean ± SD (n=5).
Only temperatures of challenged pigs are presented. No fever was detected in the contact pigs in
any of the three groups. 
 
 
developed by the non-immune control pigs (Fig. 2a). However, contact pigs in the Het-I 
group showed no detectable (2 out of 5) or only a very low HI response (3 out of 5). 
A slight increase in the HI titre in the challenged pigs in the Het-I group was also 
observed to H1N1 (Fig. 2b), indicating that some cross-reactive HI antibodies were 
produced after heterosubtypic infection. 
 
M2e-specific serum IgG, and NP-specific serum IgG and nasal IgA response 
After primary infection with H1N1 or H3N2, a low IgG response to M2e was observed. 
This response was 3-fold higher after H1N1 infection than after H3N2 infection, which 
was also observed for the anti-NP IgG response. After challenge, the anti-M2e titre 
increased by 25-fold in the challenged pigs in the Het-I group, whereas it did not 
increase in the Hom-I group. This strong IgG booster response in the Het-I group against  
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Figure 2. Mean HI titres against the virus strains A/Sw/Oedenrode/96 (H3N2)(a) and
A/Sw/Best/96 (H1N1)(b) in serum of pigs. At PID 0, pigs were inoculated with 108 TCID50 of
A/Sw/Best/96 (H1N1) (●) or A/Sw/Oedenrode (H3N2) (▲), or with non-infected cell supernatant
(■). At PID 42, pigs were challenged with A/Sw/Oedenrode/96 (H3N2). Open symbols represent
contact pigs in the three groups. Contact pigs were separated before their group mates were
challenged and were then reunited after 24 hours. Results are presented as the mean ± SD (n=5). 
M2e was not observed against the conserved NP. No increase in the M2e IgG titre was 
observed in the contact pigs in the Het-I group.  
The kinetics of the NP specific IgG and IgA antibody responses after primary 
infection with H1N1 was very similar as after infection with H3N2. However, H1N1-
infected pigs showed a higher serum IgG response (Fig. 3a), whereas H3N2-infected 
pigs showed a higher nasal IgA response (Fig. 3b). 
After challenge infection with H3N2, a slight secondary NP specific IgG response 
in the challenged pigs was observed in the Het-I group but not in the Hom-I group (Fig. 
3a). No secondary IgG response was detected in the contact pigs of the Het-I group. 
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Figure 3. Mean serum IgG antibody response to the extracellular domain of the M2 protein
(M2e) (a), and mean serum IgG (b), and nasal IgA (c), antibody responses to influenza
nucleoprotein (NP) of pigs. At PID 0, pigs were inoculated with 108 TCID50 of A/Sw/Best/96
(H1N1) (●) or A/Sw/Oedenrode (H3N2) (▲), or with non-infected cell supernatant (■). At PID
42, pigs were challenged with A/Sw/Oedenrode/96 (H3N2). Open symbols represent contact
animals in the three groups (n=5). Contact pigs were separated before their group mates were
challenged and were then reunited after 24 hours. Results are presented as the mean ± SD (n=5). 
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After challenge infection, a secondary IgA response was observed in the Het-I group, 
which was stronger than in the Hom-I group (Fig. 3b). No secondary IgA response was 
observed in the contact pigs of the Hom-I group nor in the Het-I group. 
 
Flow cytometric analysis of BALF cells 
With the MAbs used, 2 phenotypes of myeloid cells were differentiated; SWC3+CD163-
CD14+MHCII- cells (neutrophil phenotype), and SWC3+CD163+CD14+MHCII+ cells 
(monocyte and macrophage phenotype) (Fig. 4a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a. Flow cytometry analysis of leukocytes collected from the lungs of pigs. Plot showing
the two gates separating the lymphocytes from other leukocytes (I), and plots showing the
percentage of SWC3+CD163- neutrophils in the lungs of non-immune pigs 2 days after inoculation
with non-infected cell supernatant (II) or influenza infected cell supernatant (III). 
Figure 4b. Flow cytometry analysis of lymphocytes collected from the lungs of pigs after
inoculation with non-infected cell supernatant (I), primary inoculation with 108 TCID50 of
A/Sw/Best/96 (H1N1) (II) and subsequent challenge with A/Sw/Oedenrode (H3N2) (III). Cells
were double stained with MAbs directed against CD5 and CD8. These plots of representative
samples clearly show the infiltration of CD5+CD8high cytotoxic T lymphocytes (CTLs).  
By comparing the kinetics and percentages of lymphoid cells, stained with all 
combinations of MAbs, 5 phenotypes of lymphoid cells were distinguished. These 5 
phenotypes could all be seen separately when a combination of MAbs against CD5 and 
CD8 was used (Fig. 4b). The lymphoid phenotypes were: CD2+CD3-CD4-CD5-CD6-
CD8lowTCR-γδ- (NK phenotype), CD2+CD3+CD4-CD5+CD6+CD8high TCR-γδ- (CTL 
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phenotype), CD2+CD3+CD4+CD5highCD6+CD8-/low TCR-γδ- (Th phenotype), 
CD2+CD3+CD4-CD5lowCD6-CD8-/low TCR-γδ+(TCR-γδ+ T-cell phenotype) and a 
heterogeneous population of CD5-CD8- cells (-/- T cells). 
As reported previously [32], a population of large highly autofluorescent cells 
(LHAC) and a population of small low autofluorescent cells (SLAC) were distinguished 
and these were analysed separately (Fig. 4a). It was shown that the LHAC consisted 
solely of myeloid (SWC3+) cells. However, a large proportion of the SLAC at day 2 and 
4 after infection was also SWC3+. These were SWC3+CD163- neutrophils, which 
massively infiltrated the lung (Fig. 4a) as previously described [15,41]. Therefore 
corrections were made, such that the neutrophils were subtracted from the lymphoid- and 
added to the myeloid population and the percentage of the different cell phenotypes 
within the two populations could be calculated. Because the cell numbers collected from 
the BALF of pigs varied too much between samples, we did not use the cell counts to 
calculate the absolute numbers of cells of each phenotype. 
All changes in the phenotype of the BALF myeloid and lymphoid leukocyte 
populations after primary and secondary infection of the pigs are shown (Fig. 5a,b). 
After primary infection with H1N1or H3N2, an acute inflammatory response 
characterised by a massive increase of neutrophils from 6 to 40% (PID 2) of all 
leukocytes in the lungs was observed. After challenge, the infiltration was the same in 
the non-immune control group, reduced in the Het-I group and absent in the Hom-I 
group (Fig. 5a). 
As from PID 8, the percentage of lymphocytes in the lungs of both H1N1- and 
H3N2-infected pigs is higher than in the control pigs and remains elevated until PID 42. 
Further analysis of the different phenotypes within the lymphocyte population shows the 
following sequence of events after H3N2 infection: 1) An increase in percentage of NK 
cells starting at PID 2, 2) a peak in percentage of Th-cells between PID 4 and PID 11, 3) 
a massive infiltration of CTLs on PID 8 leading to a decrease in percentage of NK cells 
on this day, 4) the temporary disappearance of the CTLs from the lungs around PID 11, 
and 5) a long-lived increase in the percentage of CTLs in the lungs and the drop of NK 
cells to pre-infection level. The same sequence of events was also observed after H1N1 
infection but developed faster than after H3N2 infection (Fig. 5b). 
Upon challenge infection on PID 42, a second increase in the percentage of CTLs 
was observed in the Het-I group but not in the Hom-I group. The secondary infiltration 
of CTLs after H3N2 challenge infection (PID 42) in the Het-I group was not observed to 
be any faster than after primary infection in the control group, and even later than after 
primary H1N1 infection (PID 0) (Fig. 5b). 
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Figure 5a. Changes in the leukocyte population in the lungs of pigs (n=5). At PID 0, pigs were
inoculated with 108 TCID50 of A/Sw/Best/96 (H1N1) ("), or A/Sw/Oedenrode/96 (H3N2) (▲), or
with non-infected cell supernatant (!). At PID 42, pigs were challenged with A/Sw/Oedenrode/96
(H3N2). 
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Fig. 5b. Changes in the lymphocyte population in the lungs of pigs (n=5). At PID 0, pigs were
inoculated with 108 TCID50 of A/Sw/Best/96 (H1N1) ("), or A/Sw/Oedenrode/96 (H3N2) (▲),
or with non-infected cell supernatant (!). At PID 42, pigs were challenged with
A/Sw/Oedenrode/96 (H3N2). Results are presented as the mean ± SD (n=5). 
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Influenza specific T-cell response 
After infection with both H1N1 and H3N2 an influenza specific T-cell response of 
PBMC was measured in the lymphoproliferation assay from PID 7 onwards (Fig. 6a). 
The T-cell proliferation was partially subtype specific. PBMC of pigs infected with 
H1N1 virus showed a higher response when stimulated with A/Sw/Best/96 (H1N1) than 
with A/Sw/Oedenrode/96 (H3N2), while the opposite was true for PBMC of pigs 
infected with H3N2 (Fig. 6a,b).  
Upon secondary challenge infection on PID 42 an increase in the T-cell 
proliferation response was observed in the Het-I group but not in the Hom-I group. In 
both the challenged pigs (Fig. 6a) as well as in the contact pigs (Fig. 6b) in the Het-I 
group, a secondary lymphoproliferation response was observed.  
The vitality of PBMC was the same throughout the experimental period in all 
groups. 
 
Discussion 
Heterosubtypic immunity (Het-I), the immunity induced by infection with an influenza 
virus of one subtype against a subsequent infection with a virus of another subtype, has 
been observed in mice [11,13,21,27]. In humans, it was shown to be weak [36], although 
occasional examples have been reported [35]. Here we report the existence of clear Het-I 
in pigs, using swine viruses of two subtypes, which are currently co-circulating in the pig 
population in Europe. Infection with a swine influenza virus of the subtype H1N1 was 
shown to partially protect pigs against infection with a virus of the subtype H3N2. After 
challenge with H3N2, pigs previously infected with H1N1, did not get fever and showed 
reduced virus excretion compared to non-immune control pigs. As a consequence, less 
virus was transmitted to the unchallenged group mates and virus excretion by these pigs 
could not be detected by virus isolation. Although Het-I does not provide the complete 
protection against infection as seen with homologous immunity, it could well be 
sufficient to halt the spread of an influenza virus infection in a pig population in the 
field. 
The predominant role of haemagglutinin and neuraminidase specific virus-
neutralising IgA and IgG antibodies in protection against secondary infection with a 
homologous influenza A virus is well established. However, the immune mechanisms 
responsible for Het-I are incompletely defined. In the present study, the responses of 
different immune mechanisms to a primary and a secondary infection were monitored to 
gain insight into the immunity underlying the sub-optimal protection against infection 
with a heterologous or, in our case, heterosubtypic virus. This insight might suggest 
approaches to enhance the induction of responses leading to broad protection, by 
vaccination. 
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Figure 6a. Mean influenza specific lymphocyte proliferation responses of PBMC of pigs when
stimulated with A/Sw/Oedenrode (H3N2)(closed symbols) or with A/Sw/Best/96 (H1N1)(open
symbols). At PID 0, pigs were inoculated with 108 TCID50 of A/Sw/Best/96 (H1N1) (●) or
A/Sw/Oedenrode/96 (H3N2) (▲), or with non-infected cell supernatant (■). At PID 42, pigs
were challenged with A/Sw/Oedenrode/96 (H3N2). 
Figure 6b. Mean influenza-specific lymphocyte proliferation responses of PBMC of contact
pigs in the three groups. Contact pigs were separated before their group mates were challenged
and were then reunited after 24 hours. Results are presented as the mean ± SD (n=5). 
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HI antibodies after infection with H1N1 did not cross-react with the H3N2 virus in the 
HI assay and therefore, pre-challenge HI antibodies do not seem to be responsible for the 
observed Het-I. However, after challenge with H3N2 a rise in HI titre was also observed 
against H1N1, which suggests that cross-reactive HI antibodies are produced. 
Haemagglutinin specific virus-neutralising antibodies that cross-react between subtypes 
have been reported [28,34]. In addition, helper T-cells specific for influenza internal 
proteins can enhance the HI antibody response [31]. In this manner, subtype-specific 
antibodies will be produced faster and can contribute to Het-I, besides cross-reactive 
antibodies. In the present study, the kinetics and height of the H3-specific HI antibody 
response after challenge of pigs in the Het-I group was the same as in the non-immune 
control group, which seems to disagree with this concept. However, pre-existing 
immunity can enhance the response to challenge infection but can also inhibit the 
response by reducing antigen exposure. Therefore, it is difficult to compare the response 
to challenge infection with the response to injection with a fixed quantity of antigen, as 
studied by Russell & Liew (1979).  
Interestingly, the antibody response to the conserved extracellular domain of the 
M2 protein (M2e) was clearly boosted by the heterosubtypic infection because the serum 
M2e antibody titre increased by 25-fold between day 4 and 8 post-challenge. In 
comparison, the antibody titre to the, also conserved, NP only increased by 2-fold. 
Therapeutic treatment with an M2e-specific MAb was shown to reduce pulmonary virus 
titers by 100- to 1000-fold in mice [24,38]. It is therefore conceivable that pre- and post-
challenge M2e antibodies play a significant role in the early reduction of viral 
replication. The M2-specific antibody response in convalescent humans has been 
reported to be low and not consistently detectable [2]. The present study shows that in 
pigs, the M2e antibody response to a primary influenza infection is indeed low compared 
to the response after heterosubtypic infection. The current porcine vaccine does not 
induce a detectable M2e antibody response (unpublished result). Enhancement of the 
M2e response by vaccination may provide increased Het-I, as was previously suggested 
for humans [24,38]. Interestingly, it was shown that in the proper circumstances, 
vaccination with the extracellular domain of the M2 protein in the absence of other 
influenza virus proteins can reduce viral infection in mice [26]. 
The percentage of CD8+ cytotoxic T-lymphocytes (CTLs) in the lungs of pigs 
increased from approximately 10% before, to more than 30% after primary infection, to 
more than 50% after secondary infection. The secondary challenge only increased the 
percentage of CTLs in the lungs of heterosubtypically immune pigs, indicating that 
CTLs play a role in Het-I. The CD8+ T-cell arm of the cellular response has been 
proposed to be the major mediator of Het-I, and many studies indeed proved that CTLs 
contribute to protection in mice [12,25,37,39]. A large proportion of these cells 
recognises conserved epitopes of the NP. More than 15% of CTLs in the lungs after 
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primary infection and more than 65% after heterosubtypic challenge, were shown to be 
specific for the immunodominant NP366-374 peptide [10,13,14]. Moreover, challenge was 
performed 7 months after priming of mice, removing any concern that CTL memory is 
of short duration. However, it was also shown that the secondary CTL response develops 
in the mesenteric lymph nodes (MLN) and that it takes at least 4 to 5 days before the 
effectors are available in the infected respiratory tract of mice. In the present study, the 
infiltration of CTLs into the lungs after secondary infection with the H3N2 virus was not 
observed any earlier than after primary H3N2 infection and even later than after primary 
H1N1 infection. Such a delay could be too long for CTLs to have a major contribution to 
clearance of the hit and run influenza virus. In line with this idea, it was shown that the 
CTL response was capable of handling all but a very low challenge dose of influenza 
virus in the absence of antibody [29]. In the present study, the contact pigs in the Het-I 
group showed a similar lymphoproliferation response as the challenged pigs, but hardly 
any serum HI-antibody response, anti-M2e antibody response, or nasal anti-NP antibody 
response. Therefore, it seems that the contact pigs were indeed able to cope with the low 
dose of transmitted virus, via a T-cell response rather than a B-cell response. 
An infiltration of natural killer (NK) cells into the lungs was observed between 
PID 0 and 15 after primary infection. These cells probably kill influenza infected 
epithelial cells in the early stage of primary infection in a non-specific manner, but in a 
later stage of the primary - as well as in the early stage of secondary infection are 
possibly targeted to infected host cells by antibodies. Anti M2e MAbs and anti-NA 
MAbs that do not have virus-neutralising activity were suggested to target effectors of 
the innate immune system to infected cells, in mice [24]. An influx of CD4+CD8-/low 
helper T-cells (Th) was observed between PID 0 and 11. CD4+ T-cell mediated recovery 
from influenza virus was reported to be mediated by the promotion of an antiviral Ab 
response [23,37], and CTL response [30]. In addition, CD4+ T-cells have been suggested 
to kill infected cells in an MHCII restricted manner [7,45]. The role of TCR-γδ+ T-cells 
in protection is unclear. In mice, they have been reported to greatly increase in frequency 
during the recovery phase from influenza pneumonia [9], but this was not observed in 
pigs in the present study. 
The lymphoproliferation response increased after challenge in the Het-I group, 
but not in the Hom-I group. Probably, the pigs in the Hom-I group are so well protected 
that the challenge virus is cleared from the lungs without inducing a secondary 
lymphoproliferation response. The increase in lymphoproliferation seems to correspond 
to the increase in the percentage of CTLs in the lungs, which was also observed only in 
the Het-I group. However, in a previous experiment, in which pigs were primary infected 
and then challenged with the homologous virus 9 weeks later, a secondary 
lymphoproliferation response, but no increase in the percentage of CTLs in the lungs 
was observed (unpublished results). Probably, in Hom-I lymphoproliferation mainly 
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supports an antibody response whereas in Het-I it also supports a CTL response. The 
lymphoproliferation response was subtype-specific because it was higher when PBMC 
from infected pigs were stimulated with the homologous than with the heterosubtypic 
virus. This could be caused by the fact that the proliferation partially depends on T-cells, 
and on antigen presentation by B-cells, that recognise epitopes of the glycoproteins.  
In conclusion, the present study shows Het-I in pigs. Furthermore, it provides 
additional evidence to the notion that cross-reactive antibodies and CTLs both play a 
role in Het-I. Het-I provides a much lower level of protection than Hom-I because 
antibodies, antigen presenting B-cells, helper T-cells, and part of the CTLs are subtype 
specific, and because the less protective antibody response to conserved epitopes is low. 
Especially the antibody response to the conserved M2e after primary infection is sub-
optimal. This makes M2e an attractive candidate for vaccine induced broad-spectrum 
immunity. Additional conserved epitopes to which protective immunity can be induced, 
may be discovered in the future. Although heterosubtypic immunity does not provide the 
complete protection against infection seen with homologous immunity, it caused a 
pronounced reduction in viral replication and fever. Prevention of all viral replication 
after challenge may not be a realistic goal in cross-protection, but a significant reduction 
in viral replication and clinical disease, may well be. For humans, such a level of 
protection could be vital in case the vaccine strain does not match the circulating strain 
or in case there will be a next pandemic. For pigs, the level of protection could be 
sufficient to abrogate viral spread in case the vaccine strain does not match the 
circulating strain. 
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Summary 
In mice, vaccines inducing antibodies to the extracellular domain of the M2 protein 
(M2e) can confer protection to influenza A infection. Unlike the surface glycoproteins 
haemagglutinin and neuraminidase this domain of M2 is highly conserved, and is 
therefore a potential broad-spectrum immunogen. In this study, the protection conferred 
by vaccines inducing antibodies to M2e was evaluated in a challenge model for swine 
influenza in pigs. A protein resulting from the fusion between M2e and Hepatitis B core 
protein (M2eHBc), with or without adjuvant was evaluated. Immunisation with this 
protein was previously shown to partially protect mice from infection (Neirynck et al., 
1999). In addition, a DNA construct expressing a fusion protein between M2e and 
influenza nucleoprotein (M2eNP) was evaluated to see if the broad-spectrum protection 
conferred by antibodies could be further enhanced by T-helper cells and cytotoxic T-
cells. All vaccines induced an antibody response against M2e, and the M2eNP DNA 
vaccine additionally induced an influenza-specific lymphoproliferation response. 
However, after challenge with a swine influenza virus (H1N1), no protection was 
observed in the vaccinated groups compared to the non-vaccinated control group. On the 
contrary, vaccinated pigs showed more severe clinical signs than the control pigs. The 
M2eNP DNA vaccinated pigs showed the most severe clinical signs and three out of six 
pigs died on days 1 and 2 post-challenge. These results indicate that antibodies to M2e, 
especially in combination with cell-mediated immune responses exacerbate disease. 
Thus, clinical signs after infection should be observed closely in further studies using 
M2e as an immunogen, and caution should be exercised using M2e in humans. 
 
Introduction 
Influenza A virus expresses two highly immunogenic, but variable, transmembrane 
proteins: haemagglutinin (HA) and neuraminidase (NA). In humans, new epidemic 
strains arise every one to two years, as a result of selected point mutations in these two 
surface glycoproteins, a phenomenon known as antigenic drift. Sometimes, an exchange 
of the HA and/or NA gene segment with an animal influenza virus occurs, a 
phenomenon known as antigenic shift, and this may result in a flu pandemic. Current 
human influenza vaccines are yearly updated to induce immune responses specific for 
the prevalent strains. These vaccines are efficacious when the HA of the vaccine strain 
matches that of the circulating virus, but not when it differs as a result of antigenic drift 
or shift. 
Another transmembrane protein is the M2 protein. This protein is relatively 
invariant from strain to strain, and a number of studies showed that it is a potential 
broad-spectrum immunogen. Vaccination with M2 protein in the absence of other 
influenza virus proteins reduced viral infection [5,20], and therapeutic treatment with a 
MAb specific for the extracellular domain of M2 (M2e) was shown to reduce pulmonary 
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virus titers by 100- to 1000-fold in mice [14,22]. In a previous study in pigs, we 
observed that the antibody response to M2e, which was low after a primary influenza 
H3N2 infection, was clearly boosted by a subsequent infection with H1N1, indicating 
that antibodies to M2e have a role in heterosubtypic immunity [7]. In contrast to the HA, 
the M2 protein is not accessible to antibody, and therefore antibodies to M2e are not 
virus neutralising. However, they can bind to the M2e on infected host cells, and reduce 
viral replication by interfering with viral budding [25], and by mediating the killing of 
infected lung epithelial cells by complement or by cells of the innate immune system 
(antibody dependent cytotoxicity, ADCC [14]). In addition, antibodies that bind before 
budding of the virions could hinder them from infecting cells or could enhance the 
uptake by phagocytic cells via the Fc receptor. 
Because the M2 itself seems to be a weak immunogen and only antibodies to the 
extracellular domain of the protein can be expected to protect, Neirynck et al. (1999) 
combined this highly conserved domain with the Hepatitis B core protein [16]. The 
resulting fusion protein facilitated the presentation of M2e and induced partial immunity, 
in mice. In the present study, we investigated the protection conferred by this fusion 
protein with or without adjuvant, in a challenge model for swine influenza in pigs. In 
addition, we evaluated whether the broad-spectrum protection conferred by antibodies 
could be further enhanced by inducing T-helper and cytotoxic T-lymphocytes (CTLs). T-
helper cells can mediate recovery from influenza infection by the promotion of an 
antiviral Ab response [13], and CTL response [17]. CTLs have been proposed to be the 
major mediator of heterosubtypic immunity, and many studies indeed proved that CTLs 
contribute to protection in mice [2,15,21,23]. Moreover, a previous study we performed 
indicated that CTLs also have a role in heterosubtypic immunity in pigs [7]. After 
infection, a large proportion of these CTLs recognises conserved epitopes of the 
nucleoprotein (NP). In mice, more than 15% of CTLs in the lungs after primary - and 
more than 65% after secondary heterosubtypic influenza infection were shown to be 
specific for the immunodominant NP366-374 peptide [1,3,4]. Therefore, we made a DNA 
construct expressing a fusion protein between M2e and influenza nucleoprotein (NP). It 
was expected that the expression of M2eNP by DNA vaccination would induce an 
antibody response to the conserved M2e, as well as a T-helper and CTL response to the 
conserved NP, and would confer a better protection than M2eHBc fusion protein 
 
Materials and methods 
Propagation of influenza virus  
The influenza virus strains A/Sw/Best/96 (H1N1) and A/Sw/Oedenrode/96 (H3N2) were 
isolated from pneumonic lung tissue of pigs from outbreaks of influenza during a recent 
field survey [11]. These viruses were isolated in primary cultures of porcine thyroid 
cells, then passaged three times in these cells, and then passaged twice in Madin Darby 
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canine kidney cells (MDCK, ECACC No.: 84 121 903). Virus stocks were produced, 
and stored at 70 °C until used as inoculum or as antigen in haemagglutination inhibition 
(HI) assays, ELISAs, and T-cell proliferation assays.  
 
M2e-Hepatitis B core fusion protein 
Purified M2e-Hepatitis B core fusion protein (M2eHBc, [16]) was kindly provided by 
Dr. Sabine Neirynck, Flanders Interuniversity Instititute for Biotechnology. The amino-
acid sequence of the M2e is derived from a human influenza virus strain and is present in 
almost all presently known human influenza A field strains. This sequence differs from 
the M2e of European swine influenza viruses in 6 out of the 23 amino-acids that form 
the M2e (Fig. 1a). 
 
Construction, preparation and analysis of M2eNP DNA construct 
The two regions of gene segment 7 encoding the complete M2 protein were amplified by 
RT-PCR from RNA of influenza A/Sw/Oedenrode/96 (H3N2) and A/Sw/Best/96 
(H1N1). Primers used were Uni 12, 5AGCAAAAGCAGG 3, and V7 166R, 5 
TAGCCACTCCATGAGAGCC 3, and V7 675, 5ATGAGAACAGTTGGGACTC 3, 
and V7 1007R, 5 TTACTCCAGCTCTATGTTGAC 3. The region of gene segment 5 
encoding the complete nucleoprotein (NP) of influenza A/Sw/Oedenrode/96 (H3N2) was 
amplified using the primers Uni12 and V5 1546R, 5 GAAACAAGGGTATTTTTCT 3. 
The nucleoprotein was cloned into Escherichia coli using a PgemT cloning kit 
(Promega). The nucleotide sequences of M2 and NP were determined using the PRISM 
Ready Dye T Deoxy Terminator cycle sequencing kit and the ABI PRISM 310 Genetic 
Analyzer (Perkin-Elmer). These sequences were sent to Genbank and the accession 
numbers are AF385294 and AF385295, for the nucleotide and amino-acid sequence of 
the M2 protein of A/Sw/Best/96 (H1N1) respectively, and AF385296 and AF385297, for 
the M2 protein, and AF385293 for the NP of A/Sw/Oedenrode/96 (H3N2). 
The first 24 N-terminal amino acid residues, MSLLTEVETPTRNGWECRY 
SDSND that form the extracellular domain of the M2 protein (M2e) were identical for 
the swine influenza H1N1 and H3N2 virus strains, and differed in 6 residues from the 
universal human sequence (Fig. 1a). A 102 residue oligonucleotide was synthesised 
which comprises the complete sequence coding for swine M2e downstream of a Kozak 
motif for initiation of translation in vertebrates [10]. A 106 residue antisense strand was 
also synthesised and the two oligonucleotides were annealed together by heating for 2 
min. at 95 °C and subsequent cooling, thus resulting in a 102 basepair fragment with a 
sticky end. For directional cloning, a BclI restriction site was added at the 5 end of the 
fragment. The sticky 3 end could directly be ligated onto the DNA fragment encoding 
for the NP, after restriction of this fragment with SmlI. The fragment resulting from this 
fusion was cloned into the XbaI and BclI cloning sites of the eukaryotic expression 
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vector pVR1012 (Vical, San Diego, USA), downstream of the human cytomegalovirus 
(HCMV) promoter (Fig. 1b). The pVR1012 plasmid lacking the M2eNP DNA insert 
served as a control. Plasmids were propagated in the HB101 strain of E. coli and purified 
using Qiagen columns. 
Transient expression of the M2eNP fusion protein was confirmed in confluent 
monolayers of SK-6 cells [8], using MAbs against the NP (ATCC No.: HB 65, H16-
L10-4R5) and M2e (14C2-S1-4, kindly provided by Dr. Walter Gerhard, The Wistar 
Institute). The proper size of the fusion protein was confirmed by radio-immuno 
precipitation (RIP), using the MAb against the NP, and subsequent SDS-PAGE (Fig. 1c). 
 
Pigs, immunisation, and challenge 
Twenty-four Dutch Landrace pigs were obtained from the SPF herd of the Institute for 
Animal Science and Health. They were assigned to four groups of 6 pigs and each group 
was housed in a separate room. Starting at the age of 10 weeks, all pigs were inoculated 
three times with a 3-week interval with 2 ml inoculum. Pigs in the M2eHBc group were 
immunised intramuscularly with 50 µg protein in saline. Pigs in the M2eHBc plus 
adjuvant group, were immunised intramuscularly with 50 µg protein in adjuvant 
(CoVaccine, The Netherlands). Pigs in the M2eNP DNA group were injected 
intradermally, behind the ear, with 200 µg of M2eNP-encoding plasmid. Pigs in the 
control group were injected with 200 µg of empty plasmid.  
At post-inoculation day (PID) 70, 4 weeks after the third vaccination, all pigs 
were challenged with the field isolate A/Sw/Best/96 (H1N1). Pigs were challenged with 
an aerosol produced by nebulisation of 2 ml culture supernatant containing 108 TCID50 
virus, using an air brush device (Badger, No.: 100LG, Franklin, IL, USA). The institutes 
ethical committee for experiments in animals approved the experiment. 
 
Clinical observations and sampling  
Clinical signs and body temperature of all pigs were monitored and oropharyngeal fluid 
was collected daily for eight days following challenge inoculation (PID 70-78). The 
following clinical signs were scored: laboured breathing, abdominal breathing, anorexia, 
apathy, and coughing. Blood was collected at PID 0, 3, 7, 10, 17, 24, 31, 38, 45, 52, 66, 
73, 77, 80, and 87. Serum was collected to determine the titres of HI antibodies in the HI 
assay, and of IgG antibodies specific for the extracellular domain of M2 (M2e) and for 
the nucleoprotein (NP) in ELISAs. Heparinised blood was collected for the isolation of 
peripheral blood mononuclear cells (PBMC) to be used in a T cell proliferation assay. 
Bronchioalveolar lavage fluid (BALF) and nasal swabs (NS) were collected at PID 66, 
72, 74, 78, and 88. To collect NS and BALF, animals were anaesthetised by injection 
(ketamine, midazolam, medetomidine). NS was collected to determine antibody titres in 
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Figure 1a. Alignment of the amino-acid sequences of the extracellular domain of the M2 protein
(M2e) from European swine and human influenza viruses.  
Figure 1b. Schematic representation of the expression vector M2eNP pVR1012. The expression
vector was constructed from pVR1012 (Vical, San Diego, USA), a mammalian expression vector
containing the CMV immediate-early transcriptional enhancer, promoter, and intron A regulatory
elements and the poly (A) signal and transcription termination sequences of the bovine growth
hormone (bGH) in a pUC18 backbone. The gene fragments encoding the extracellular domain of
M2 (M2e) and the nucleoprotein of influenza A/Sw/Oedenrode/96 were fused, and cloned into the
multiple cloning site of the vector. 
Figure 1c. Analysis of the M2eNP fusion protein. Influenza infected minipig kidney cells, and
M2eNP pVR1012 transfected or non-transfected SK-6 cells were incubated with 35S-labeled
cysteine and methionine. Proteins from the cell lysates were immunoprecipitated with an influenza
NP-specific MAb (ATCC, HB65), and analysed by SDS-PAGE. The M2eNP fusion protein is
larger than the wild-type NP (59 and 56 kD respectively). 
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the anti-NP IgA ELISA, and BALF to monitor the changes in phenotypes of BALF cells 
by flow cytometry.  
 
Virus isolation 
Ten-fold serial dilutions, starting at a dilution of 1:10, of oropharyngeal fluid were 
prepared in cell culture infection medium (McCoys medium without serum, 
supplemented with 5 µg/ml trypsin). Dilutions were inoculated on MDCK cells in 
microtitre plates, which were incubated at 37 °C and examined for a cytopathic effect 
after 4 days. Of the samples that were negative in the microtitre assay, 1 ml was tested 
for the presence of virus by inoculating a monolayer of MDCK cells in 25 ml tissue 
culture flasks. Virus titres were calculated by the method of Spearman-Kärber.  
 
Haemagglutination inhibition (HI) assay 
The HI assay was performed essentially as described previously [9], using 0.5 % chicken 
erythrocytes for haemagglutination and four haemagglutinating units of A/Sw/Best/96 
(H1N1). 
 
ELISA for IgG specific for the extracellular domain of M2 (M2e) 
The ELISA to detect IgG specific for M2e was recently described [7]. A synthetic 
peptide with the amino acid sequence MSLLTEVETPTRNGWECRY of the M2e of the 
swine influenza viruses was made and a conjugate of this peptide with keyhole lipid 
haemocyanin was used to coat 96-well ELISA plates (Costar EIA/RIA, Cat. no. 3590, 
Costar, Cambridge, UK). Plates were then blocked with 1% BSA in PBS, incubated with 
2-fold serial dilutions of serum samples starting at a dilution of 1:20, incubated with a 
MAb against swine IgG1 (23.49.1) conjugated to HRPO, and then incubated at room 
temperature with chromogen/substrate solution. The absorbance at 450 nm was read with 
an ELISA reader (Spectra Reader, SLT labinstruments, Salzburg, Austria), and antibody 
titres were expressed as the reciprocal of the sample dilution still giving an optical 
density (OD) value of 1.0.  
 
ELISAs for IgG and IgA specific for the nucleoprotein (NP) 
The ELISAs to measure influenza nucleoprotein (NP)-specific IgG, and IgA antibodies 
in pigs were described previously [6]. Absorbance and antibody titres were determined 
as described for the anti-M2e IgG ELISA.  
 
Flow cytometric analysis of BALF cells  
The technique that was used to obtain BALF was previously described [24]. 
Approximately 30 ml of PBS was added to the BALF to render a total volume of 50 ml. 
The BALF cells were collected by centrifugation at 300 x g for 10 min at 4 ºC and 
washed once with 50 ml PBS. Cells were then suspended in 1 ml PBS containing 2% 
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heat-inactivated bovine serum and 0.01% sodium-azide (FACS-buffer) and the total 
number of recovered cells was determined. Cells were spun down in 96-well U-
bottomed microtitre plates by centrifugation at 230 x g for 3 min. The supernatant was 
discarded and the cells were incubated for 30 min. on ice with various combinations of 
MAbs to leukocyte differentiation antigens. The MAbs used to differentiate myeloid 
cells were directed against the following cell markers: SWC3 (clone 74-22-15, IgG1), 
and CD163 (clone CVI 517.2, IgG2b). The MAbs used to differentiate lymphoid cells 
were directed against: CD4 (clone 74-12-4, IgG2b), CD5 (clone b53b7, IgG1), CD6 
(clone a38b2, IgG1), and CD8 (clone 295/33 IgG2a). These MAbs were previously used 
to analyse changes in the phenotype of leukocytes in the BALF of pigs infected with 
influenza virus [7]. After incubation the cells were washed three times with FACS 
buffer, and then incubated for 30 min on ice with the appropriate fluorescein 
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated goat anti-mouse IgG isotype 
specific antibodies, diluted in FACS buffer. Subsequently, the cells were washed three 
times, re-suspended in FACS buffer, and transferred to tubes. Fluorescence was 
measured using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, 
USA).  
  
T-cell proliferation assay 
The T-cell proliferation assay to measure influenza specific T-cell responses of pigs was 
performed essentially as described for pseudorabies virus [18]. Briefly, PBMC were 
isolated from heparinised blood samples by centrifugation onto Lymphoprep (Nycomed 
Pharma A., Oslo, Norway), and were washed twice with PBS. The isolated PBMC were 
seeded in 96-well flat-bottom plates (M29, Greiner, The Netherlands) at a density of 5 x 
105 cells per well in 100 µl medium (RPMI 1640 containing 10% porcine serum, 2 mM 
L-glutamine, 50 µM β-mercaptoethanol, 200 U/ml penicillin, 200 µg/ml streptomycin, 
and 100 U/ml mycostatin). To the PBMC, 100 µl medium containing 105 TCID50 of 
influenza A/Sw/Best/96 (H1N1), 2 µg/ml of purified M2eHBc fusion protein, a control 
sample prepared from non-infected cells (mock control), or 5 µg/ml of Con A (vitality 
control), were added in quadruplicate. After 4 days incubation at 37 °C in a 5% CO2 
atmosphere, the cultures were pulsed with 0.4 µCi [3H]-thymidine (Amersham, The 
Netherlands). After 4 h of incubation, cells were harvested and the incorporated 
radioactivity was measured in a Betaplate scintillation counter (Wallac, EG&G 
Instruments, The Netherlands). Proliferation was expressed as the number of counts 
(mean of quadruplicate) of antigen stimulated PBMC minus the number of counts of the 
mock control stimulated PBMC (delta counts).  
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Statistics 
Comparisons of mean clinical score, temperatures, virus excretion, and changes in the 
phenotype of cells in the BALF, between immunised groups and control groups, and 
comparison of T-cell proliferation when PBMC were stimulated with ConA before and 
after challenge were evaluated by two-sided Students t-tests. Probability (p) values 
<0.05 were considered significant 
 
Results 
Clinical signs and virus excretion  
Unexpectedly, clinical signs after challenge were more severe in all immunised groups 
compared to the control group. In the M2eNP DNA group clinical signs were extremely 
severe, and one pig died on post-challenge day (PCD) 1, and two more died on PCD 2, 
during the lung lavage. The clinical signs laboured breathing, abdominal breathing, 
anorexia, apathy, and coughing were all given a score of 0 if absent, and of 1 if present. 
The mean accumulated clinical scores of all groups are presented (Fig. 2a). The highest 
clinical score was found in the M2eNP DNA group, in which 3 pigs died.  
In all groups, pigs developed fever (≥ 40 °C) for at least one day between PCD 0 
and 6. The mean temperatures in the different groups did not correlate with the clinical 
signs. On the contrary, pigs in the control group showed the highest mean temperatures, 
whereas in the M2eNP DNA group mean temperatures were the lowest (Fig. 2b). No 
significant reduction in virus excretion was observed in the immunised groups compared 
to the control group (Fig. 2c). In all groups, pigs excreted virus from PCD 1 to 5. 
 
HI responses 
No significant differences between groups were observed in the HI response after 
challenge (results not shown). 
 
M2e-specific serum IgG and NP-specific serum IgG and nasal IgA responses 
In all immunised groups, an antibody response against M2e was detected after 
vaccination, in the ELISA. The response was highest in the M2eHBc protein plus 
adjuvant group, intermediate in the M2eNP DNA group, and low in the M2eHBc 
without adjuvant group (Fig. 3a). After challenge an increase in the antibody titre to M2e 
was observed, which was fastest in the M2eNP DNA group, probably as a result of the 
promotion of the antibody response by T-helper cells, in this group. 
Also, an antibody response against NP was detected in the M2eNP DNA group. The titre 
against the NP did not correlate with the titre against M2e. In pigs with high titres 
against the NP, low titres with M2e were found, and vice versa, showing an individual 
preference for epitopes. Nevertheless, all pigs were able to respond to the peptide 
because all pigs showed a detectable antibody response to M2e in the M2eHBc + 
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Figure 2. Mean clinical score, temperatures and virus excretion of pigs immunised with M2eHBc
fusion protein (▲), M2eHBc fusion protein + adjuvant (#), M2eNP DNA ("), and of control
pigs (!), after challenge infection. Pigs were immunised three times with three-week intervals
and challenged four weeks after the third immunisation with influenza A/Sw/Best/96 (H1N1). In
the M2eNP DNA immunised group 3 pigs died on post-challenge day 1 and 2. Results are
presented as the mean ± SD (n=6). The means in each immunised group were compared with the
mean in the control group. Significant differences (P<0.05) of the mean in the M2eHBc fusion
protein (a), M2eHBc fusion protein + adjuvant (b), and M2eNP DNA (c) immunised groups are
indicated. 
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 Figure . Mean serum IgG antibody response to the extracellular domain of the M2 protein (M2e),
and the influenza nucleoprotein (NP) of pigs immunised with M2eHBc fusion protein (▲),
M2eHBc fusion protein + adjuvant (#), M2eNP DNA ("), or control DNA (!). Pigs were
immunised (arrows) three times with three-week intervals and challenged four weeks after the
third immunisation with influenza A/Sw/Best/96 (H1N1). In the M2eNP DNA immunised group 3
pigs died on post-challenge day 1 and 2. Results are presented as the mean ± SD (n=6).  145
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adjuvant group, and in a previous study, all pigs sequentially infected with influenza 
H1N1 and H3N2 virus showed a detectable response [7]. 
After challenge, in the M2eNP DNA group, the titre against NP quickly increased 
to a maximum between day 4 and 7 after challenge, which was faster than in the other 
groups (Fig. 3b). No nasal IgA response against the NP was detected before challenge. 
After challenge, all groups responded with an anti-NP IgA response, which like the 
serum IgG response was fastest in the M2eNP DNA group (results not shown). 
 
T-cell proliferation 
Before challenge, only in the M2eNP DNA group a proliferation response of PBMC was 
observed when cells were stimulated with influenza A/Sw/Best/96 (Fig. 4a). Only in the 
M2eHBc plus adjuvant group a response was observed when cells were stimulated with 
M2eHBc protein (Fig. 4b). The absence of a proliferation response of PBMC of M2eNP 
DNA vaccinated pigs when stimulated with M2eHBc and of M2eHBc vaccinated pigs 
when stimulated with influenza virus indicates that T-cells are only stimulated by the 
carrier protein and not by the M2e peptide. 
After challenge, the antigen specific proliferation response decreased strongly, 
especially in the M2eNP DNA group. This is probably because antigen specific T-cells 
are recruited from the blood to the lungs and local lymph nodes. All groups developed a 
similar proliferation response to stimulation with influenza A/Sw/Best/96 after challenge 
with this virus. 
The lymphoproliferation response of PBMC when stimulated with ConA dropped 
significantly after challenge in all immunised groups (P<0.001 for M2eHBc and 
M2eHBc + adjuvant, P<0.01 for M2eNP group), but not in the control group (P>0.05). 
Possibly, in the immunised groups, the acute inflammatory response is enhanced, 
attracting macrophages and in the M2eNP DNA group also T-cells, from the blood to the 
lungs thereby reducing the responsiveness of PBMC to ConA. 
 
Flow cytometric analysis of BALF cells 
With the MAbs used, we distinguished 2 phenotypes of myeloid cells; SWC3+CD163- 
cells (neutrophil phenotype), and SWC3+CD163+ cells (monocyte and macrophage 
phenotype), and 5 phenotypes of lymphoid cells; CD4-CD5-CD6-CD8lowTCR-γδ- (NK 
phenotype), CD4-CD5+CD6+CD8high (CTL phenotype), CD4+CD5highCD6+CD8-/low (Th 
phenotype), CD4-CD5lowCD6-CD8-/low (TCR-γδ+ phenotype) and a heterogeneous 
population of CD5-CD8- cells (-/- T cells). 
The changes in the absolute number of cells collected from the BALF, and all 
changes in the phenotype distribution of the BALF myeloid and lymphoid leukocyte 
populations after challenge of the pigs are shown (Fig. 5a,b). Because the cell numbers 
collected from the BALF of pigs varied too much between samples, we could not 
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Figure 4. Mean lymphocyte proliferation responses of PBMC of pigs when stimulated with
influenza A/Sw/Best/96 (H1N1), M2eHBc protein, or ConA. Pigs were immunised with
M2eHBc fusion protein (▲), M2eHBc fusion protein + adjuvant (#), M2eNP DNA ("), or
control DNA (!). Pigs were immunised (arrows) three times with three-week intervals and
challenged four weeks after the third immunisation with influenza A/Sw/Best/96 (H1N1). In the
M2eNP DNA immunised group 3 pigs died on post-challenge day 1 and 2. Results are presented
as the mean ± SD (n=6). 
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Figure 5a. Changes in the leukocyte population in the lungs after challenge of pigs immunised
with M2eHBc fusion protein (▲), M2eHBc fusion protein + adjuvant (#), M2eNP DNA ("),
or control DNA (!). Pigs were immunised three times with three-week intervals and challenged
four weeks after the third immunisation with influenza A/Sw/Best/96 (H1N1). In the M2eNP
DNA immunised group 3 pigs died on post-challenge day 1 and 2. Results are presented as the
mean ± SD (n=6). The means in each immunised group were compared with the mean in the
control group. Significant differences (P<0.05) of the mean in the M2eHBc fusion protein (a),
M2eHBc fusion protein + adjuvant (b), and M2eNP DNA (c) immunised groups are indicated. 
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Figure 5b. Changes in the lymphocyte population in the lungs after challenge of pigs
immunised with M2eHBc fusion protein (▲), M2eHBc fusion protein + adjuvant (#), M2eNP
DNA ("), or control DNA (!). Pigs were immunised three times with three-week intervals and
challenged four weeks after the third immunisation with influenza A/Sw/Best/96 (H1N1). In the
M2eNP DNA immunised group 3 pigs died on post-challenge day 1 and 2. Results are presented
as the mean ± SD (n=6). The means in each immunised group were compared with the mean in
the control group. Significant differences (P<0.05) of the mean in the M2eHBc fusion protein
(a), M2eHBc fusion protein + adjuvant (b), and M2eNP DNA (c) immunised groups are
indicated. 
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calculate the absolute numbers of cells of each phenotype. 
The most relevant observation was a higher percentage of T-helper cells after 
challenge in the M2eNP DNA group than in the other groups (Fig. 5b). This percentage 
was significantly (P<0.05) higher than in the control group on PCD 4 and 8. In addition, 
the percentage of CTLs is higher on PCD 4 in the M2eNP DNA vaccinated group than in 
the other groups. Although this difference was not significant, it was observed even 
though the percentage of T-helper cells was also higher in this group.   
In the M2eHBc protein group and the M2eHBc protein plus adjuvant group, the 
percentage of NK cells on PCD 4 was higher than in the control group, but this 
difference was not significant.  
 
Discussion 
The experimental vaccines evaluated in the present study induced the desired immune 
responses. All vaccines induced an antibody response to the extracellular domain of the 
M2 protein of influenza A virus, and the M2eNP DNA vaccine additionally induced a 
nucleoprotein specific lymphoproliferation response. However, no protection was 
observed when the vaccinated pigs were challenged with a swine influenza virus. 
Clinical signs and virus excretion were not reduced in the vaccinated groups compared 
to the non-vaccinated control group. On the contrary, the vaccinated pigs showed more 
severe clinical signs after challenge than the control pigs. Especially the M2eNP DNA 
vaccinated pigs showed severe signs and three out of six pigs died on days 1 and 2 post-
challenge. Previous studies in mice suggested that enhancement of the antibody response 
to the M2 protein by vaccination may provide broad-spectrum immunity to humans 
[14,16,22], and we suggested the same for pigs [7].  However, the results of the present 
study in pigs indicate that antibodies to M2e can also exacerbate disease. Therefore, 
clinical signs after infection should be observed closely in further studies using M2 as an 
immunogen, and caution should be exercised using M2 in humans.  
Vaccination of pigs with M2eHBc fusion protein did not confer protection against 
influenza challenge infection, which does not agree with results of a previous study in 
which mice were partially protected after immunisation with the same material [16]. The 
difference in results could be caused by several reasons. One reason could be that in the 
previous study a human challenge virus was used with the same amino-acid sequence of 
the M2e used for immunisation, while in the present study a swine influenza challenge 
virus was used of which the sequence of the M2e differed (Fig. 1a). Nevertheless, 
antibodies induced by the immunisation were shown to bind to the peptide with the 
amino-acid sequence of the swine influenza challenge virus in the ELISA. If the 
sequence difference caused the absence of protection after vaccination then this would 
mean that the spectrum of protection conferred by immunisation with M2e does not 
include viruses with the swine influenza M2e sequence. A second reason could be that in 
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the present study, pigs instead of mice were used, that pigs were challenged by aerosol 
instead of intranasal instillation and that the dose of challenge differed. Since the pig is a 
natural host of influenza, the swine influenza model seems a better model than the mice 
model to study vaccination strategies for pigs, but also for humans. The course of 
infection with influenza A virus in pigs is similar to that in humans. In fact, the same 
strains can infect both pigs and humans, and pigs have been implicated as a mixing 
reservoir for the generation of new pandemic strains [19]. In contrast, influenza virus 
challenge in rodents typically leads to lethal pulmonary infection, and protection is 
scored by survival rather than progression of infection. 
A possible explanation for the observed enhancement of disease is that the 
vaccines induce an antibody-dependent cytotoxic hypersensitivity. In contrast to 
antibodies against the heamagglutinin (HA), the antibodies against M2e are not virus 
neutralising (VN), i.e. do not prevent the attachment of influenza virions to the surface 
of lung epithelial cells [25]. Therefore, many cells will become infected and will express 
the M2 protein on the membrane surface. Binding of the antibodies to the M2 will now 
promote the death of infected cells via several cell targeting (CT) mechanisms: i) the 
antibodies can promote contact with phagocytes either by reduction in surface charge, by 
adherence directly via the Fc or via complement factor C3 bound to the Fc, ii) the 
antibodies can promote contact with, and killing by NK cells (antibody dependent 
cellular cytotoxicity, ADCC), or iii) the antibodies can activate the full complement 
system, producing direct membrane damage. Initially, these immune mechanisms were 
of course expected to operate in protection against influenza infection. However, in the 
present study, they may have become overwhelmed because the viral challenge dose was 
too high to cope with in the absence of VN antibodies, and the immune mechanisms 
caused damage rather than provided protection. In the M2eNP DNA group, T-helper 
cells probably played a central role in the hypersensitivity by stimulating inflammatory 
responses and possibly excessive killing by CTLs. However, in previous studies with NP 
DNA vaccination in mice [2,23], but also in pigs [12], no exacerbation of disease was 
observed after challenge, suggesting that in the present study the antibodies to M2e are 
indeed responsible for the observed hypersensitivity. 
Clinical outcome of influenza infection depends on a race between the virus and 
the immune response of the host. Probably, cell-targeting mechanisms either have to 
diminish viral replication in an early stage and/or need to be accompanied by VN 
antibodies to control viral spread. The synergism between CT and VN activity was 
suggested to underlie the high efficacy of HA-specific antibodies in combating influenza 
infection [14]. If the infection is not controlled in an early stage because VN antibodies 
are absent or the challenge dose is too high to cope with, CT mechanisms may 
exacerbate diseases, as observed in the present study. Thus, the challenge dose could 
have an important effect on the final outcome of disease in immunised individuals. A 
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low challenge dose might result in protection by CTLs and antibodies to M2e, while a 
high challenge dose might even result in exacerbation. Unfortunately, the dose of virus 
administered in this study is necessary to induce clinical signs in non-immunised pigs 
under the experimental conditions. In general, the variations in the experimental models 
and conditions probably account for the difficulties in correlating immune mechanisms 
with protection against influenza.  
Vaccination with the DNA construct expressing a fusion protein of M2e to the N-
terminus of the NP induced a detectable antibody response to M2e. This shows that the 
NP does present the M2e peptide to B-cells and indicates that the peptide is exposed on 
the surface of the fusion protein. Indeed, a MAb to the peptide (14C2, [26]) was shown 
to bind to the fusion protein in an ELISA (result not shown). To our knowledge this is 
the first study to report the presentation of a peptide to the immune system by fusion to 
influenza NP. In addition, the DNA vaccination with the M2eNP construct induced a 
lymphoproliferation response similar to that seen after infection. Elevated percentages of 
T-helper cells as well as CTLs in the lungs of pigs 4 days post-challenge, compared to 
non-immunised pigs indicate that the DNA vaccination indeed induces cellular immune 
responses in addition to an antibody response. 
In conclusion, the present study does not exclude the possibility that M2e can be 
used as an immunogen to broaden the spectrum of protection conferred by current 
influenza vaccines. However, it does indicate that antibodies to M2e can exacerbate 
clinical signs of disease, and that caution should be exercised therefore. Other ways of 
inducing broad-spectrum immunity than by vaccination with M2e and/or NP only, might 
be safer. For example, successive infection with an attenuated H1N1 strain and a H3N2 
strain will induce both M2e and probably other subtype cross-reactive IgA and IgG 
antibodies, as well as CTLs, in the lungs. Although such drastic vaccination strategies 
are not applicable to pig farming they might be applied as a strategy of immunisation in 
case of a next human pandemic. 
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Antigenic analysis of swine influenza viruses and updating of vaccine 
strains 
As usual with influenza viruses, both swine H3N2 and H1N1 viruses display a 
considerable antigenic variation. The nature of this variation is different for the two 
subtypes. Swine H3N2 viruses showed a considerable degree of antigenic drift during 
the 1990s but contemporary strains show a high degree of homogeneity [16]. The drift 
has resulted in a loss of cross-reactivity of recent field isolates with the human A/Port 
Chalmers/1/73 (H3N2), which is the current strain in the swine influenza vaccine. 
Therefore, replacement of this vaccine strain by a more recent swine H3N2 isolate has 
been recommended [16]. Swine H1N1 viruses have not been submitted to such 
systematic changes over time, but recently isolated strains showed a marked antigenic 
and genetic heterogeneity (chapter 2). This heterogeneity may hamper the control of 
swine influenza by vaccination. One of the H1N1 virus strains commonly incorporated 
in current swine influenza vaccines is A/swine/Netherlands/25/80 [21,29]. Ferret 
antiserum against this strain showed HI titres against most of the strains examined that 
were fourfold or more below the homologous HI titre. Post-vaccination swine sera 
showed titres against recent isolates that were on average sixfold lower than those 
against the vaccine strain. One of the important criteria of the WHO for updating 
influenza vaccines for humans, is that ferret antiserum to the vaccine strain shows at 
least a fourfold lower HI titre to an emerging strain than to the vaccine strain itself [67]. 
According to this criterion replacement of the current H1N1 vaccine strain, like of the 
H3N2 vaccine strain, would be justified. 
However, the antigenic drift in swine influenza H3N2 viruses did not appear to 
strongly impair the protection conferred by the current vaccine, as measured in our 
vaccination-challenge experiment, in which pigs were vaccinated twice with a three-
week interval, and challenged 6 weeks later (chapter 3.2). The recent field virus used for 
challenge, A/Sw/Oedenrode/96(H3N2), showed a more than 60-fold lower titre with a 
ferret antiserum against the vaccine strain A/Port Chalmers/1/73, than the vaccine strain 
itself [16]. Nevertheless, vaccination reduced viral titres in lung tissue by 10,000-fold, 
and prevented fever and virus transmission to the unchallenged group mates. The 
antigenic drift of swine H3N2 viruses therefore does not yet appear to jeopardise the 
efficacy of the current vaccine. Nonetheless, it can be expected that better matching 
vaccines will induce higher antibody titres to the recent field strains and will provide 
better protection for a longer period. To demonstrate this, vaccines containing A/Port 
Chalmers/1/73 and A/Sw/Oedenrode/96 as the H3N2 component should be compared in 
a vaccination-challenge experiment. A high level of protection is necessary because, 
ideally, influenza vaccines should not only prevent clinical signs but also viral 
replication in the host. If the vaccine allows the virus to replicate in the presence of 
immunity, escape variants could evolve, leading to an acceleration of antigenic drift and 
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consequently a loss of vaccine efficacy. 
In the vaccination-challenge experiment, sera from infected pigs showed an 18-
fold difference and sera from vaccinated pigs only showed a 3-fold difference in HI titres 
against the vaccine and the field virus strain. These results indicate that post-infection 
antisera of ferrets are more discriminating than those of pigs and far more than post-
vaccination antisera of pigs, although surprisingly, this is less apparent from the 
antigenic analysis of H1N1 viruses (chapter 2). The overall results indicate that it is 
difficult to predict the vaccine efficacy based on HI titres of ferret and porcine post-
infection antisera, against the vaccine strain. Therefore, results of HI assays should only 
be used as an indication for loss of vaccine efficacy in swine influenza surveillance. In 
order to confirm the indication, vaccines should also be regularly evaluated in 
vaccination-challenge experiments in pigs, using recently isolated strains as challenge 
virus. Recently, an H1N2 influenza virus emerged in pigs in the UK [10] and 
subsequently in Belgium [60], causing severe clinical disease and economic losses. The 
H1 was shown to originate from a human H1N1 virus, and is antigenically 
distinguishable from the avian-like swine H1N1 viruses. The H1N2 virus is replacing the 
existing viruses in the British pig population and possibly in Europe. Moreover, 
preliminary results of a vaccination-challenge experiment indicated that current 
commercial vaccines did not protect pigs from clinical signs, and did not reduce virus 
excretion after challenge with the H1N2 virus (Van Reeth, personal communication). 
Also, no cross-protection was observed when pigs were infected with an avian-like 
swine H1N1 virus and subsequently challenged with an H1N2 virus [62]. These 
developments stress the need for a regular influenza surveillance among pigs in large 
geographical areas.   
If the antigenic drift in swine H3N2 viruses is driven by immune pressure, then it 
is likely that maternally derived antibodies (MDA) in finishing pigs are involved. 
Finishing pigs form by far the largest part of the pig population and viral escape from 
immunity in these pigs will therefore strongly determine the reproductive success of the 
virus. Because finishing pigs only live for 6 months they usually will not be infected 
more than once during their lifetime and immune pressure by their active immunity will 
therefore hardly play a role. Moreover, influenza virus can replicate extensively in 
piglets with MDA [5,30-32,45], and was even observed to replicate longer in piglets 
with than in piglets without MDA (chapter 4). It is conceivable that the extensive 
replication in the presence of antibodies results in antigenic drift. Sows, which live for 
years, can be infected in consecutive seasons and sustain antigenic drift, therefore. Their 
small numbers make it unlikely, however, that they could accomplish this without 
involvement of the finishing pigs. After infection of piglets with MDA, the MDA could 
select for escape mutants. Subsequently, these mutants could infect sows and induce 
antibodies. Antigenic drift has started.  
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It is unclear what causes the difference in rate of antigenic drift between swine H1N1 
and H3N2 viruses. Assuming that the drift is caused by immune pressure, one 
explanation may be that H3N2, but not H1N1 viruses, have recently evolved from a 
single ancestor causing homogenous immunity in a large part of the pig population and a 
high level of immune pressure. This may have happened when the human H3N2 virus 
reassorted with the avian H1N1 virus, and acquired its internal proteins. This reassortant 
H3N2 virus suddenly became more successful as is apparent from the fact that it became 
more virulent and has completely replaced the original human H3N2 (chapter 2, [12]). 
The reassortment occurred around 1984 [13], since then it may have taken some years to 
infect the whole European pig population including the breeding sows, after which drift 
has started.  
The internal proteins of the recent swine H3N2 and H1N1 virus strains were 
confirmed to be of avian and not of human origin (chapter 2). This means that the human 
internal gene segments have disappeared from the European swine population and that 
swine influenza in Europe may pose a lesser zoonotic threat than when the original 
human H3N2 virus was circulating. Simultaneous infection of swine with a virus with 
human internal proteins and an avian virus could have given rise to a reassortant virus 
with avian external and human internal proteins. Viruses with these characteristics have 
caused the human pandemics of the past century. Nevertheless, the close contact 
between humans and pigs allows human viruses to be readily transmitted to pigs, and 
reassortment resulting in a virus with avian external and human internal proteins can still 
occur. Also for this reason, regular surveillance among pigs world-wide is 
recommendable. Especially viruses of influenza subtypes to which little or no immunity 
exists in the human population, such as the H9N2 recently isolated from pigs in Asia 
[24], should be monitored closely. 
 
Maternal immunity 
The limited antigenic drift of swine influenza viruses did not seem to markedly reduce 
the vaccine efficacy (chapter 3.2), but it remains uncertain how effective the vaccine is 
in the field. Pigs used in the vaccination-challenge experiment did not have maternally 
derived antibodies (MDA), which inhibit the active immune response induced by 
vaccination [7,59]. Maternal immunity was observed to inhibit the active immune 
response to infection in the study described in chapter 4. Piglets infected in the presence 
of MDA developed lower serum HI antibody responses, and serum IgM, and nasal IgA 
responses against the NP. MDA seemed to have a less inhibiting effect on the serum IgG 
response to the NP, and on the lymphoproliferation response of PBMC.  
Although clinical signs and fever were reduced in MDA-positive piglets after 
primary infection, the virus excretion detected in oropharyngeal swabs early after 
infection was not significantly different in piglets with or without MDA. Interestingly, 
 159
General Discussion 
 
piglets with MDA excreted virus even longer than piglets without MDA. In a previous 
study in pseudorabies virus (PRV) infected pigs this was also observed [7]. Possibly, the 
level of virus replication depends on the tissues that are sampled. Whereas influenza 
virus titres may not seem to be reduced in oropharyngeal swabs of piglets with MDA, 
they may still be reduced in the lungs. The maternal antibodies are of the IgG isotype, 
and IgG contributes more to immunity in the lungs than to immunity in the upper 
respiratory tract. The tendency of IgG antibodies to inhibit viral replication in the lungs 
more than in the upper respiratory tract has also been demonstrated in our vaccination-
challenge experiment (chapter 3.2). Whereas virus titers in lung tissue were 
approximately 10,000-fold reduced, titres in oropharyngeal swabs were only 1000-fold 
reduced by vaccination. Moreover, an unknown proportion of the virus that is found in 
oropharyngeal swabs possibly originates from the lungs and it is therefore difficult to 
predict to what extent replication is actually reduced in the upper respiratory tract itself. 
Thus, the primary role of maternal antibodies (and IgG antibodies in general) to 
influenza virus, may be to prevent disease by reducing viral replication in the lungs, but 
they may not significantly reduce replication in the upper respiratory tract.  In addition to 
induction of a mucosal antibody response by intranasal vaccination, the absence of 
maternal IgG antibodies in the nose, may contribute to the observation that intranasal 
vaccination of MDA-positive pigs induced better protection against PRV than 
intramuscular vaccination [59]. After intramuscular injection, but not after intranasal 
vaccination, much of the antigen may be caught by maternal IgG antibodies and rapidly 
degraded, instead of presented to the immune system.  
When the pigs were infected for a second time, both the MDA-negative as well as 
the MDA-positive pigs were protected from clinical signs (chapter 4). Also, no virus was 
excreted by MDA-negative pigs and hardly any by MDA-positive pigs. However, 
several results suggest that the immunity after infection in the MDA-positive pigs was 
weaker. The second infection induced a much stronger HI antibody response, nasal IgA 
response, and lymphoproliferation response, in the MDA-positive than in the MDA-
negative pigs, indicating that viral replication still occurs in the MDA-positive pigs. In 
addition, an acute drop in lymphoproliferation response after second infection was 
observed in the MDA-positive pigs, which is correlated with a lower level of protection 
(chapter 3.2). This drop probably results from the recruitment of influenza virus-specific 
T cells to the respiratory tract and local lymph nodes. Because the protection after 
vaccination is weaker than after infection (chapter 3.2), and MDA are likely to inhibit 
immunity after vaccination more than after infection, protection after vaccination in 
MDA-positive pigs can be expected to be weak. The case of an outbreak of swine 
influenza H3N2 virus in finishing pigs that were vaccinated twice, two months before 
the outbreak [16], may be, at least partly attributed to interference by MDA. 
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Protective immune mechanisms  
The immune mechanisms operating in protection against influenza infection have been 
extensively studied in humans, and especially in mice. It is now firmly established that 
antibodies, CD4+ T-cells and CD8+ cytotoxic T lymphocytes (CTLs), are mainly 
responsible for protection. CD4+ T helper lymphocytes (Th) contribute to protection by 
providing help to B cells to produce antiviral antibodies, by stimulating proliferation of 
CTLs, and by production of cytokines [17,25,34,42,49,57]. Antibodies can be divided 
into virus neutralising (VN) and non-VN antibodies. VN antibodies can block the 
interaction of virions with receptors on the host cell, by reacting with antigenic sites on 
the globular head region of the HA on the surface of mature virions, and thus prevent 
infection. Five antigenic domains have been defined on the HA1 of human H3 influenza 
viruses [44,66]. Although minor differences between HI and VN activity of antibodies 
have been reported (HI antibodies seem to be more cross-reactive than VN antibodies 
[46], chapter 3.2) there is generally thought to be a good correlation between HI and VN 
activity. Also, there is generally a good correlation between HI antibody titres present 
prior to infection, and protection in humans, horses [37], and pigs [61]. Furthermore, 
non-VN antibodies can be divided into cell-targeting (CT) antibodies and antibodies 
directed against influenza internal proteins. CT antibodies cannot prevent the initiation 
of infection but can bind to the HA, NA or M2 on the surface of infected cells and 
thereby reduce the production of progeny virus [35,36]. They can achieve this by 
interfering with viral budding [72]. Antibodies against NA are thought to inhibit NA 
enzymatic activity and to cross-link virions budding from cells thereby inhibiting release 
of progeny virions. Also, CT antibodies can mediate the killing of infected epithelial 
cells by complement or by cells of the innate immune system (antibody dependent 
cytotoxicity, ADCC [36]). In addition, CT antibodies that bind before budding of the 
virions could hinder them from infecting cells or could enhance the uptake by 
phagocytic cells via the Fc receptor. The importance of VN antibodies in protection 
against influenza infection is apparent from the observation that amino-acid substitutions 
in the antigenic sites recognised by VN antibodies underlie the generation of epidemics 
in humans [66]. VN antibodies can also act as CT antibodies and the synergism between 
CT and VN activity was suggested to underlie the high efficacy of VN antibodies in 
combating influenza infection [36]. Non-VN antibodies directed against internal proteins 
are thought not to interfere with viral replication [2,15]. 
The next paragraphs of the discussion will focus on the contribution of VN and 
CT antibodies, and CTLs in immunity against influenza infection and disease. The 
contribution of VN and CT antibodies, and CTLs is likely to depend on the degree of 
antigenic difference between the influenza virus encountered, and the virus an individual 
or herd is previously infected or vaccinated with. Therefore, the roles of VN and CT 
antibodies, and CTLs in homologous immunity, in immunity to a drift variant, and in 
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heterosubtypic immunity will be discussed separately.  
 
Homologous immunity (Hom-I), the immunity after infection, against secondary 
infection with the same influenza virus strain is generally accepted to be primarily 
mediated by VN antibodies [1,3,42,49,52]. Results of the studies presented in this thesis 
also support this. No virus was isolated from pigs challenged with the same influenza 
strain, 9 weeks after primary infection, and only a mucosal IgA antibody response, no 
serum IgG antibody response, and no increase in frequency of CTLs in the lungs, was 
induced (chapter 3.2, chapter 5.1). This indicates that the challenge virus was 
immediately neutralised and hardly any or no virus replication occurred, because virus 
replication usually induces serum IgG and CTL responses (chapter 3.2 in previously 
vaccinated pigs, chapter 4 after secondary infection in MDA+  group, chapter 5.1 after 
heterosubtypic infection). Although a secondary T-cell proliferation response was also 
induced this probably supported the antibody production rather than a generation of 
cytotoxic T lymphocytes CTLs. No increase in the frequency of CTLs in the lungs was 
observed in another study in which pigs were challenged 9 weeks after primary infection 
(chapter 5.1, results not shown). Also, in our study on maternal immunity (chapter 4) it 
can be seen that the presence of MDA during primary infection led to a weaker 
immunity to secondary infection, which was associated with reduced HI titres but not 
with a reduced T-cell proliferation response at the moment of secondary infection. Taken 
together, these results support earlier suggestions that antibodies, particularly VN 
antibodies, are highly effective in Hom-I [1,2]. Probably, the effectiveness of VN 
antibodies to prevent and combat infection, combined with their longevity, is such that 
CTLs do not become involved in Hom-I. Although the frequency of CTLs in the lungs of 
pigs remained elevated for a considerable time (it was not observed to decline for 9 
weeks following infection, in the studies described in chapter 5.1), their longevity and 
effectiveness in Hom-I is probably less than that of antibodies. In humans, levels of 
CTLs after infection are back to baseline after 6 months [19,20]. Recruitment of CTLs to 
the lungs was shown to take some time (4 to 5 days in mice [18,22,23], 4 days in pigs 
(chapter 5.1)), whereas production of IgA and, if necessary, IgG by local antibody 
secreting cells (ASC) is probably more rapid. In our studies only a slight increase in 
nasal IgA, and serum IgG and HI antibody titres was observed on day 4 (chapter 3.2, 4, 
5.1) after secondary infection. However, the nasal IgA and serum HI response were 
clearly accelerated in pigs that were previously infected compared to naive pigs (chapter 
4) whereas this was not seen for the CTL response (chapter 5.1). In horses, a sharp rise 
of local antibodies was measured as early as two days after intranasal vaccination and 
subsequent challenge with influenza virus [6].   
In time, the influenza-specific activity of IgA after infection became much higher 
in the nose and in the lungs than in serum (chapter 3.1). This reflects the migration of 
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influenza-specific IgA-ASC to the respiratory tract. After 4 weeks, IgA had almost 
disappeared from the serum, and the specific activity of IgA in the nose and lungs was 
more than 200 times higher than in serum. Also, the specific activity of IgG1 was 
approximately 14 times higher in the lungs than in serum suggesting a local production 
of this isotype in the lungs as well. These data indicate that by parenteral vaccination one 
would need at least a 10 times higher serum IgG antibody titre than after infection, to 
achieve the same levels of antibodies in the lungs. Ideally one would like to vaccinate 
via the respiratory route, therefore, and also to induce an IgA antibody response to 
protect the upper respiratory tract and to approach the quality of immunity after 
infection.  
The levels of nasal IgA antibodies decline faster than those of  IgG antibodies 
(chapter 3.2, 4, 5.1). This could mean that the upper respiratory tract becomes 
susceptible to re-infection earlier than the lungs. Because the lungs are more vital to the 
host, the nose and upper respiratory tract may thus be sacrificed by the host in order to 
sample the environment for pathogens.  
 
Immunity to a drift variant, or to a newly introduced variant of the same subtype, like 
Hom-I, will usually be primarily mediated by VN antibodies. However, in this case, the 
level of VN antibodies is lower than in Hom-I or VN antibodies are even absent 
depending on the degree of antigenic difference between the newly and the previously 
encountered strain, as well as the time since the previous infection. IgA antibodies were 
shown to be more cross-reactive between influenza strains than IgG antibodies 
[26,50,54,55,64], and IgA rather than IgG antibodies may reduce the number of cells that 
becomes infected, with a drift variant. This would be another argument in favour of 
intranasal vaccination versus parenteral vaccination because the latter does not induce a 
mucosal IgA response (chapter 3.2). In humans, intranasal vaccination with a live-
attenuated influenza virus vaccine was observed to protect well in a season in which the 
circulating strain did not match the vaccine strain [4]. Clearance of a drift variant virus 
more than of the homologous virus depends probably also on cross-reactive CT 
antibodies.  CTLs may be involved in clearance of virus, in the theoretical case of a 
sequential infection with two drift variants of the same influenza subtype, soon after one 
another, but this does not happen in humans, and is also not likely in pigs. 
 
Heterosubtypic immunity (Het-I), the immunity after infection with one subtype of 
influenza virus to infection with another subtype is weak because it probably mainly 
depends on subtype cross-reactive CTLs and CT antibodies. Whereas in immunity to a 
drift variant there may still be some VN antibodies, probably only very few, if any, VN 
antibodies exist that cross-react between the subtypes H1N1 and H3N2, circulating in 
humans and pigs. In the study described in chapter 5.1, it was shown that CTLs and CT 
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antibodies against the conserved extracellular domain of M2 (M2e) but not antibodies 
against the conserved internal protein NP were specifically induced after a 
heterosubtypic infection. These results suggest that the CTLs and CT antibodies against 
M2e present prior to infection contribute to Het-I. Probably there are also CT antibodies 
reacting with the HA and NA that cross-react between the subtypes H1N1 and H3N2. 
HA specific antibodies that cross-react with a number of subtypes have been reported 
[11,41,51,58]. In our study on Het-I (chapter 5.1) we did not observe a difference in the 
kinetics of HI antibody responses after challenge in the Het-I group and the naive group. 
This indicates that there were no cross-reactive antibodies with HI activity, prior to 
challenge. Also, the HI titre with H1N1 only increased slightly after challenge with 
H3N2 indicating that also after challenge, few, if any, cross-reactive antibodies had HI 
activity. In mice, it was observed that heterosubtypic immunity to H5N1 after infection 
or intranasal vaccination with H3N2, was correlated with non-neutralising antibodies 
that reacted with H5HA rather than with CTL activity [58].  
In the past, CTLs have been proposed to be the major mediator of Het-I 
[39,56,63,65,68,70,71], but more recent studies suggest that, like in Hom-I, B cells also 
play a predominant role over CTLs in Het-I [40,58]. The importance of CTLs in 
protection against influenza viruses probably depends on the following factors: 
1) The nature of the secondarily infecting virus. The more distant the virus is from the 
one previously encountered, the less antibodies are effective, and the more CTLs are 
involved (chapter 5.1). 
2) The number of CTLs that are still surveying the respiratory tract. This depends on 
the time between the infections. Also it depends on the history of infections. 
Successive infections with two subtypes will induce higher levels than with one 
subtype, and levels may be more durable (chapter 5.1). 
3) The viral challenge dose. Because of the exponential increase in the number of 
virions after infection (how many progeny virions per cell?), it is conceivable that 
the effect of the killing of infected cells by CTLs will be more significant in an early 
phase of infection and in case of a low initial dose of virus (discussed in chapter 
5.1).  In this sense CTLs may have an advantage over CT antibodies because CTLs 
can kill infected cells as soon as viral peptides are presented to them via MHC class 
I, whereas CT antibodies become effective in a later stage of viral replication, when 
viral proteins are expressed on the cell surface. 
In summary, there is an enormous diversity in experimental influenza infections and 
immunity, ranging from a low dose infection with a highly similar strain to the strain the 
individual is previously infected or vaccinated with, to a high dose infection with another 
subtype. The protective role that is attributed to the various immune mechanisms 
depends strongly on the experimental set-up. 
For the application of vaccines in pig farming, and in humans, it is desirable that 
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in addition to preventing clinical signs in the individual, vaccines also reduce 
transmission of virus in the population. Although, these two goals can be directly related 
this is not necessarily the case. The induction of cross-reactive immunity is likely to 
increase vaccine efficacy by reducing transmission in the population rather than by 
directly preventing clinical signs in the individual. Therefore, introducing naive infected 
pigs in a vaccinated population may be a more sensitive way then intratracheal challenge 
or challenge by aerosol to determine the contribution of cross-reactive immunity to the 
protective efficacy of a vaccine. In the study in chapter 5.1, the contact pigs in the Het-I 
group showed a similar lymphoproliferation response as the challenged pigs, but hardly 
any serum HI-antibody response, anti-M2e antibody response, or nasal anti-NP antibody 
response. Therefore, it seems that CTLs already present in the respiratory tract of the 
contact pigs were able to quickly deal with the low dose of transmitted virus, thus 
preventing the induction of an antibody response. Perhaps a good indication of the 
protective effect of Het-I can be learned from nature. The sudden disappearance of the 
old subtype when a new subtype arises in humans (antigenic shift), may be the effect of 
Het-I, as previously suggested [38]. The introduction of a new subtype probably 
specifically boosts the cross-reactive cytotoxic T lymphocytes and antibodies, in a large 
part of the population, which (in addition to the specific immunity to the old subtype) 
makes it impossible for the old subtype to continue circulating. Inducing the immune 
mechanisms operating in Het-I by vaccination, has the potential to lifelong (6 months in 
finishing pigs) prevent clinical signs and reduce spread of an antigenically unexpected 
virus (chapter 5.1). In humans, inducing the immune mechanisms operating in Het-I by 
vaccination of the whole population, would possibly reduce the spread of a new 
pandemic strain and the concomitant morbidity and mortality.  
 
Immunity after vaccination with the vaccine currently used in pigs, which is 
administered intramuscularly, seems mainly based on VN and CT IgG antibodies 
(chapter 3.2). Because no IgA response is induced, the nose and trachea are less 
protected and viral replication at these sites is not prevented. In contrast, immunity after 
infection, will reduce replication at these sites, giving the immune system more time to 
mount a secondary response. In addition, the IgG antibody secreting cells after 
vaccination will not be localised near the sites of infection, like after a previous infection 
(chapter 3.1). Also, the average affinity of the IgG antibodies is probably lower after 
vaccination ([8], discussed in chapter 3.2). The IgG antibody response after 
intramuscular vaccination was highly cross-reactive in the in vitro HI and VN assays 
used, but because of the lower affinity of the antibodies can be expected to be less 
effective in vivo. Finally, the cellular response was lower after vaccination (chapter 3.2), 
which means that the IgG antibodies have to cope with less help from T-helper cells and 
with a lesser contribution of CTLs.  
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Immune mechanisms and proposed contribution to protection against influenza 
 
 
 
 
 
 
 
 
 
 
 
 
VN IgA VN IgG CT IgA CT IgG CTL Tha
level of
protection
Nose ++ ± + ± ±
Lung + ++ + + +
Duration +b ++ +b ++ -c ++
Hom-I ++ ++ +d +d -c ++ ++
Drift variant + + + + - cd + +
Het-I - - + + + c + ±
Swine Vaccine - ++ - + - ++ +
 
 
 
 
 
 
VN = Virus Neutralising, CT = Cell Targeting, CTL = cytotoxic T-lymphocyte, Th = helper T
lymphocyte  
Hom-I / Het-I = immunity to homologous / heterosubtypic virus after infection 
a: Th function by stimulating antibody production and proliferation of CTLs, and by production
of cytokines 
b: Levels decline but presence of antibody secreting cells at mucosae ensures rapid production  
c: Levels decline and generation of effector CTL in lymph nodes is slow  
d: Are only involved if level of VN antibodies is low 
Therefore, after vaccination, the serum IgG levels have to be considerably high to 
prevent replication in the lungs, and when these levels have declined, an infection may 
result in clinical signs. If an antigenic drift variant is encountered, part of the VN IgG 
will not be able to bind to the epitope they are directed against, and clinical signs are 
more likely to occur. However, fattening pigs only live six months and therefore the 
current swine vaccine should be sufficiently efficacious to protect them, at least from 
clinical signs. Probably only if the response to vaccination is inhibited in case MDA are 
present, pigs may become clinically infected within those 6 months.  
The lower affinity of the HI and VN IgG antibodies after vaccination than after 
infection probably results from the different routes by which the antigen is presented 
after infection and vaccination. After infection antigen is caught by dendritic cells, which 
will present it to B cells, and selectively stimulate B cells that produce high affinity, and 
high specificity antibodies. In contrast, although after primary vaccination, the antigen 
will also be presented by dendritic cells, after secondary booster vaccination, the B cells 
will catch most of the antigen themselves leading to their own proliferation, stimulated 
by Th cells (the booster response). Especially if a high dose of antigen is given at once, 
many low affinity B cells will proliferate. In chapter 3.2 (fig. 2) it can be seen that the HI 
response to the first vaccination is indeed more specific than to the second vaccination. 
In addition to catching viral antigen, dendritic cells were suggested to transport 
and release live cytopathic vesicular stomatitis virus in secondary lymphoid tissues to 
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induce optimal VN antibody responses [28]. It would be extremely interesting to 
investigate whether DC also present live influenza virus to B cells. If so, dendritic cells 
may thus selectively induce highly effective, high affinity and specificity VN antibodies, 
by the controlled expression of viral proteins in their natural setting (i.e. release 
influenza virions). This may be another reason why the life-long immunity to the 
homologous virus after infection is difficult to achieve by parenteral vaccination with 
killed virus. On the other hand, the cross-reactivity of immunity after infection may be 
improved upon by directing the immune response also to non-virus neutralising CT 
epitopes, which are known to be conserved among influenza viruses. 
 
Another protective immune mechanism? 
In addition to VN and CT antibodies, and CTLs, there may be another immune 
mechanism that contributes to protection against influenza, namely antibodies to internal 
proteins. Although antibodies to internal proteins do not prevent or diminish viral 
replication directly, they mediate removal of the foreign viral proteins from the 
respiratory tract. Thus, they could diminish possible toxic effects of the proteins, and at 
the same time help to direct the antibody response to the glycoproteins. Several 
observations in studies by others, and in the studies described in this thesis suggest that 
the NP is highly immunogenic, and possibly acts as a decoy during primary infection: 1) 
The NP induces strong antibody responses, which do not protect against viral replication 
[2,53]. 2) In the study in chapter 4, the primary response to NP is high, and the HI 
response is low whereas the opposite is true for the secondary response. The primary 
response to HA, but not to NP was affected by MDA. This has also been previously 
reported [43]. 3) In chapter 5.1, the primary response to NP is high, and the response to 
M2 is low whereas the opposite is true for the secondary response. 4) Mucosal 
immunisation with NP protected mice from a lethal challenge, which was correlated with 
high titres of IgA and not with CTL activity [48]. Taken together, these observations 
suggest that mucosal antibodies to internal proteins contribute to protection by removing 
viral proteins from the respiratory tract. Although antibodies against internal proteins 
will only play a minor role in protection, as is apparent from the observation that people 
previously infected with one subtype are not protected from clinical signs due to 
infection with another subtype, its contribution to the weak Het-I may be significant. 
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Possible improvements to vaccines 
A replacement of the strains in the current vaccines by more recent strains would 
probably induce more antibodies with higher affinity to field strains, and could slightly 
improve and prolong the protection. The current vaccine containing A/Port 
Chalmers/1/73 still seemed rather efficacious in our vaccination-challenge experiment 
(chapter 3.2), but influenza vaccines should not only prevent clinical signs but also 
reduce viral replication and transmission as much as possible. If the vaccine allows the 
virus to replicate in the presence of immunity, escape variants may evolve, leading to an 
acceleration of antigenic drift and consequently a loss of vaccine efficacy. However, the 
regular updating of influenza vaccines is costly and impractical. Antigenic shifts occur 
frequently in pigs, and the recent appearance of an H1N2 virus with an H1 antigenically 
different from the H1N1 virus in the vaccine stresses the impracticality of frequently 
updating swine influenza vaccine strains.  
Enhancing the responses to conserved antigens, if shown to be protective 
responses, may make the regular updating of influenza A vaccine strains unnecessary. 
The porcine vaccine already induces cross-reactive responses more than the current 
human vaccines. It contains all viral proteins whereas the sub-unit vaccines, which are 
more commonly applied than whole virus vaccines in humans, only contain the purified 
glycoproteins. Thus, in addition to antibodies, the porcine vaccine induces T-helper cells 
against conserved antigens, whereas human vaccines do not. This may also partially 
account for the good protection against the drift variant after vaccination of pigs (chapter 
3.2). In humans, successive vaccinations may even reduce the natural cross-protection 
and increase the susceptibility to unexpected strains. The human vaccines specifically 
stimulate an HA and NA-specific antibody and cellular response. Thus, the immunity 
will be further directed against the most variable proteins and not against other proteins 
of influenza virus. At the same time, these vaccinations may prevent infections, which 
would also have induced responses against more conserved antigens. Moreover, natural 
infections, but not the current vaccines, would result in the presence of IgA and IgG 
ASC and CTLs in the lungs. These effectors, their target proteins, and their localisation 
are exactly the factors that have been indicated by others and by the studies described in 
this thesis, to be involved in broad-spectrum immunity.   
The response of CT antibodies to conserved epitopes on the stem region of the 
HA, on the NA, and on the M2, as well as the CTL response to the conserved internal 
proteins could be enhanced by future vaccines. In the study described in chapter 5.2, the 
potential of CT antibodies to the highly conserved extracellular domain of M2 (M2e) 
only, or in combination with CTLs and Th to the NP was evaluated. No protection was 
observed when vaccinated pigs were challenged with a swine influenza virus. Clinical 
signs and virus excretion were not reduced in the immunised groups compared to the 
non-immunised control group. On the contrary, vaccinated pigs showed more severe 
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clinical signs after challenge than the control pigs. These results indicated that CT 
antibodies to M2e could exacerbate clinical signs. Consequently, clinical signs should be 
observed closely in further studies using M2e as an immunogen, and caution should be 
exercised using M2e in humans. However, the results do not exclude the possibility that 
M2e can be used as an immunogen to broaden the spectrum of protection against 
influenza A viruses conferred by current influenza vaccines. As already discussed, both 
CT antibodies and CTLs do not prevent the virus from penetrating the cells and are 
therefore less protective than VN antibodies. Therefore, CTLs and CT antibodies are 
likely to be most effective in the early stage of challenge infection when only few cells 
are infected, and need to be present in the respiratory tract in sufficient amounts, prior to 
challenge. This means that local induction of these mechanisms is probably much more 
efficient than parenteral induction.  
However, heterotypic non-neutralising antibodies have been suggested to mediate 
enhancement of dengue infections, causing dengue haemorrhagic fever and dengue 
shock syndrome [14,33,69]. These observations stress the danger of specifically 
inducing subtype cross-reactive non-neutralising antibodies by vaccination. Moreover, 
they raise the question whether enhancement of disease by heterosubtypic immune 
mechanisms could also occur in natural infections with influenza. An infection with a 
new subtype could specifically trigger the response of cross-reactive Th, CTL, and cross-
reactive CT antibodies such as those against M2. Although they could provide protection 
it is possible that if they do not manage to reduce viral replication quickly enough the 
immune mechanisms are overwhelmed, are triggered and fully activated, and start 
exacerbating disease. Does this perhaps explain the high mortality during the 1918 
Spanish flu pandemic, in healthy people between the age of 20 and 30? Did they have 
immunity to the previous pandemic strain? A possible way of investigating this would be 
a long-term study in which pigs, chickens (or possibly mice) are infected and challenged 
with another subtype after various periods of time. Studies on clinical outcome of 
disease are best performed in natural hosts of influenza. 
Mucosal vaccination could induce a specific mucosal IgA as well as IgG 
response, which would provide a better, more durable, protection. The failure of current 
vaccines to induce a good local IgA and IgG response could explain their limited 
efficacy to protect, compared to a previous infection. In addition, as discussed 
previously, CT antibodies and CTLs, in cooperation with T-helper cells could be much 
more effective when induced locally than when induced parenterally. Successive 
infection with an attenuated H1N1 strain and an H3N2 strain will induce both M2e and 
probably other subtype cross-reactive IgA and IgG antibodies, as well as CTLs, in the 
respiratory tract (chapter 5.1). Although such drastic vaccination strategies are not 
applicable to pig farming they might be applied as a strategy of immunisation in case of 
a next human pandemic.  
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Diagnosis by antibody detection in ELISAs 
The ELISAs for detection of nucleoprotein-specific IgM and IgG in serum, and for nasal 
IgA, could be used as an alternative to the HI assay, to diagnose influenza infections in 
the field. In humans, this possibility was also investigated and detection of 
nucleoprotein-specific serum IgA was shown to be highly indicative of an acute 
influenza A virus infection [47]. After primary infection, serum IgM was detected from 
post-infection day (PID) 6 to 25 (chapter 3.1, 3.2, 4), IgG from PID 10 onwards 
(chapters 3.1, 3.2, 4, 5.1, 5.2), and nasal IgA from PID 10 to 70 (chapters 3.2, 4, 5.1). 
The advantage of the nucleoprotein specific ELISAs is that the nucleoprotein is highly 
conserved so that the ELISAs can be used to detect infections with all influenza A 
viruses. In contrast, in the HI assay, only infections with viruses antigenically similar to 
the viruses used as antigen will be detected, and not with new subtypes or antigenic 
variants within the subtype. Therefore, the virus strains used in the HI assay need to be 
regularly updated. Thus, the heterogeneity of influenza viruses in swine is a major 
problem for the use of HI assays. Other advantages of the ELISAs over the HI assay, are: 
they are entirely based on monoclonal antibodies, they do not need many reagents that 
are difficult to standardise, and the read out can be easily automated. These factors 
assure an easy reliable test for unlimited time. 
An advantage of ELISAs for detection of serum IgM and nasal IgA antibodies, 
would be that they would not require the use of paired serum samples for diagnosis, 
because unlike the HI assay or an IgG ELISA, they do not have to demonstrate an 
increase in antibody titre. Pre-existing IgA antibody levels will be absent in piglets with 
MDA (chapter 4) and vaccinated pigs (chapter 3.2). Also, they will be low in previously 
infected pigs because nasal IgA levels decline rapidly after infection compared to serum 
IgG. Neither infection of a herd with the same subtype, nor with another subtype 
(chapter 5.1) of influenza virus, is likely to occur before IgA has disappeared. However, 
IgM is only produced after primary infection, and not after secondary infection, or 
infection after vaccination (chapter 3.2), and the diagnostic value of IgM therefore seems 
limited.  
Production of nucleoprotein-specific IgM, and IgA, as well as of HI antibodies, is 
strongly inhibited by MDA (chapter 4). Therefore the sensitivity of the ELISAs as well 
as the HI assay to detect infections in an MDA-positive herd, may be low. In this 
respect, serum IgG seems a more reliable indicator of an infection. Although it has the 
disadvantage that like the HI assay it needs paired serum samples, the anti-NP IgG 
ELISA seems more sensitive than the HI assay to detect a response in MDA-positive 
piglets. The HI response, but not the anti-NP IgG response was inhibited by MDA 
(chapter 4), which has also been reported previously [43]. Overall, the results suggest 
that the different assays should be thoroughly compared using many field samples, to 
further evaluate their performance. Preliminary results of analysis of field samples 
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suggest that there is a good correlation between the occurrence of an infection and 
detection of IgA in nasal swabs, collected 3 weeks after clinical signs were observed 
(results not shown). 
Whereas for influenza diagnosis, the ELISAs may be an alternative, HI assays 
will be required for surveillance purposes because they provide essential information 
about antigenic properties of the circulating influenza viruses. A primary screening of 
herds by ELISA followed by analysis of a few sera in HI assays seems a plausible 
strategy in prevalence studies, as well as for surveillance, as it will ensure detection and 
analysis of all influenza viruses circulating in swine. 
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Summary 
Swine influenza is a highly contagious acute viral disease of the respiratory tract in pigs, 
which is prevalent worldwide. The disease causes considerable economic damage 
primarily due to reduced weight gain in finishing pigs and reduced reproductive 
performance of sows [9]. A field survey performed in the winter of 1995-96 in the 
Netherlands revealed that swine influenza virus is a major cause of outbreaks of acute 
respiratory disease in finishing pigs [27]. This finding indicated that influenza is a bigger 
problem amongst pigs than was commonly thought. In addition, influenza is a zoonotic 
disease, because swine influenza viruses can transmit to, and cause disease in people, 
and pigs can be a source of new human influenza strains. Moreover, antigenic drift of the 
swine influenza A H3N2 viruses was demonstrated in the Netherlands and Belgium. 
This drift has led to a loss of cross-reactivity of recent field isolates with the human 
A/Port Chalmers/1/73 (H3N2), which is the current strain in the swine influenza vaccine. 
Therefore, replacement of this strain by a more recent swine H3N2 isolate has been 
recommended [16]. The increasing economic impact of swine influenza infections, its 
zoonotic risk, and the unexpected antigenic drift observed, prompted us to intensify 
research on swine influenza virus infections in the field, and on vaccine development. 
The studies described in this thesis deal with factors that are relevant to the development 
of swine influenza vaccines, and hence, may be relevant to the development of human 
influenza vaccines.  
In contrast to swine H3N2 viruses, no significant antigenic drift was observed in 
swine H1N1 viruses isolated from the late 1980s to1996. However, a marked antigenic 
and genetic heterogeneity was detected, which might hamper the control of swine 
influenza by vaccination. Nevertheless, a current commercial split virus in oil adjuvant 
vaccine was shown to be significantly efficacious in protecting pigs against a drift 
variant of H3N2 in a vaccination-challenge experiment. Therefore, there does not yet 
seem to be an urgent need for the A/Port Chalmers/1/73 (H3N2) strain to be replaced by 
a more recent strain, in order to protect fattening pigs from clinical signs during their 
short life span. Maternal immunity of the piglets however, will inhibit the immune 
response to vaccination and will further jeopardise protection in the field. Replacing the 
vaccine strains for strains that better match the current field strains would result in higher 
antibody titres to the field strains, which would further improve and prolong protection. 
Higher antibody titres would reduce the likelihood of viral replication and transmission 
in the population, and thus also of further antigenic drift. Therefore, a regular influenza 
surveillance among pigs is recommendable to ensure that the field strains are not too 
different from the vaccine strain, be it the result of antigenic drift or of new 
introductions. The swine vaccine may confer a broader protection than human sub-unit 
vaccines possibly because of the presence of the other viral proteins in addition to the 
HA and NA. Current vaccines are administered intramuscularly and protection may 
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strongly depend on the induction of sufficiently high IgG antibody levels. Theoretically, 
intranasal vaccination would be extremely attractive, as it would induce mucosal IgA, 
IgG, and cellular immune responses. These responses could provide protection against a 
broader spectrum of influenza viruses. Moreover, intranasal vaccination would probably 
be less hampered by maternal immunity than intramuscular vaccination. Unfortunately, 
intranasal vaccination is not practical in pig farming. One aspect of the vaccine that 
could be improved however, is its ability to protect against a broader spectrum of 
influenza viruses. Antibodies to the highly conserved extracellular domain of M2 and 
CTLs to the NP seemed to be involved in broad-spectrum protection in pigs, but are not 
induced by current vaccines. However, an experimental vaccine that induced those 
effectors, and no antibodies to the HA and NA, enhanced instead of prevented clinical 
signs after challenge. This indicates that those effectors can even exacerbate disease, 
when induced parenterally and/or if other effectors are absent. Nevertheless, including 
conserved antigens in vaccines and enhancing the response against them could improve 
protection. However, caution must be exercised and special attention given to non-
neutralising cell-targeting antibodies, to make sure they do not enhance disease after 
vaccination with novel generations of vaccines. Successive intranasal vaccination with 
an attenuated H1N1 strain and an H3N2 strain will specifically induce mucosal subtype 
cross-reactive IgA and IgG antibodies, as well as CTLs. Although such drastic 
vaccination strategies are not applicable to pigs they might be applied as a strategy of 
immunisation in case of a next human pandemic. Improvement of the current swine 
influenza vaccine nor of the human influenza vaccines will be easy, and will remain an 
exciting challenge. 
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Het influenza A virus kan een groot aantal diersoorten infecteren waaronder mensen, 
varkens, paarden, zeezoogdieren en vogels. In zoogdieren veroorzaakt het virus een 
acute luchtweginfectie, bij mensen bekend als influenza of griep. Het influenza A virus 
staat bekend om zijn enorme variabiliteit waardoor het kan ontsnappen aan immuniteit 
en een individu meerdere malen kan infecteren. De twee eiwitten op het oppervlak van 
het influenza virus, haemaglutinine (HA) en neuraminidase (NA) zijn de belangrijkste 
antigenen waartegen beschermende antilichamen in de gastheer worden opgewekt en 
vertonen de grootste variatie. Ze kunnen worden onderscheiden in een aantal subtypen 
op grond van het feit dat haemagglutinatie  en neuraminidaseremmende antilichamen 
niet kruisreageren tussen de subtypen. Van het HA zijn 15 subtypen (H1 t/m H15) en van 
het NA zijn 9 subtypen (N1 t/m N9) bekend. Elk virus bezit een HA en een NA subtype 
in willekeurige combinatie. Hoewel slechts enkele combinaties zijn geisoleerd van 
zoogdieren, zijn alle subtypen in de meeste combinaties geïsoleerd bij vogels. Het wordt 
daarom algemeen aangenomen dat vogels en met name watervogels de primaire bron 
zijn van alle influenza A virussen bij zoogdieren. 
Een verandering van het HA subtype al dan niet tesamen met het NA ten opzichte 
van het eerder circulerende influenzavirus heeft in de twintigste eeuw vier keer 
geresulteerd in een humane pandemie, in 1918 (H1N1), 1957 (H2N2), 1968 (H3N2) en 
1977 (H1N1). De meest rampzalige pandemie was de 1918 Spaanse griep die het leven 
kostte aan ongeveer 40 miljoen mensen. Pandemische virussen worden gedacht te zijn 
ontstaan door drie mechanismen: 1) genetic reassortment; uitwisseling van 
gensegmenten tussen aviaire en humane influenza A virussen die tegelijkertijd hetzelfde 
individu infecteren, 2) het overspringen van een compleet virus van dier naar mens, en 3) 
de herintroductie van een virus dat jaren eerder al circuleerde. Naast deze abrupte 
antigene veranderingen genaamd antigene shift als gevolg van een wisseling in subtype 
vinden er ook meer geleidelijke antigene veranderingen plaats genaamd antigene drift. 
Antigene drift is het gevolg van selectie van virus varianten onder druk van antilichamen 
en is de oorzaak van de jaarlijks terugkerende humane griepepidemieën. 
Varkensinfluenza is een zeer besmettelijke en acute virusinfectie van de 
luchtwegen en de klinische symptomen zijn vergelijkbaar met die in mensen. Secundaire 
infecties kunnen de ernst van de ziekte verergeren en kunnen complicaties zoals 
longontsteking veroorzaken. De ziekte brengt wereldwijd aanzienlijke economische 
schade toe aan de varkenshouderij met name door verminderde groei van mestvarkens. 
Daarnaast kan er na een influenza uitbraak in een zeugenstapel een verminderde 
vruchtbaarheid, abortus en doodgeboorte optreden. Op basis van onderzoek van slacht-
sera van varkens weten we al lange tijd dat 70-90% van de varkens in aanraking komt 
met influenza. In hoeverre dergelijke infecties ook met klinische symptomen gepaard 
gaan was tot voor kort onduidelijk. Echter, uit recent onderzoek in Nederland blijkt dat 
influenza steeds vaker kan worden aangewezen als de primaire verwekker van acute 
 180
Samenvatting 
 
luchtwegaandoeningen bij vleesvarkens. In een veldsurvey in de periode 1995-96 kon bij 
50% van de bedrijven met een historie van ademhalingsproblemen influenza worden 
aangewezen als de primaire oorzaak. Een vervolgstudie over de laatste paar jaar, waarbij 
aselect bedrijven met acute luchtwegprblemen bij varkens werden onderzocht, 
bevestigde wederom dat ruim de helft van alle acute luchtwegproblemen primair aan 
influenza moet worden toegeschreven. Hoewel varkens in principe gevoelig zijn voor 
alle HA/NA subtypen, infecteren totnogtoe voornamelijk de subtypen H1N1, H1N2 en 
H3N2 het varken. 
Naast een belangrijke veroorzaker van luchtwegaandoeningen bij varkens is 
varkensinfluenza ook een zoönose en een risico voor de mens. Varkensinfluenzavirussen 
kunnen mensen infecteren en griep veroorzaken. Daarnaast wordt het varken gezien als 
intermediaire gastheer voor de adaptatie van aviaire influenzavirussen aan zoogdieren. 
Het luchtwegepitheel van het varken draagt receptoren voor zowel aviaire - als 
zoogdierinfluenza virusstammen. Dubbelinfecties met influenzastammen van 
verschillende origine zijn in het varken dus mogelijk, waardoor het varken kan fungeren 
als "Mixing Vessel" bij de vorming van nieuwe influenzastammen door genetic 
reassortment. Humaan-aviaire influenza reassortants zijn in Europa geïsoleerd uit 
varkens en vervolgens uit kinderen. Daarnaast vormt het varken een reservoir van "oude" 
humane stammen, die zijn overgegaan van de mens naar het varken en lange tijd binnen 
varkenspopulaties kunnen blijven circuleren. Dergelijke stammen vormen een nieuw 
risico voor de mens als de immuniteit in de humane populatie is verdwenen.  
Recente infecties bij mensen in Hong Kong laten zien dat aviaire H5N1 en H9N2 
subtypen ook direct de mens kunnen infecteren met soms fatale gevolgen. Maar 
dergelijke infecties lijken niet makkelijk te spreiden, daarvoor is waarschijnlijk eerst een 
adaptatie bijvoorbeeld via het varken nodig zoals hiervoor beschreven. Dat een 
dergelijke ontwikkeling niet denkbeeldig is blijkt uit het feit dat in ZO-Azië ook bij 
varkens infecties met de H5N1 en H9N2 zijn waargenomen. 
Recent epidemiologisch onderzoek in de UK, België en Nederland wijst uit dat de 
antigene veranderingen in varkens influenza virussen de laatste jaren veel sterker zijn 
geweest dan verondersteld. In de UK en in België zijn reassortant H1N2 virussen 
geïsoleerd. In de UK is dit H1N2 subtype endemisch geworden en is het 
verantwoordelijk voor het grootste deel van de klinische uitbraken. Mogelijk moet dit 
virus spoedig in het varkensvaccin worden opgenomen aangezien het sterk antigeen 
verschilt van de H1N1 varkensinfluenzavirussen. Daarnaast is gebleken dat in België en 
Nederland het H3N2 influenza subtype bij varkens als gevolg van antigene drift sneller 
is veranderd ten opzichte van de humane influenza A/Port Chalmers/1/73 (H3N2), dan 
verwacht. Omdat dit de huidige varkensvaccinstam is moet een vervanging van dit virus 
voor een recenter virus in vaccins worden overwogen. 
Het onverwacht grote belang van varkensinfluenza als verwekker van acute 
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luchtwegaandoeningen, het zoönotische risico en de recent waargenomen onverwachte 
antigene veranderingen in varkensinfluenzavirussen gaven aanleiding tot nader 
onderzoek naar varkensinfluenza, tot het bestuderen van de werkzaamheid van een in de 
praktijk gebruikt vaccin en tot vaccin ontwikkeling. De in dit proefschrift beschreven 
studies zijn relevant voor de ontwikkeling van varkensinfluenzavaccins en kunnen ook 
belangrijk zijn voor de ontwikkeling van humane vaccins. Omdat varkens in 
tegenstelling tot muizen natuurlijke gastheren van influenza zijn en omdat dezelfde 
virusstammen zowel varkens als mensen infecteren, is het varken een beter modeldier 
dan de muis voor influenza studies. Echter, economische argumenten en de 
beschikbaarheid van een groter arsenaal aan analytische assays en reagentia bepalen de 
keus voor de muis als meest gebruikte modeldier.  
Varkensinfluenza H1N1 virus-veldstammen werden antigeen en genetisch 
gekarakteriseerd. Deze studie had als primair doel te kunnen beoordelen of de H1N1 
veldstammen sterk afwijken van H1N1 virusstammen gebruikt in huidige vaccins. In 
tegenstelling tot de varkens H3N2 virussen bleken de H1N1 virussen over de afgelopen 
jaren niet of nauwelijks veranderd als gevolg van antigene drift. Daarentegen bleek er 
wel een veel grotere variatie in H1N1 stammen dan in H3N2 stammen geisoleerd binnen 
één jaar op verschillende bedrijven. De waarneming dat de H1N1 varianten strict 
bedrijfsgebonden waren wijst er mogelijk op dat H1N1 virussen over een langere periode 
binnen een bedrijf blijven circuleren, terwijl H3N2 virussen ieder jaar opnieuw worden 
geïntroduceerd. De grote variatie in het H1N1 varkens influenza virus zou kunnen 
betekenen dat het moeilijk is om een vaccinstam te vinden die goed beschermt tegen alle 
varianten. 
De aanzienlijke antigene drift in varkensinfluenza H3N2 virussen en de grote 
variatie in de H1N1 virussen zouden de werkzaamheid van huidige vaccins kunnen 
verminderen. Echter, in een vaccinatie-challenge experiment waarin twee maal werd 
gevaccineerd met een huidig commercieel split-virus-in-olie-vaccin en 6 weken later 
werd gechallenged met een H3N2 veldstam bleek dat het vaccin goed beschermde. Het 
voorkwam koorts bij de varkens en virusspreiding naar ongechallengde groepsgenoten. 
Aangezien het antigene verschil tussen de gebruikte H3N2 veldstam en de H3N2 
vaccinstam groter is dan tussen alle momenteel circulerende H1N1 stammen en de 
A/swine/Neth/25/80 (H1N1) vaccinstam lijkt er geen reden te veronderstellen dat 
updaten van de huidige H1N1 noch van de H3N2 vaccinstam op dit moment 
noodzakelijk is. Niettemin zou een vevanging van de huidige H1N1 en H3N2 
vaccinstammen voor stammen die beter overeenkomen met de momenteel of in de 
toekomst circulerende stammen, zorgen voor een hogere antilichaamtiter tegen de 
veldstammen en voor een betere en langduriger bescherming. Hierdoor wordt de kans 
dat er toch sub-klinische infecties optreden en er virusspreiding plaatsvindt verkleind, en 
daarmee de kans op antigene drift en verlies van vaccinwerkzaamheid. 
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Daar komt nog bij dat er in biggen vaak maternale antilichamen aanwezig zijn die de 
respons op vaccinatie remmen waardoor het niveau van bescherming lager zal liggen in 
het veld dan in het vaccinatie-challenge experiment. In een studie waarin de respons op 
infectie in biggen met maternale antilichamen vergeleken werd met de respons in biggen 
zonder maternale antilichamen werd aangetoond dat maternale passieve immuniteit de 
actieve immuunrespons remde waardoor het niveau van bescherming tegen een tweede 
infectie lager lag. Deze resultaten geven aan dat er naar een zo goed mogelijk vaccin 
moet worden gestreefd om zeker te zijn van afdoende bescherming na vaccinatie. Een 
regelmatige surveillance naar influenza in varkens in Nederland en Europa is daarom 
belangrijk om te zorgen dat de vaccinstam als gevolg van antigene drift of introductie 
van een nieuw virus niet te sterk afwijkt van de veldstammen. 
Hoewel de bescherming tegen een H3N2 infectie na vaccinatie met een huidig 
commercieel vaccin relatief goed bleek was de bescherming toch niet optimaal. Enige 
virusreplicatie in de luchtwegen van de varkens kon toch nog worden gedetecteerd in de 
gevaccineerde varkens, terwijl varkens die natuurlijk immuun waren door een eerdere 
infectie, geen virus uitscheidden. Vergelijking van de immuunresponsen na vaccinatie en 
eerdere infectie wees uit dat het lagere niveau van bescherming na vaccinatie 
waarschijnlijk veroorzaakt werd door de afwezigheid van een mucosale IgA antilichaam 
respons en een zwakkere cellulaire respons. Daarnaast was in een eerdere proef al 
gebleken dat niet alleen IgA maar, hoewel in mindere mate, ook IgG locaal 
geproduceerd wordt in de mucosa langs de luchtwegen. Deze proeven gaven aan dat men 
door intranasale vaccinatie mogelijk een hoger niveau van bescherming zou kunnen 
bereiken dan na intramusculaire vaccinatie. 
Omdat de variabiliteit van het influenza virus zowel voor vaccinatie van varkens 
als ook van mensen een groot probleem is werden vervolgens immuunmechanismen 
bestudeerd die een breder spectrum aan influenzavirussen aangrijpen dan virus 
neutraliserende antilichamen tegen het HA. Het gericht stimuleren van dergelijke 
immuunmechanismen zou mogelijk het frequent updaten van vaccinstammen onnodig 
maken en bescherming kunnen bieden als de veldstam sterk afwijkt van het verwachte 
virus. Mogelijk zou een dergelijke vaccin-strategie zelfs gebruikt kunnen worden in het 
geval van een antigene shift en als preventief middel als een pandemie wordt gevreesd. 
De rol van de cellulaire respons in bescherming werd meer in detail bestudeerd. Hiervoor 
werd na primaire en secundaire infectie gekeken welke typen cellen naar de longen 
migreren om daar de virusinfectie te bestrijden. Het bleek dat er een groot aantal 
cytotoxische T-lymfocyten (CTLs) naar de longen gaan en daar gedurende lange tijd 
aanwezig blijven om bij een eventueel hernieuwd contact de virusreplicatie te stoppen. 
Tevens bleek dat de CTLs met name een functie hebben als het hernieuwd contact 
plaatsvindt met een influenza virus waarvan het HA en NA afwijkt van het virus 
waarmee het primaire contact plaatsvond. Wanneer de varkens primair werden 
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geïnfecteerd met een virus van het H1N1 subtype en vervolgens met een H3N2 subtype 
(heterosubtype infectie), nam het aantal CTLs in de longen sterk toe terwijl dit niet het 
geval was als de varkens primair al met hetzelfde H3N2 virus waren geïnfecteerd 
(homologe infectie). Tegen homologe infectie zijn antilichamen tegen het HA en NA 
afdoende. Deze experimenten hebben ons behalve over immuunmechanismen in 
bescherming tegen influenza, ook meer duidelijkheid gegeven over de phenotypen aan 
T-lymfocyten in varkens en hun rol in virale infecties in het algemeen.  
Naast de rol van CTLs in breed-spectrum immuniteit tegen influenza wordt er ook 
een rol toegeschreven aan antilichamen tegen minder variabele epitopen op het HA en 
NA, en het extracellulaire domein van M2 (M2e). Dit domein steekt ook uit aan de 
buitenkant van het virale membraan maar is, in tegenstelling tot het HA en NA, zeer 
geconserveerd. Het bleek dat de antilichaam respons tegen M2e sterk geboosterd werd 
als varkens met een ander subtype in contact kwamen dan het virus waarmee zij in eerste 
instantie zijn geïnfecteerd. Deze booster respons werd niet gezien tegen het 
nucleoproteine, wat ook een geconserveerd eiwit is. Dit wijst erop dat antilichamen tegen 
M2e inderdaad een rol in breed-spectum bescherming hebben. Hoewel het niveau van 
bescherming tegen heterosubtype infectie lager was dan tegen homologe infectie kan 
deze bescherming wellicht toch voldoende zijn om virusspreiding en/of kliniek in 
varkens en mensen te beperken. Het stimuleren van een CTL respons tegen 
geconserveerde eiwitten en het stimuleren van de antilichaam respons tegen M2e door 
vaccinatie zou het spectrum van de immuniteit tegen influenza kunnen verbreden. 
Daarom werd in een volgende studie de beschermende werking van antilichamen 
tegen het M2e dan wel antilichamen tegen het M2e in combinatie met nucleoproteine-
specifieke T helper lymphocyten en CTLs tegen het nucleoproteine bestudeerd. Hiertoe 
werden varkens gevaccineerd met een M2e-hepatitis B fusie-eiwit waarvan door anderen 
in muizen reeds was aangetoond dat het enige bescherming gaf tegen influenza infectie. 
Daarnaast werd een groep varkens gevaccineerd met een DNA construct dat codeert voor 
een influenza M2e-nucleoproteine fusie-eiwit. Hoewel het M2e-hepatitis B fusie eiwit 
antilichamen tegen het M2e opwekte en het M2e-nucleoproteine DNA construct 
antilichamen tegen het M2e en een T-cel respons tegen het nucleoproteine opwekte 
gaven deze de varkens geenszins bescherming tegen infectie. Integendeel, de 
gevaccineerde groepen kregen meer klinische symptomen dan de controle groep. Met 
name de M2e-nucleoproteine DNA gevaccineerde varkens vertoonden ernstige kliniek 
en 3 van de 6 varkens overleden als gevolg van de challenge. Deze resultaten indiceren 
dat antilichamen tegen M2e ziekte als gevolg van influenza kunnen verergeren en dat het 
daarom niet op voorhand verstandig lijkt deze antilichamen specifiek op te wekken via 
vaccinatie. De ziekte verergerende potentie van antilichamen tegen M2e moet verder 
worden onderzocht en voorzichtigheid moet in acht worden genomen bij het toepassen 
van het M2 eiwit in toekomstige vaccins. 
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Mogelijk kunnen antilichamen tegen het M2e wel een rol hebben in bescherming maar 
alleen als ze al in afdoende hoeveelheden in de luchtwegen aanwezig zijn. Hetzelfde zou 
ook kunnen gelden voor CTLs. Dit zou betekenen dat intranasale vaccinatie ook voor het 
induceren van breed-spectrum bescherming beter zou zijn dan vaccinatie via de 
parenterale route zoals in de uitgevoerde studie. Een intranasale vaccinatie met een 
geattenueerd influenza H1N1 virus gevolgd door een H3N2 virus induceert 
waarschijnlijk IgA en IgG antilichamen alsmede CTLs in de luchtwegen tegen een breed 
spectrum aan influenza virussen. Hoewel een dergelijke drastische vaccinatie strategie 
niet toepasbaar zal zijn voor varkens zou het mogelijk toegepast kunnen worden in het 
geval een volgende pandemie wordt gevreesd. Het verbeteren van huidige varkens 
influenza vaccins noch van humane influenza vaccins zal eenvoudig zijn en blijft een 
grote uitdaging. 
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